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Abstract 
 
The difficulties associated with the clinical application of next generation 
sequencing (NGS) approaches can be substantial. However, the technology 
holds great potential to improve outcomes and risk management for inherited 
heart disease patients and their families.  
 
This PhD thesis focuses on three critical challenges associated with the clinical 
application of NGS technologies; (i) Understanding correlations between 
genetics and the clinical phenotype; (ii) the impact of uncertainty created by NGS-
based genetic testing on the patient; and (iii) developing evidence-based 
approaches for improving current and future methods for returning complex 
genetic results.  
 
Two studies focused on understanding correlations between genetics and the 
clinical phenotype. Firstly, the study reported in Chapter two, which aimed to 
analyse genetic and phenotypic findings from a consecutive cohort of 
hypertrophic cardiomyopathy (HCM) families who had undergone 
comprehensive cardiac panel testing. We showed that increasing the number of 
genes included on HCM panels beyond the eight established sarcomere genes 
does not increase the diagnostic yield. However, identification of variants of 
uncertain significance increased dramatically from 13% to 36%. This result has 
important clinical implications. Increasing the number of genes screened does 
not necessarily improve the chance of identifying a family’s cause of disease but 
is likely to increase identification of uncertain results that can increase the 
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complexity of discussions around inheritance and risk. We also showed that 
identification of multiple rare variants was associated with earlier disease onset, 
greater likelihood of family history of sudden cardiac death (SCD) and overall 
worse event-free survival (5/18 events versus 29/170 events, log-rank test 
p=0.008). Clinical heterogeneity is a hallmark feature of HCM and here we show 
one factor that can contribute to worse outcomes.  
  
The study reported in Chapter three aimed to describe the diverse genetic and 
phenotypic features of an international cohort of patients with a truncating variant 
in the desmoplakin (DSP) gene traditionally considered to cause arrhythmogenic 
right ventricular cardiomyopathy (ARVC). This is the first complete report of the 
diverse phenotype spectrum of DSP cardiomyopathy, suggesting that truncating 
variants in DSP should be considered its own entity. We show that the phenotype 
associated with truncations in DSP is severe, with a high rate of SCD and 
characterised by left ventricular dysfunction and structural left ventricular 
involvement when compared with ‘classic’ ARVC. In addition, we show the 
functional domain in which DSP truncating variants reside has clinical 
significance.  
 
Key results from Chapter two and three emphasise the importance of correlating 
genetic variants with phenotype information. Data from this work is a step 
towards precision medicine whereby patients’ risk will be assessed and managed 
based on their genotype.  
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In Chapter four we designed a qualitative study to explore attitudes, 
preferences, recall and psychosocial consequences of uncertain genetic results 
returned to HCM probands. The major themes we identified were knowledge and 
recall of complex genetic information, individual experiences with HCM genetic 
testing and communication and the value of information. In addition, those with 
uninformative results had a unique set of issues. We found that HCM probands 
undergoing genetic testing require additional support and information beyond the 
current practice model employed in the multidisciplinary specialist clinic setting. 
Importantly, many of the probands interviewed who received an uninformative or 
uncertain genetic result showed poor recall and understanding of genetic 
information.  
 
The final aim was to determine if a genetic counsellor led intervention using a 
communication aid for the delivery of HCM genetic test results improves the 
ability and confidence of the proband to communicate genetic results to at-risk 
relatives. This work is presented in Chapter five. We developed a study protocol 
for a randomised controlled trial with the primary outcome being the ability and 
confidence of the proband to communicate genetic results to at-risk relatives. We 
focused on transforming findings from the previous chapters into improved 
clinical practice.  
 
The a priori primary outcome did not show statistically significant differences 
between the control and intervention group, though the majority of probands in 
the intervention group achieved fair communication scores and had higher 
genetic knowledge scores than those in the control group. Importantly, we found 
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that 29% of at-risk relatives were not informed of a genetic result in their family. 
We highlight the significant gap in our current approach to supporting family 
communication about genetics.  
 
The studies presented highlight that whilst genetic testing has significant 
potential for benefit in inherited heart disease families in terms of diagnosis, 
management and family screening there are issues to address in order to 
improve the clinical utility and application of a comprehensive approach to 
testing. Overall, the work contributes to understanding the genetic architecture of 
inherited heart diseases, the clinical impact of NGS results for patients, as well 
as highlighting that more work is needed to improve the clinical utility from an 
NGS approach to genetic testing.  
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1 Introduction 
 
Genetic technologies, testing and personalised medicine have garnered the 
interest of the medical, scientific and general community since completion of the 
human genome project in 2003. Commonly referenced by mass media, 
politicians and the wider public, genetics is portrayed as the state-of-the-art 
technology holding the answer to many unanswered medical questions.  
 
In recent years, genetic technologies have advanced rapidly, with next 
generation sequencing (NGS) allowing simultaneous testing of thousands of 
genes. For the scientific and medical community, advances in genetic 
technologies hold the potential to diagnose, guide therapy and define the 
molecular underpinnings of various diseases more effectively. Currently, the 
most notable clinical utility of NGS technology is the availability of test platforms 
to identify the underlying genetic cause of a patient’s phenotype including large 
cardiac panels, exome and genome sequencing. These test platforms are 
characterised by increasingly faster turnaround times and decreasing cost. 
Importantly, identifying the underlying genetic aetiology of disease allows at-risk 
relatives to be screened and managed appropriately. More broadly, NGS 
represents an opportunity for improved access to testing, increased diagnostic 
yield, greater opportunity for sudden cardiac death (SCD) risk-reduction and the 
potential for cure and personalised treatment via gene therapy and genome 
editing (Figure 1.1) (Dainis and Ashley, 2018). However, the technology itself has 
far surpassed our ability to interpret the data that is generated. This is a critical 
challenge that limits the current clinical application and utility.  
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For families affected by inherited heart disease, genetic testing can be used for 
improved patient and family management. However, to maximise the benefit, 
thorough evaluation and research into the clinical application of NGS 
technologies is required. This PhD focuses on improving the clinical application 
of genetic testing for families with inherited heart diseases. The candidate 
performing the studies in this thesis is a cardiac genetic counsellor. Trained and 
uniquely placed as the conduit between genetic information and families with 
inherited heart disease.  
Figure 1.1 State-of-the-art genetic technologies [from (Dainis and Ashley, 
2018)] 
Figure legend: The potential outcomes from NGS technologies for patients with 
inherited heart disease. 
Abbreviations: FH= familial hypercholesterolemia; LQTS= long QT syndrome; 
iPSC= induced pluripotent stem cells; DNA= deoxyribonucleic acid; DMD= 
Duchenne muscular dystrophy.   
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1.1 Inherited Heart Diseases 
 
Inherited heart disease is a term encompassing both cardiomyopathies, such as 
hypertrophic cardiomyopathy (HCM) and primary arrhythmogenic disorders, 
including long QT syndrome (LQTS) (Table 1.1). Inherited heart diseases are 
characterised by clinical and genetic heterogeneity. Collectively, these are 
heritable conditions with typically autosomal dominant inheritance, such that first-
degree relatives have a 50% chance of inheriting the disease (Ackerman et al., 
2012). Clinical outcomes range from asymptomatic individuals to heart failure, 
cardiac arrest and SCD (Bagnall et al., 2016, Priori et al., 2013, Girolami et al., 
2018). Across the inherited heart diseases, there are common management 
approaches such as annual clinical review, medication and implantable 
cardioverter defibrillator (ICD) for those considered to be at highest risk of SCD. 
Importantly, inherited heart diseases are a major cause of mortality and morbidity 
in the young (Bagnall et al., 2016, Ho et al., 2018, Priori et al., 2013). 
 
A number of genes have been implicated in the pathogenesis of inherited heart 
diseases, albeit with some degree of overlap. These include genes that encode 
proteins making up ion channels, the sarcomere and the desmosome (Table 1.2). 
Importantly, there is emerging data highlighting the genetic and phenotypic 
overlap between the primary arrhythmogenic disorders and cardiomyopathies. 
For example, Brugada syndrome, historically considered an arrhythmogenic 
disorder has mounting evidence for structural involvement, particularly involving 
the right ventricular outflow tract (Gray et al., 2018a). Brugada syndrome is due 
to variants in the cardiac sodium channel alpha subunit (SCN5A), a gene 
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implicated in LQTS, dilated cardiomyopathy (DCM) and conduction system 
disease (Girolami et al., 2018, Hosseini et al., 2018).  
 
Table 1.1 Inherited cardiomyopathies and primary arrhythmogenic 
disorders 
Inherited cardiomyopathies Primary arrhythmogenic disorders 
Hypertrophic cardiomyopathy Long QT syndrome 
Arrhythmogenic right ventricular 
cardiomyopathy 
Brugada syndrome 
Dilated cardiomyopathy Catecholaminergic polymorphic ventricular 
tachycardia 
Left ventricular noncompaction Cardiac conduction disease 
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Table 1.2 Summary of common inherited heart disease genes [adapted 
from (Ackerman et al., 2012, Ingles et al., 2018)] 
 
Genes listed account for ≥5% of disease.  
Gene Locus Protein Disease 
proportion  
Long QT syndrome (LQTS) 
KCNQ1 (LQT1) 11p15.5 Iks potassium channel alpha subunit  30-35% 
KCNH2 (LQT2)  7q35-q36 Ikr potassium channel alpha subunit  24-40% 
SCN5A (LQT3) 3p21 Sodium voltage-gated channel alpha subunit 5  5-10% 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) 
RYR2 (CPVT1) 1q42.1-q43 Ryanodine receptor 2 60% 
Brugada syndrome (BrS) 
SCN5A 3p21 Sodium voltage-gated channel alpha subunit 5  20-30% 
Cardiac conduction disease (CCD) 
SCN5A 3p21 Sodium voltage-gated channel alpha subunit 5   5% 
Hypertrophic cardiomyopathy (HCM) 
MYBPC3 11p11.2 Cardiac myosin-binding protein C 20-45% 
MYH7 14q11.2-q12 β-Myosin heavy chain 15%-20% 
TNNT2 1q32 Cardiac troponin T type 2 1%-7% 
TNNI3 19q13.4 Cardiac troponin I type 3 1%-7% 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
PKP2 12p11 Plakophilin 2 25%-40% 
DSG2 18q12.1 Desmoglein 2 5%-10% 
DSP 6p24 Desmoplakin 2%-12% 
DSC2 18q12.1 Desmocollin 2 2%-7% 
Section VII- Dilated cardiomyopathy (DCM) 
None of the >25 known disease-associated genes have been shown to account for ≥5 %  
Dila ed cardiomyop thy with or without cardiac conduction defect (DCM + CCD) 
TTN 2q31.2 Titin Up to 30% 
PLN 6q22.31 Phospholamban Up to 12% 
SCN5A 3p21 Sodium voltage-gated channel alpha subunit 5  5%-10% 
LMNA 1q22 Lamin A/C 5%-10% 
Left ventricular noncompaction 
LDB3 10q22.2-q23.3 LIM binding domain 3 ~ 5% 
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1.1.1 Inherited Cardiomyopathies 
 
Inherited cardiomyopathies are characterised by structural abnormalities of the 
heart with or without arrhythmia. The most common inherited cardiomyopathies 
include HCM, DCM, arrhythmogenic right ventricular cardiomyopathy (ARVC) 
and left ventricular noncompaction (LVNC) (Figure 1.2). They are genetically and 
clinically heterogeneous diseases with a combined prevalence of at least 1 in 
500 in the general population (Semsarian et al., 2015a). The diagnostic yield of 
genetic testing for inherited cardiomyopathies ranges from <20% to 50%. 
Therefore, in many cases the underlying genetic cause remains unknown 
(Ackerman et al., 2012, Ingles et al., 2018). 
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Figure 1.2 Schematic of inherited cardiomyopathy hearts [from (Wilde and 
Behr, 2013)] 
A. Normal heart 
B. Dilated left ventricle in dilated cardiomyopathy (DCM) 
C. Hypertrophic cardiomyopathy (HCM): asymmetric (left) and apical (right) 
D. Arrhythmogenic right ventricular cardiomyopathy (ARVC) with fibrofatty 
replacement of the right ventricle.  
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1.1.1.1 Hypertrophic Cardiomyopathy 
 
1.1.1.1.1. Clinical Characteristics and Disease Characterisation 
 
HCM is a heterogeneous myocardial disease, first described in 1958 (Teare, 
1958). The disease is characterised by left ventricular hypertrophy, myocyte 
disarray and interstitial fibrosis on histopathological examination in the absence 
of loading conditions such as hypertension (Figure 1.3) (Maron et al., 2006a, 
Teare, 1958, Watkins et al., 2011, Maron et al., 2012b). With a prevalence of at 
least 1 in 500 (Semsarian et al., 2015a), it is one of the most common inherited 
heart diseases. Diagnosis is made via 2-dimensional echocardiography (in the 
presence of maximal left ventricular wall thickness ≥ 15mm), alongside clinical 
examination, electrocardiogram (ECG) and review of the family history (Gersh et 
al., 2011). 
 
By echocardiography, there is often predominant involvement of the 
interventricular septum in an asymmetric pattern though phenotypic expression 
is variable (Watkins et al., 2011, Maron, 2018). Left ventricular outflow tract 
obstruction may be present in up to 70% of cases and impaired diastolic function 
can occur (Maron, 2018, Maron et al., 2006b). Cardiac magnetic resonance 
(CMR) imaging may provide a more reliable assessment in a subset of patients; 
particularly with borderline hypertrophy or to further delineate risk of SCD (Maron 
and Maron, 2015, Gersh et al., 2011).  
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Figure 1.3 Histopathology and postmortem examination of hypertrophic 
cardiomyopathy (HCM) [adapted from (Society for Cardiovascular 
Pathology, 2018)] 
A. Marked hypertrophy of the interventricular septum 
B. Myocyte disarray 
C. Myocyte disarray accompanied with interstitial fibrosis in blue. 
 
1.1.1.1.2. Disease Progression and Management 
 
Clinically, the impact on patients can be extremely variable. Many patients have 
few clinically significant symptoms, do not require treatment and have a normal 
lifespan (Maron et al., 2016). However, the risk of SCD, potential for arrhythmias 
including atrial fibrillation in up to 20% of patients, stroke, symptomatic outflow 
tract obstruction and heart failure are important clinical consequences of disease 
(Figure 1.4) (Watkins et al., 2011, Maron, 2018, Rowin et al., 2017, Ho et al., 
2018). For those considered to be at high risk, an ICD, capable of detecting 
ventricular arrhythmias and instigating appropriate therapy is recommended 
A B
C
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(DiMarco, 2003, Maron and Maron, 2016). Other common therapies include 
pharmacological therapies such as beta blockers, calcium channel blockers and 
diuretics (Maron, 2002). For those with symptomatic outflow tract obstruction and 
impaired quality of life, alcohol septal ablation and surgical myectomy may be 
considered (Maron, 2018). It is recommended that first-degree relatives undergo 
clinical screening at intervals dependent on their age. Clinical screening should 
include echocardiography and ECG examination (Table 1.3) (Semsarian and 
CSANZ, 2018). 
 
The risk of SCD in HCM is estimated to be <1% annually (Maron, 2010, Ho et 
al., 2018). There have been many studies focusing on SCD risk stratification but 
increased risk is generally recognised to be based on; history of cardiac arrest, 
severity of hypertrophy, presence of non-sustained ventricular tachycardia, 
unexplained syncope, and a family history of SCD (Maron and Maron, 2016, 
Maron et al., 2007). To date, genotype has had little impact on risk stratification. 
Small studies have suggested an increased risk of worse disease for those 
carrying more than one pathogenic genetic variant (Kelly and Semsarian, 2009, 
Tsoutsman et al., 2008a, Ingles et al., 2005, Van Driest et al., 2004, Olivotto et 
al., 2008, Richard et al., 1999). Recent data including >2500 genotyped HCM 
patients provides stronger evidence that young age of diagnosis, and the 
presence of a sarcomere variant are powerful predictors of adverse outcomes 
(Ho et al., 2018). This highlights that genotype has the potential to provide clarity 
around management, risk stratification and offers opportunities for tailored 
therapy in the not too distant future (Akhtar and Elliott, 2018, Dainis and Ashley, 
2018, Ho et al., 2018). 
CHAPTER 1 - INTRODUCTION 
    12 
Table 1.3 Clinical screening recommendations for first-degree relatives of 
probands with hypertrophic cardiomyopathy (HCM) [adapted from 
(Semsarian and CSANZ, 2018)]  
Age (years) Frequency of screening (years) 
0-11 Optional unless suspicious symptoms or 
malignant family history 
12-20 1-1.5 
21-40 2-3 
40+  3-5 
 
 
 
 
 
Figure 1.4 The clinical spectrum of hypertrophic cardiomyopathy (HCM) 
[from (Maron et al., 2016)] 
Figure legend: The clinical spectrum of HCM ranging from stable/benign to heart 
failure and sudden death. 
Abbreviations: HCM= hypertrophic cardiomyopathy; ICD= implantable 
cardioverter defibrillator; AF= atrial fibrillation; RF= radiofrequency. 
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1.1.1.1.3. Genetic Characteristics 
 
At least 15 genes have been described in HCM with thousands of variants 
published. The first three disease genes identified were genes encoding 
components of the sarcomere; the major contractile element of heart muscle 
(Watkins et al., 2011, Thierfelder et al., 1994). Since that time, variants in 8 
sarcomere genes have the strongest evidence linking them to HCM. The 
diagnostic yield of genetic testing in HCM is between 30-50% and it has been 
proposed a large sub-set of unsolved disease may be a combination of 
environmental, lifestyle and nonfamilial factors (Ingles et al., 2017a, Ingles et al., 
2018). In fact, a recent study suggested up to 40% of HCM probands present 
with no family history of disease, even after clinical screening in first-degree adult 
relatives (Ingles et al., 2017a). 
 
In-vitro analysis and mouse models have shown that mutant variants in the 
sarcomere and sarcomere-related genes contribute to increased contractility of 
myofilaments and excess energy use (Figure 1.5) (Watkins et al., 2011). These 
changes in energy utilisation and diminished capacity for myocyte relaxation 
ultimately promote myocyte growth and hypertrophy of the heart (Watkins et al., 
2011). Further studies highlight that cardiomyocyte contraction and electrical 
activity in the heart is dependent on intracellular movement of calcium. Therefore, 
calcium handling and calcium homeostasis also contribute to the 
pathophysiological development of left ventricular hypertrophy (Akhtar and Elliott, 
2018, Lan et al., 2013, Semsarian et al., 2002). 
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Importantly, there exist at-risk relatives who carry pathogenic or likely pathogenic 
variants in high evidence HCM genes but do not show phenotypic evidence of 
disease (Gray et al., 2011). Studies using induced pluripotent stem cells (iPSC) 
aim to establish the underlying mechanisms that may be involved in penetrance 
and clinical heterogeneity exhibited in this disease (Ross et al., 2017, Ross et al., 
2016). 
 
 
Figure 1.5 Excess energy production in hypertrophic cardiomyopathy 
(HCM) [from (Watkins et al., 2011)] 
Figure legend: Increased use of energy by the sarcomere in HCM is a proposed 
mechanism for disease. 
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One of the biggest challenges for HCM genetic testing is the diversity and lack of 
consistency in genes tested. Typically, hundreds of genes are included on 
current HCM genetic testing panels, the majority of which have weak evidence 
for disease causality. As a consequence of this, the clinical significance of 
variants identified in these genes is largely unknown (Alfares et al., 2015). 
Incorrectly classified variants have the potential to cause harm, such as 
inappropriately released relatives from ongoing cardiac investigation and use of 
incorrectly classified variants in family planning decisions (Rehm et al., 2015).  
 
1.1.1.2 Arrhythmogenic Right Ventricular Cardiomyopathy 
 
1.1.1.2.1 Clinical Characteristics and Disease Characterisation 
 
ARVC is an arrhythmogenic cardiomyopathy characterised by fibrofatty 
replacement of the right ventricular myocardium with a propensity towards 
ventricular arrhythmias, systolic dysfunction and an increased risk of SCD 
(Corrado et al., 2017). The prevalence is thought to be between 1 in 1000-5000 
(Corrado et al., 2017, Calkins et al., 2017). Clinical diagnosis is evolving, and is 
currently based on major and minor International Task Force Criteria (Marcus et 
al., 2010b).  
 
The clinical picture and diagnosis of ARVC is challenging (Marcus et al., 2010a, 
Marcus et al., 2010b, James and Calkins, 2018). Historically, diagnosis involved 
identification of localised myocyte loss and fibrofatty tissue of the right ventricle 
only, however left ventricular involvement is increasingly recognised and the 
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phenotype spectrum is much wider than previously appreciated (Bomma et al., 
2004, Sen-Chowdhry et al., 2007, James and Calkins, 2018). In fact, with the 
growing recognition of the diverse spectrum of the ARVC phenotype there is now 
a move to consider the many sub-types of the disease as arrhythmogenic 
cardiomyopathy more broadly. Diagnosis at postmortem examination is an 
important issue, with isolated fibrofatty infiltration insufficient to confirm disease 
(Tansey et al., 2005). Histological examination should reveal degenerative 
myocyte changes with fatty infiltration and replacement fibrosis (Figure 1.6) 
(Basso et al., 2017, Marcus et al., 2010a). In recent years, postmortem findings 
of “ARVC” have likely been over-diagnosed due to lack of expertise in assessing 
these characteristics.   
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Figure 1.6 Pathologic features of arrhythmogenic right ventricular 
cardiomyopathy (ARVC) fibrosis (blue stain) [from (Corrado et al., 2017)] 
A. Gross transverse section of the heart showing classic right ventricular wall 
thinning and aneurysm 
B. Histology of the posterior and C. anterior wall with fibrofatty tissue replacement 
D. Gross transverse section of the heart showing biventricular involvement 
E. Histology of the right ventricular free wall confirms myocardial atrophy with 
fibrofatty replacement 
F. Histology of the left ventricular wall shows fibrofatty replacement.  
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1.1.1.2.2 Disease Progression and Management 
 
The phenotype expression of ARVC varies considerably from asymptomatic 
patients through to heart failure and SCD. Patients generally present between 
the second and fourth decade of life with symptoms associated with ventricular 
arrhythmias including palpitations, syncope and cardiac arrest (Corrado et al., 
2017, James and Calkins, 2018). The mortality data cited in the literature ranges 
from 0.08% though to 3.6% per year which may reflect the lack of consistency in 
defining the phenotype and the wide spectrum of disease presentations (Corrado 
et al., 2017). In the largest ARVC cohort to date, 11% presented with SCD or 
resuscitated cardiac arrest (Groeneweg et al., 2015). Importantly, risk of 
dangerous ventricular arrhythmia occurs during adolescence, highlighting the 
need for early and clear risk stratification and diagnosis (James and Calkins, 
2018).  
  
An additional challenge in the field of AVRC is the impact of exercise on the right 
ventricle. There are two issues that must be considered. The first is the effect of 
high-level, high-intensity exercise on development of the entity known as 
‘athletes’ heart whereby haemodynamic load increases right ventricular afterload 
resulting in cardiac remodelling and larger right ventricular volumes (La Gerche 
et al., 2011, La Gerche et al., 2017, Prakken et al., 2010). This disproportionate 
impact on the right ventricle can create diagnostic overlap with ARVC, which may 
be problematic in the clinic (La Gerche et al., 2017). Overlap aside, there is 
emerging evidence linking high-level exercise to disease progression in ARVC 
itself with increased risk of ventricular arrhythmias, heart failure and disease 
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progression particularly in desmosomal variant carriers (James et al., 2013, La 
Gerche et al., 2017, Sawant et al., 2016). As a result, ARVC patients are advised 
to avoid high-intensity and strenuous exercise (Sawant et al., 2016). 
 
Management of ARVC is dependent on the risk of SCD, symptoms and clinical 
presentation. Consensus for therapeutic options includes beta blockade, anti-
arrhythmic medication, catheter ablation, ICD implantation and heart 
transplantation (Corrado et al., 2015). Risk is generally accepted to fall into three 
categories of high, intermediate and low risk being dependent on the presence 
or absence of recognised risk factors (Figure 1.7) (Corrado et al., 2015). Recent 
data examining the performance of the International Task Force risk stratification 
algorithm highlights further refinements in risk stratification are needed (Orgeron 
et al., 2018).  
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Figure 1.7 Risk factors for sudden cardiac death in arrhythmogenic right 
ventricular cardiomyopathy (AVRC) for implantation of implantable 
cardioverter defibrillator (ICD) [from (Corrado et al., 2017)] 
Figure legend: Risk factors assessed for ICD implantation in ARVC patients. 
Abbreviations: ICD= implantable cardioverter defibrillator; VF= ventricular 
fibrillation; VT= ventricular tachycardia; RV= right ventricular; LV= left ventricular; 
PVB= premature ventricular beat; ARVC= arrhythmogenic right ventricular 
cardiomyopathy.  
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1.1.1.2.3 Genetic Characteristics 
 
ARVC is a disease of the desmosome and intercalated disk with loss of adhesion 
between cardiac myocytes, resulting in detachment, cell death and replacement 
with fibrofatty tissue (Wilde and Behr, 2013). Variants in genes that encode 
desmosomal proteins account for the majority of cases (Ackerman et al., 2012). 
Although autosomal recessive and syndromic forms of ARVC exist, ARVC is 
most often inherited as an autosomal dominant trait. The yield of genetic testing 
is between 40-60% (Bhonsale et al., 2015, Ackerman et al., 2012). Population 
studies of ARVC associated genes have shown there is a high prevalence of 
variants in the healthy population, reflecting a high rate of background noise 
(Kapplinger et al., 2011). Gene variants in ARVC genes should therefore be 
evaluated with caution. 
 
1.1.1.3 Other Inherited Cardiomyopathies 
 
1.1.1.3.1 Dilated Cardiomyopathy 
 
DCM is a major cause of heart failure characterised by dilation and impaired 
contraction of the left (and in some cases) right ventricle. DCM can occur as a 
primary cardiomyopathy or in association with other factors such as coronary 
artery disease or alcoholism (Fatkin, 2012). DCM can also present in childhood, 
particularly as part of syndromes with neuromuscular involvement for example. 
Diagnosis is based on echocardiography with evidence of left ventricular 
dilatation and reduced systolic function (Fatkin, 2012). A diagnosis of familial 
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DCM relies on the presence of a positive family history with at least two clinically 
affected individuals and exclusion of acquired cause for dilatation and contractile 
dysfunction. A genetically heterogeneous disease, there have been over 30 
genes implicated in DCM but genetic testing has a low yield (< 20%) (van 
Spaendonck-Zwarts et al., 2013). Unlike HCM, a disease primarily of the 
sarcomere, no single pathogenic mechanism has been elucidated in familial 
DCM. The sarcomere, cytoskeletal and other proteins have been implicated in 
disease (Fatkin and Graham, 2002). Further, of the genes previously associated 
with DCM, there is limited consensus regarding causality. Titin (TTN) is the 
largest gene in the human genome and truncating variants in TTN are proposed 
to account for 25% of familial DCM. However, there is a high rate of background 
noise in TTN, and it has been hypothesised that variants in this gene may play a 
contributory rather than causative role (Herman et al., 2012, Norton et al., 2013, 
Fatkin and Huttner, 2017). In addition, there is evidence that lamin A/C (LMNA) 
and sodium voltage-gated channel alpha subunit 5 (SCN5A) variants cause DCM 
and progressive conduction system disease (Ackerman et al., 2012, Bozkurt et 
al., 2016, Fatkin, 2011, Fu and Eisen, 2018). 
 
1.1.1.3.2 Left Ventricular Noncompaction 
 
LVNC is a recently classified but poorly defined cardiomyopathy characterised 
by excessive trabeculations in the left ventricle (Ackerman et al., 2012, Bennett 
and Freudenberger, 2016). The yield of genetic testing for LVNC is low. Although 
the Heart Rhythm Society (HRS) expert consensus document quotes 17-41% 
(Ackerman et al., 2012), there have been a number of genes and inheritance 
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patterns published with no causative gene predominating. The high prevalence 
of noncompaction in the general population alongside the overlap with various 
cardiomyopathy phenotypes have caused speculation regarding the definition of 
LVNC as a distinct disease entity (Arbustini et al., 2014, Oechslin and Jenni, 
2011). Reflective of this lack of clarity, the American Heart Association names 
LVNC as a genetic cardiomyopathy compared to the European society defining 
LVNC as a non-classified entity (Elliott et al., 2008, Maron et al., 2006a).  
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1.1.2 Primary Arrhythmogenic Disorders 
 
Primary arrhythmogenic disorders are characterised by electrical abnormalities 
in the presence of, in most cases, a structurally normal heart. These include 
LQTS, Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular 
tachycardia (CPVT). However, emerging evidence highlights the genetic and 
phenotypic overlap between the primary arrhythmogenic disorders and inherited 
cardiomyopathies. For example, there is evidence of structural involvement in 
BrS particularly involving the right ventricular outflow tract (Gray et al., 2018a). 
Abnormalities in intracellular ion channels lead to the primary arrhythmogenic 
disorders and predispose patients to ventricular arrhythmias. Knowledge of the 
underlying genetics is in some ways better defined for the primary 
arrhythmogenic disorders and in some cases genotype-phenotype associations 
allow genetic diagnosis to influence clinical management. 
 
1.1.2.1  Familial Long QT Syndrome 
 
LQTS is a primary arrhythmogenic disorder caused by ion channel abnormalities 
leading to abnormal ventricular repolarisation and a prolonged QT interval on the 
ECG. Clinical manifestations include syncope or cardiac arrest due to torsades 
de pointes and ventricular fibrillation (Priori et al., 2013). Diagnosis is made in 
the presence of a prolonged QT interval when corrected for heart rate using 
Bazett’s formula (QTc). The Schwartz score which takes into account factors 
such as syncope, family history of SCD and QT prolongation in the recovery 
phase of exercise stress testing is also used to establish the diagnosis 
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(Napolitano et al., 2003, Schwartz et al., 1993, Schwartz et al., 1975, Sy et al., 
2011). There are up to 15 genes associated with LQTS and genetic test yield is 
approximately 70% for clinically confirmed cases. Pathogenic variants in KCNQ1, 
KCNH2 and SCN5A account for the majority of cases (Ackerman et al., 2012, 
Priori et al., 2013, Wilde and Behr, 2013).  
 
Genetic testing for LQTS has arguably provided the most benefit to the clinical 
management of patients and their families when compared with other inherited 
heart diseases. The yield of testing is high, there is evidence for treatment of 
asymptomatic concealed gene carriers, and genotype-phenotype correlations 
exist. Between 10 and 40% of genotype positive individuals have a normal QT 
interval, and although low, there is risk of ventricular arrhythmia in these patients, 
highlighting the utility of a genetic diagnosis (Priori et al., 2003, Goldenberg et 
al., 2011, Burns et al., 2016a). Uniquely, the literature also provides evidence for 
potential prognostic, therapeutic and management implications. For example, 
individuals with a KCNQ1 mutation are at higher risk of ventricular arrhythmia 
during exercise and are more responsive to beta-blocker therapy compared to 
individuals with a KCNH2 mutation who are at greater risk during the postpartum 
period or after auditory stimuli (Mazzanti et al., 2018, Priori et al., 2003).  
 
1.1.2.2 Brugada Syndrome 
 
BrS is a disease involving the inward sodium current resulting in the characteristic 
coved-type ST elevation on ECG. Clinical manifestations of BrS include 
ventricular arrhythmia and SCD due to ventricular fibrillation (Brugada and 
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Brugada, 1992). Diagnosis is made in the presence of spontaneous or drug 
induced type 1 Brugada ECG (≥ 2mm ST elevation with type 1 morphology in 
more than one lead) (Priori et al., 2013).  
 
The genetic aetiology of BrS is largely elusive and highly topical. The example of 
BrS genetics can be used to illustrate some of the perils of the assumption that 
all genes included on large NGS test panels cause disease. As a consequence 
of small candidate gene studies and limited scientific and statistical evidence, 
NGS panels used by diagnostic laboratories for BrS typically incorporate over 20 
genes. Recently published data has shown of 30 accredited diagnostic 
laboratories offering BrS testing, the number of genes tested ranged from 3-23 
(Hosseini et al., 2018). Notably, only four genes were present on all 30 panels 
reflecting a critical lack of consistency (Figure 1.8). Remarkably, of the 21 genes 
curated for clinical validity in BrS, only one gene (SCN5A) had definitive evidence 
as causing disease (Hosseini et al., 2018). Findings from this paper highlight that 
inclusion of a gene on a comprehensive NGS panel should not imply a 
scientifically valid disease association. 
 
1.1.2.3 Catecholaminergic Polymorphic Ventricular Tachycardia 
 
CPVT is a rare, but highly lethal arrhythmogenic disorder characterised by 
bidirectional ventricular tachycardia that is adrenergically stimulated (Leenhardt 
et al., 2012). Presentation is usually severe, with patients presenting in childhood 
or adolescence. One study suggests a 58% event rate, 13% that were fatal or 
near fatal (Hayashi et al., 2009). The yield of genetic testing in CPVT is 50-65% 
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(Ackerman et al., 2012) with two genes accounting for the majority of genotyped 
cases, autosomal recessive CASQ2, and autosomal dominant RYR2 (Ackerman 
et al., 2012, Laitinen et al., 2001, Priori et al., 2001). Recent advances in genetic 
technologies have facilitated discovery of an autosomal dominant CASQ2 
variant, identifying another mechanism of disease (Gray et al., 2016). 
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Figure 1.8 Vast lack of consistency in genes tested for Brugada syndrome (BrS) by diagnostic laboratories [from (Hosseini 
et al., 2018)] 
Figure legend: Vast lack of consistency in genes tested by commercial laboratories for BrS.  
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1.2 Genetic Testing in Inherited Heart Disease 
 
1.2.1 Next Generation Sequencing Approaches 
 
Since the development of Sanger sequencing (dideoxy or chain termination 
sequencing) in 1977, genetic testing approaches and technologies have evolved 
significantly (Sanger et al., 1977). Although Sanger sequencing has remained an 
influential technique, playing a pivotal role in defining the genetic basis of 
Mendelian and single gene disorders, new methods, broadly encapsulated under 
the umbrella term of NGS have since been developed to overcome the limitations 
of Sanger sequencing which include the cost and time-consuming nature of the 
low throughput chain terminating approach. 
 
NGS became widely available in 2005 and allowed for simultaneously performed 
multiple independent reactions (Dewey et al., 2012, Bamshad et al., 2011). 
Though the various NGS platforms can differ in approach, the processes 
incorporated into the term broadly include: 
1. Template preparation via a deoxyribonucleic acid (DNA) library; 
2. Simultaneous or massively parallel sequencing of short read sequences; 
3. Alignment of sequence reads; and  
4. Sequence assembly followed by pipeline preparation and analysis of data 
(Figure 1.9). 
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NGS allows large amounts of data to be analysed quickly and comprehensively 
and reduces the costs previously associated with Sanger sequencing (Bamshad 
et al., 2011, Metzker, 2010). Modalities and test platforms incorporated under the 
NGS umbrella regularly used in inherited heart diseases include: 
1. NGS cardiac panel testing; 
2. Exome sequencing; and 
3. Genome sequencing. 
 
In the clinical context, cardiac panel testing is the most frequently used approach. 
Panel testing is a commercially attractive product with the benefit of allowing for 
quick, recurrent sequencing of multiple genes packaged into a ‘panel’ easily 
selected by the referring clinician (Rehm, 2013). Though exome and genome 
sequencing are increasingly incorporated into patient care, commercial 
availability of panel testing and near complete gene coverage mean it is the most 
common genetic test ordered for inherited disease patients. Disadvantages 
include the increased detection of variants of uncertain significance (VUS) and 
the inconsistency and lack of robust scientific data to support many genes 
included on panels (Alfares et al., 2015, Rehm, 2013, Hosseini et al., 2018). The 
most common NGS modalities used for inherited heart disease genetic testing 
along with advantages and disadvantages are summarised in Table 1.4. 
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Figure 1.9 Key principles of next generation sequencing (NGS) platforms 
[from (Rizzo and Buck, 2012)] 
Figure legend: The process involved in NGS testing platforms including template 
generation, sequencing reactions and detection as well as data analysis. 
Abbreviations: dsDNA= anti double stranded deoxyribonucleic acid; NGS= next 
generation sequencing.  
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Table 1.4 Most common next generation sequencing modalities used for patients with inherited heart diseases  
Method Advantages Disadvantages 
NGS cardiac panel testing Time efficient 
Good coverage of genes 
Commercially and readily available 
Multiple genes sequenced simultaneously 
Most useful when genetic basis of disease well characterised 
Increased variants of uncertain significance 
Weak level of evidence for many genes placed on disease 
panels 
No new gene discovery 
Additional sequencing required as new disease genes identified 
Exome sequencing Time efficient 
Bioinformatics gene collapsing and burden analysis possible 
Decreasing cost 
Identification of new candidate genes 
Useful when phenotypic overlap exists 
Can be reanalysed with discovery of new disease genes 
Coverage may be poor  
Large regions of the genome not covered 
No coverage of intronic regions 
 
Genome sequencing Identification of new candidate genes 
Identification of new molecular mechanisms (e.g. deep intronic 
and structural variants) 
Time consuming bioinformatics and analysis 
Significant cost and storage space 
 
Abbreviations: NGS= next generation sequencing. 
CHAPTER 1 - INTRODUCTION 
    33 
1.2.2 Workflow Associated with Next Generation Sequencing Approach 
 
The workflow required to sequence, annotate, filter and interpret variants 
detected by NGS should not be overlooked. Typically, thousands of variants are 
identified in a single patient and the technical and bioinformatic analysis of the 
data generated can be substantial (Figure 1.10) (Girolami et al., 2018, Yang et 
al., 2013). Beyond the technical challenges, the clinical expertise and time 
required to interpret and draw clinically valid conclusions accounts for substantial 
workforce input. Clinical application of these technologies requires careful 
consideration regarding implementation of these workflow processes into current 
practice. Genetic counselling is one key aspect to this process and clinical 
application of NGS relies on comprehensive pre- and post-test genetic 
counselling to coordinate and appropriately inform patients and their families of 
the increasingly complex results that are generated from an NGS approach.  
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Figure 1.10 Workflow associated with next generation sequencing (NGS) 
approaches [from (Girolami et al., 2018)] 
Figure legend: The significant workflow associated with NGS from pre-test 
genetic counselling through to library preparation, variant prioritisation and 
generation of a report. 
Abbreviations: NGS= next generation sequencing; Qc=quality control. 
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1.2.3 Rationale and Utility of Genetic Testing in Inherited Heart Disease 
 
1.2.3.1 Predictive Genetic Testing 
 
Informative genetic testing, whereby the pathogenic or likely pathogenic genetic 
variant is identified, is a valuable tool in family management. The benefits of 
genetic testing for inherited heart disease families are summarised in Figure 1.11. 
The greatest utility of genetic testing lies in identification of at-risk relatives. After 
identification of the pathogenic/likely pathogenic variant in the proband, relatives 
can then undergo genetic testing. This process is referred to as predictive (or 
cascade) genetic testing, whereby at-risk relatives can determine if they have 
inherited the disease-causing variant and should be cared for by a cardiologist. 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 The benefits of genetic testing for inherited heart disease 
families 
Figure legend: The five current and future benefits of a genetic result.  
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1.2.3.2 Genotype-Phenotype Correlations 
 
In addition, although genotype-phenotype correlations are largely unpredictable, 
genotype may guide management, confirm diagnosis and predict outcomes and 
medication response in certain patient sub-sets (Girolami et al., 2018). For 
example, individuals diagnosed with LQTS identified as carrying KCNH2 and 
SCN5A variants and QTc intervals >500ms are at greater risk of ventricular 
arrhythmias than individuals with a KCNQ1 variant and a very long QTc (Figure 
1.12) (Mazzanti et al., 2018).   
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Figure 1.12 Genotype-phenotype correlations and risk by genotype in long 
QT syndrome (LQTS) [from (Mazzanti et al., 2018)] 
Figure legend: Risk amongst genotyped LQTS patients. 
Abbreviations: LAE=left atrial enlargement; LQT1= long QT syndrome type 1; 
LQT2= long QT syndrome type 2; LQT3= long QT syndrome type 3; ms= 
milliseconds; QTc= QT interval corrected using Bazett’s formula. 
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1.2.3.3 Family Planning 
 
Identifying the underlying genetic cause of disease in a family allows for family 
planning options. Families with inherited heart disease have three options when 
planning children in the future. For future children they can take the 50% chance 
that each child will inherit the disease risk and manage the children adhering to 
clinical screening and management guidelines. Undergo invasive prenatal testing 
through use of a chorionic villus sample or amniocentesis to test for the presence 
of absence of the causative genetic variant with the view to pregnancy 
termination. Finally, patients can undergo pre-implantation genetic diagnosis 
(PGD) and in-vitro fertilisation, where a 6-8 cell embryo is tested. Following 
genetic testing, only embryos found not to carry the causative variant are 
implanted back into the uterus (Fortuny et al., 2009, Amato et al., 2013). 
 
1.2.3.4 Sudden Cardiac Death Families 
 
Genetic testing plays an important role in families who present after the SCD of 
a young relative (Bagnall et al., 2016, Semsarian et al., 2015b). Determining the 
cause of death of a young person is a critical step in elucidating appropriate 
clinical management in surviving at-risk relatives. Molecular autopsy allows for 
genetic testing of the decedents blood sample to try and identify the underlying 
genetic cause (Figure 1.13) (Semsarian et al., 2015b). In those individuals who 
present with out of hospital cardiac arrest, or SCD, with no structural 
abnormalities of the heart, genetic testing can elucidate the cause in up to 30% 
of cases (Bagnall et al., 2016). SCD is a devastating event with considerable 
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long-term impact on the family and community. Providing some clarification about 
the cause of death, as well as providing direction for appropriate screening and 
management in families, should not be overlooked (Ingles et al., 2016). 
 
 
Figure 1.13 The molecular autopsy [from (Semsarian et al., 2015b)] 
Figure legend: The process involved in a molecular autopsy from blood sample 
collection through to genetic analysis and reporting of variants identified. 
Abbreviations: DNA= deoxyribonucleic acid. 
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1.2.3.5 Future Utility 
 
Knowledge of the underlying genetic aetiology holds the potential to improve 
patient outcomes and to understand in greater detail how gene variants lead to 
diverse clinical outcomes. Research into novel therapeutic targets, development 
of gene therapy, use of iPSC to model disease and techniques such as CRISPR-
cas9 (clustered regularly interspaced short palindromic repeats) represent 
opportunities for further advancements in the field (Girolami et al., 2018, Ross et 
al., 2017, Ross et al., 2016). CRISPR-cas9 is a system that allows for gene 
editing by introduction of small ribonucleic acid (RNAs) that bind and guide cas9 
nuclease to target sites in the genome through base pairing. A double stranded 
break is introduced activating cellular DNA repair mechanisms which are then 
harnessed to introduce or correct a gene variant (Cathomen and Ehl, 2014).  
 
One recent study used in utero gene editing via CRISPR-cas9 in mice to modify 
mutations in the gene PCSK9 associated with lethality and high cholesterol. This 
study showed persistent gene correction in cells, reduced cholesterol levels and 
rescue of the lethal phenotype (Rossidis et al., 2018). Another used CRISPR-
cas9 to correct an MYBPC3 variant in human pre-implantation embryos showing 
correction of the variant with no introduction of unwanted genetic changes (Ma 
et al., 2017). Studies like these highlight the potential for genetic technologies to 
contribute significantly to therapeutic benefits in patients. However, there are 
significant challenges to overcome. These include introduction of off-target gene 
variants, difficulties associated with the delivery of gene therapy and ethical 
considerations, all of which are considerable (Ma et al., 2017). 
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1.3 Challenges Associated with NGS Implementation 
 
1.3.1 The Challenge of Variant Classification 
 
With the expansion of cardiac panel testing and NGS approaches, there has 
been increased identification of rare variation in both population and disease 
cohorts. Population-based studies, and databases such as gnomAD (genome 
aggregation database) and ExAC (exome aggregation consortium), contain over 
120,000 exome and genome sequences from unrelated disease specific cohorts 
(http://gnomad.broadinstitute.org/) providing prevalence data regarding rare 
variation in the normal population (Lek et al., 2016). These resources highlighted 
for the first time that identification of a rare variant in a plausible gene is not 
sufficient to classify a variant as disease-causing, as had historically been the 
case. The finding that rare variation occurs commonly in both general and 
disease populations has called into sharp focus the need for stringent, 
standardised and disease specific variant classification (Lek et al., 2016, 
Richards et al., 2015).  
 
In 2015, the American College of Medical Genetics and Genomics and 
Association for Molecular Pathology (ACMG/AMP) released updated standards 
and guidelines for the interpretation of sequence variants, a joint consensus 
document that highlights the difficulties associated with classification (Richards 
et al., 2015). It cautions against an approach that classifies rare variants as 
pathogenic based on non-stringent criteria (Richards et al., 2015). In summary, 
the guidelines advocate a five-point system based on a combination of very 
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strong, strong, moderate and supportive criteria. A scoring matrix is then 
employed to classify a variant into one of five categories including: 
1. Pathogenic; 
2. Likely pathogenic; 
3. VUS; 
4. Likely benign; and 
5. Benign. 
 
1.3.2 The Probabilistic Nature of Genetic Results 
 
Due to imperfect variant classification criteria, along with the need for improved 
data regarding gene and disease associations our best prediction as to whether 
a variant is causative or not can be considered along a gradient from pathogenic 
(i.e. ~99% chance the variant is the cause of disease) to variants that are almost 
certainly benign (Figure 1.14) (Plon et al., 2008). Many variants have insufficient 
or conflicting evidence and are considered a VUS.  
 
Genetic results should be considered probabilistic, whereby evidence is 
considered at a point in time and a decision is made regarding pathogenicity 
(Ingles and Semsarian, 2014). The way in which we convey this is a challenge 
and current practices of returning genetic results to families must be carefully 
considered. The role of the cardiac genetic counsellor is pivotal in providing pre- 
and post-test counselling. The aim is to obtain informed consent and adequately 
equip the patient and family with an understanding of test outcomes by providing 
education, information and support (Resta et al., 2006). It is important that 
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families have a reasonable understanding of the information provided to them 
from a genetic test result. Clinically significant (pathogenic/likely pathogenic) 
variants can be used for predictive testing of at-risk relatives to either release 
from screening or target for closer follow up. 
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Figure 1.14 The gradient of variant classification [adapted from (Maron et al., 2012)] 
Figure legend: The spectrum of variants identified ranging from pathogenic to benign, with the greatest clinical utility through to least 
clinical utility. 
Abbreviations: VUS= variant of uncertain significance. 
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1.3.3 Improving Variant Classification  
 
Uncertainty regarding which variants are disease-causing and which are benign 
is an ongoing challenge in the field of genetics. Considering the evidence for the 
gene that the variant is identified in is a logical but only recently proposed first 
step in classifying a variant. For example, if the gene has poor association with 
disease then classification of the variant should not occur for that patient.  Gene 
curation efforts are focused on assessing gene-disease evidence to facilitate 
variant classification (Strande et al., 2017). There are a number of strategies, 
projects and collaborations that aim to improve this process. One example is 
ClinVar. ClinVar is a public repository of variant interpretation information 
providing open access to over 5000 variant classifications submitted by 
diagnostic, commercial and research laboratories 
(https://www.ncbi.nlm.nih.gov/clinvar/). It is a resource increasingly used as a 
point of reference for international teams performing variant classification 
(Landrum et al., 2016). Specifically, it is often used to source case counts i.e. the 
number of patients reported carrying the same variant and to obtain evidence 
that might otherwise be privately held by a diagnostic service or research group. 
In the research context, it has been used to highlight discordance between 
genetic variant classifications amongst diagnostic laboratories and clinicians 
(Yang et al., 2018, Harrison et al., 2018, Wain et al., 2018). These discordant 
variant classifications in ClinVar highlight that ambiguity around whether a given 
variant is disease-causing or not remains problematic. However, ClinVar when 
used cautiously, is an invaluable data sharing tool, that can assist with the 
increasingly complex task of determining pathogenicity (Harrison et al., 2018). 
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With wide uptake of the ACMG/AMP guidelines and with increasing knowledge 
of the frequency of rare variation in the general population, it is apparent that 
many variants published in the literature and on ClinVar are inappropriately 
classified. ClinGen (NIH-funded Clinical Genome Resource) reported that 
amongst >2000 variants submitted to ClinVar, 17% had conflicting interpretations 
by various submitters (Rehm et al., 2015). The rate of discordance of a variant 
classification appears to vary, however when considering clinically relevant 
discordance (for example VUS to pathogenic) subsequent studies have found 
~6-8% show disagreement (Yang et al., 2018, Shah et al., 2018). Variants 
classified earlier, and often prior to standardised criteria and public sharing of 
data, were more likely to be discordant, indicating the practice of variant 
classification does appear to be improving (Shah et al., 2018, Yang et al., 2018).  
 
One approach to improve concordance and overall classification of variants and 
genes is public sharing of data. International collaborative efforts such as 
ClinGen have focused on combining field specific expertise to create 
standardised approaches to classifying variants and genes, and to ultimately 
contribute to a systematic approach to sequence annotation (Rehm et al., 2015, 
Rivera-Munoz et al., 2018). The goal of ClinGen is to utilise field specific 
expertise and community resources to improve understanding of genetic 
variation and the clinical application of this information (Figure 1.15). A recent 
pilot study published by ClinGen showed that reassessment and data sharing of 
variant and clinical information was able to resolve 87% of discordant variants 
(Harrison et al., 2017, Harrison et al., 2018). Another study involving five expert 
HCM centres found 21% of variants had clinically significant discordance, with 
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reassessment and data sharing reducing this to 11% (Furqan et al., 2017). Our 
editorial for this study highlighted data sharing and collaborative efforts are key 
to improving variant classification (Ingles et al., 2017b). Sharing variant data and 
expertise facilitates classification and allows for the opportunity to reassess 
variants and resolve differences.  
 
The outcomes of inappropriately classified variants can be significant. There may 
be misdiagnosis, inappropriate release of at-risk relatives, inappropriate 
implantation of ICDs and use of medication, as well as inappropriate use of 
variants in family planning. Efforts to improve the current practice are essential, 
particularly given the increasing availability of genetic tests due to NGS 
technologies.  
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Figure 1.15 NIH-funded Clinical Genome Resource (ClinGen): improved 
patient care through genomic medicine [from (Rehm et al., 2015)] 
Figure legend: The ClinGen ethos has an overall goal of improved patient care 
through genomic medicine. This includes gene and variant curation and sharing 
of genetic and health data. 
Abbreviations: ClinGen=NIH-funded Clinical Genome Resource. 
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1.3.4 The Challenge of Correlating Genotype with Phenotype 
 
Inherited heart diseases display vast clinical and genetic heterogeneity and this, 
alongside the variant classification issues described above highlight a key 
challenge in the clinical application of NGS technologies. Indeed, it is well known 
that a single genetic variant is often not completely deterministic of a phenotype, 
with environmental and non-genetic factors likely playing an important role. The 
example of SCN1B and BrS illustrates the dangers of reporting variants in genes 
with spurious disease association. SCN1B was first reported in 2008 in three 
families using a candidate gene approach. In a recent cohort of SCN1B positive 
patients, amongst 23 genotype positive individuals, only two demonstrated 
diagnostic BrS ECGs. This study highlighted that the frequency of SCN1B 
variants in gnomAD, a supposed control population is 0.004%, exceeding the 
estimated prevalence of BrS itself and indicating variants in this gene are unlikely 
to account for a rare cause of a rare disease. This demonstrates a lack of 
evidence for SCN1B causing BrS (Gray et al., 2018b).  
 
Greater effort is needed to ensure robust gene-disease associations. 
Establishing causality relies on a combination of scientifically sound data, 
particularly in the absence of linkage studies. The type of data required to provide 
evidence for genotype-phenotype correlations includes clinical information such 
as co-segregation data, de novo occurrences, case-control studies as well as 
gene burden analysis and experimental data (Strande et al., 2017). In addition, 
continued refinement of the ACMG/AMP criteria is essential. Prior to inclusion of 
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candidate disease genes on diagnostic gene panels there should be a robust 
gene-disease association established.  
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1.3.5 Balancing Increased Clinical Yield with the Potential for Secondary 
Findings 
 
Approaches that increase the diagnostic yield of inherited heart disease genetic 
testing should be considered. This is important, given the modest genetic test 
yield for most inherited heart disease and the utility of a genetic diagnosis. 
Cardiac panel testing is the most commonly used approach for inherited heart 
diseases. However, there are many genes included on inherited heart disease 
panels that do not increase yield. In HCM for example, >50% of cases remain 
genetically elusive in spite of panel tests incorporating an increasingly large 
number of genes (Alfares et al., 2015, Cirino et al., 2017). Recently, in a cohort 
of HCM patients with previously inconclusive genetic testing, genome 
sequencing allowed for an increased test yield of 20% with five of the nine genetic 
variants identified in non-coding regions of the genome not previously sequenced 
using exome sequencing or cardiac panel testing (Bagnall et al., 2018).  
 
However, the benefits and consequences of each approach should be 
considered in the clinic setting (Cirino et al., 2017). Beyond the technical aspects 
of each test, the growing tendency towards genome or exome sequencing leads 
to the possibility of secondary genetic findings. Secondary findings are clinically 
significant variants identified in genes unrelated to the indication for testing. The 
ACMG has generated a list of 56 genes they class as medically actionable and 
recommend disease-causing variants in these genes be returned to patients 
(Richards et al., 2015, Kalia et al., 2017). While a more comprehensive approach 
to testing is useful for gene discovery research or in cases where there is 
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multisystem disease, the increased likelihood of unexpected findings when used 
as a first-line test is important. Identifying secondary findings means specialist 
clinics must attend to individuals with cardiac variants and no cardiac phenotype, 
and this is currently occuring worldwide.  
 
Data regarding the prevalence of secondary findings is emerging. One 
publication used a systematic approach to estimate the prevalence of secondary 
findings in 1092 patients from the 1000 genomes project and concluded 
approximately 1% (12/1092) were likely to have medically relevant secondary 
findings identified (Olfson et al., 2015). A large study using the Clinical 
Sequencing Exploratory Research Consortium found a similar prevalence of 
1.2% (Hart et al., 2018). In comparison, an additional study comparing genome 
sequencing versus cardiac panel testing found the occurrence of secondary 
findings for Mendelian autosomal dominant disease was 12% (5/41), though the 
definition of secondary findings was not in strict accordance with the ACMG 
recommendations (Cirino et al., 2017).  
 
Overall, it appears the current consensus regarding the clinical application of 
genome and exome sequencing relies on balancing the clinical indication for the 
test, needs and preference of the patient alongside potential adverse outcomes 
such as secondary findings.  
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1.4 Communication of Genetic Information to Families 
 
1.4.1 Genetic Counselling and Family Management 
 
Genetic counselling can assist patients and their families to adapt to medical, 
psychosocial and familial implications of genetic disease (Resta et al., 2006). 
Genetic counsellors play an increasingly important role in multidisciplinary teams 
throughout the public health system in Australia both within clinical genetics 
departments and increasingly in sub-specialities such as cardiology, neurology 
and cancer. Research genetic counsellors also exist, where the skills of the 
genetic counsellor in obtaining informed consent and communicating complex 
genetic information, assisting in interpretation of genetic variants as well as 
liaising with family members regarding co-segregation testing are employed. On 
top of this, the role of the genetic counsellor is quickly expanding in to the private 
setting and commercial laboratories in science liaison and variant interpretation 
capacities (Christian et al., 2012).  
 
1.4.2 Specialised Multidisciplinary Clinics 
 
Specialised multidisciplinary inherited heart disease clinics include cardiac 
genetic counsellors and cardiologists as well as a range of other staff and strong 
collaborations with support services (Figure 1.16). These clinics have been 
shown to provide an effective model of care for the complex inherited heart 
disease patient (Ingles et al., 2008). The role of the cardiac genetic counsellor 
within this clinic has changed with greater availability and access to genetic 
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testing (Ingles et al., 2011). The role is diverse, but at the core is the ability to 
communicate with patients and their families regarding inheritance risk, results 
and familial implications of findings. Genetic counsellors are skilled in the delivery 
of complex genetic information to families and assisting the multidisciplinary team 
in the delivery of genetic testing and care to families. Practically, this entails 
investigation and confirmation of the family history, discussion of inheritance risk, 
discussion and facilitation of genetic testing, support for communication with at-
risk relatives and increasing involvement in variant curation. 
 
 
Figure 1.16 The ideal multidisciplinary inherited heart disease clinic 
[adapted from (Ingles et al., 2011)] 
Figure legend: The ideal approach to managing inherited heart disease families 
includes a multidisciplinary team including cardiac genetic counsellors and 
cardiologists. There is an increasing role for cardiac surgeons in this clinic not 
highlighted by this 2011 figure.  
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1.4.3 The Importance of Communicating Genetic Information Amongst 
Families 
 
For the family, an informative genetic result enables asymptomatic family 
members to make proactive decisions regarding their risk of disease. For those 
families where no underlying genetic cause can be identified, the need for 
relatives to understand clinical screening recommendations remains important. 
To realise the benefits of genetic testing, we rely on relatives being informed of 
their inheritance risk. At present, the responsibility for this disclosure lies with the 
proband. Despite our best efforts, conveying accurate information in a family can 
be problematic. This can be more evident following a SCD, where there is 
heightened emotion and often no cause of death identified (Semsarian et al., 
2015b). The responsibility to communicate with family in this instance falls with 
the spouse or parents of the decedent, a complex task during a tragic time. 
Understanding factors that may help or hinder communication are therefore of 
critical need.  
 
1.4.4 The Communication Process 
 
Communication of genetic information is a two-part iterative process. First, 
probands must have sufficient understanding of inheritance risks and of their 
genetic test result. Second, they must be able to convey this information to 
relatives (Figure 1.17). In turn, relatives must have sufficient information to 
understand the recommendation and then connect to appropriate services. We 
know from previous studies that probands report difficulty in disclosing genetic 
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risk information to family members (Gaff et al., 2007, Burns et al., 2016b). Few 
studies have addressed these challenges for inherited heart diseases. As a 
result, there is limited knowledge to assist cardiologists and multidisciplinary 
teams with family communication.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17 The two-part process of family communication [from (Burns et 
al., 2018)] 
Figure legend: Family communication relies on proband understanding and their 
ability to effectively communicate with at-risk relatives. 
 
While communication challenges vary between families there are key and 
transferable issues that can be addressed by the multidisciplinary team to 
support family communication. The key issues include: 
 
1. The challenge of managing uncertainty; and 
2. Personal and family factors. 
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1.4.5 Managing Increasing Uncertainty in Genetic Test Results 
 
A key challenge faced by the multidisciplinary team is the increased detection of 
VUS. Feedback of uncertain gene results requires a more challenging discussion 
with the family, and there is greater likelihood of misunderstanding. Ongoing re-
classification of variants incorporating new knowledge is therefore essential (Das 
et al., 2014). Debate remains regarding who has responsibility for periodic re-
classification, i.e. is it the laboratory performing the testing, or the clinician who 
ordered it. One option may be to leverage disease registries, that provide a 
framework for storing variant data, with the ability to link patients with the same 
variant and thereby give real time notification of a change in classification. While 
a process for this may not be entirely straightforward, particularly regarding 
whose responsibility it is to re-contact the patient themselves, at the very least, 
the issue of re-classification should be explicitly discussed with each family. 
 
1.4.6 The Impact of Uncertainty 
 
Many patients cite the need for certainty as the primary benefit in the uptake of 
testing. Uncertainty is not uncommon in medicine, but it does impact the patient. 
One study illustrated the difficulty family members had dealing with uncertain 
ECG results suggesting a possible diagnosis of LQTS (Hendriks et al., 2008). 
Those with uncertain findings reported greater distress than those with a definite 
diagnosis. Considering the already heightened worry due to the risk of SCD, 
clinical heterogeneity and background poor psychosocial difficulties amongst 
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patients the impact of casting even further uncertainty should not be 
underestimated (Newson et al., 2016, Ingles et al., 2016). 
Little is known about the patient perspective in processing uncertain and complex 
information, and its subsequent impact on communication. A number of small 
studies highlight issues in recall and understanding of genetic results that can 
inevitably lead to family miscommunication (Turbitt et al., 2015, Kiedrowski et al., 
2016, Daly et al., 2016). For example, there is a perception that genetic testing 
is only required for those with children (Whyte et al., 2016). Others incorrectly 
believe an indeterminate gene result gives false reassurance that their disease 
is not genetic (Daly et al., 2016, Patenaude et al., 2006). Incorrect recall of 
information is likely to influence the quality of the information conveyed to 
relatives (Young et al., 2017). 
 
1.4.7 Personal and Family Factors Influencing Communication 
 
Communication is a multi-factored process. Personal preferences, values, beliefs 
and familial dynamics will directly influence the probands ability and desire to 
communicate genetic information. The literature, largely based on inherited 
cancer cohorts, highlights many factors influencing this. Common reasons cited 
as communication barriers by the proband include guilt over passing a variant to 
children, emotional distress, psychosocial factors, gender and comprehension of 
the result. Female family members are often found to be the communicators of 
genetic information though this may be biased by the strong literature available 
within breast cancer genetics (Daly et al., 2016, Whyte et al., 2016, Patenaude 
et al., 2013, Hudson et al., 2018). Probands will often selectively disclose genetic 
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risk information. They will consider their at risk-relatives’ ability, coping skills, 
stage of life, risk status and need for genetic risk information in their decision to 
communicate with this relative or not (Daly et al., 2016, Smart, 2010). Poor health 
literacy also contributes and it is conceivable that advances in genetics may 
widen the inequalities in health due to poor genomics literacy, failure to 
communicate amongst families and low uptake of genetic health services 
(Kaphingst et al., 2016, Nakamura et al., 2017). In a qualitative study examining 
African American patient perceptions and feasibility of a tool designed to help 
patients document their family history the authors found that socioeconomic 
factors contribute to inaccurate information (Pettey et al., 2015). All patients in 
the study met criteria for poverty (Pettey et al., 2015). In our editorial for this study 
titled ‘The social gradient of taking a family history’ we highlight the utility of family 
history information hinges on its accuracy and this is dependent on factors 
including sociodemographic variables and health literacy (Ingles and Burns, 
2015). With the need for sufficient knowledge to access services, appropriately 
interpret and pass on genetic information, poor health literacy is likely to 
negatively impact communication amongst families (Nakamura et al., 2017, 
Ingles and Burns, 2015).  
 
At a family level, emotional distance and family conflict are reasons against 
communication (Daly et al., 2016, Burns et al., 2016b). Amongst a cohort of 
LQTS patients, those individuals with higher levels of anxiety and depression, 
lower comprehension of the result and poor family relationships perceived 
greater barriers to the communication process (Burns et al., 2016b). In other 
studies, the probands uncertainty regarding the benefit of genetic testing 
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contributed to ambivalence and difficulty in communication and pursuit of testing 
(Smart, 2010). Amongst an HCM cohort probands surveyed regarding family 
communication of genetic information cited responses ranging from blame 
through to accusation and denial (Hudson et al., 2018). Disclosure of genetic 
information amongst the family is a process rather than a single act and by 
preparing the proband adequately and considering personal and family dynamics 
the multidisciplinary team can support the communication process (Forrest et al., 
2003). 
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1.5 Key Points for Supporting Family Communication about 
Genetics 
 
Even in the absence of an informative genetic result, clear understanding and 
communication of inheritance risks and clinical screening recommendations is 
necessary. Although more research is needed, drawing on the literature we can 
recommend some relevant components to address in the context of inherited 
heart disease genetic testing and family communication (Figure 1.18). These 
include: 
1. Careful interpretation of variants to be returned to probands; 
2. Referring patients for cardiac genetic counselling within specialised clinics; 
3. Supporting communication in the context of personal and family factors; and 
4. Providing resources to support knowledge and communication.  
 
1.5.1 Careful Interpretation of the Variants to be Returned 
 
Which variants are included on a gene report can impact on the amount of 
uncertainty perceived by the patient (Burns et al., 2017b, Kiedrowski et al., 2016). 
Current practice, which varies between laboratories, often includes reporting of 
VUS in genes with little evidence of causation of the phenotype in question. 
Measures to better prepare patients and ensure correct understanding need to 
be implemented. Accurate risk perception has been shown to improve health 
behaviour (Carpenter and Niedenthal, 2017). Therefore, helping patients to 
understand the sources of uncertainty is critical.  
  
CHAPTER 1 – INTRODUCTION  
 62 
1.5.2 Cardiac Genetic Counselling and Specialised Clinics 
 
Experienced cardiac genetic counsellors can spend valuable time with patients 
educating and exploring risk perceptions. A discussion to elicit informed consent 
that clearly outlines the potential for uncertainty is central to managing patient 
expectations about what genetic testing can reasonably achieve. Management 
in a specialised multidisciplinary clinic is important in this regard.  
 
Pre-test genetic counselling and informed consent is the primary means by which 
families and individuals process the potential for uncertainty, secondary findings 
and consider family communication in the context of their own experiences. This 
has been shown to be a key factor in preparing patients for the challenges 
associated with NGS testing (Forrest et al., 2008, Bergner et al., 2014, Tabor et 
al., 2012). Indeed, interventions led by genetic counsellors can improve and 
support the communication process (Forrest et al., 2008, van der Roest et al., 
2009). These discussions can improve the patients experience and 
understanding (Kaphingst et al., 2012, Bergner et al., 2014).  
 
1.5.3 Providing Resources to Support Families 
 
Use of a resource, such as a communication aid, may be an appropriate method 
to improve the delivery of results. A communication aid is a tangible resource 
(booklet, pamphlet, letter, online tool) containing key and simple information to 
assist health care providers to deliver health information. These may increase 
knowledge levels, stimulating patients to feel more informed (Stacey et al., 2014).  
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Providing written material generally, such as a family letter, has been shown to 
improve communication in the inherited heart disease setting previously (van der 
Roest et al., 2009). An important aspect of this letter is contact details for the 
multidisciplinary team. They form an important resource for family members, 
answering questions and assisting with organising family screening or genetic 
testing. One recent study reported HCM probands may face difficulties when 
seeking out resources to facilitate family communication and emphasised the 
need for resources and greater education to facilitate family communication 
about genetics (Hudson et al., 2018). There is current debate regarding direct 
contact with relatives from the healthcare provider or multidisciplinary team. 
Underpinning this are ethical and privacy issues, considering the balance 
between an individual’s right not to know and the duty to warn, alongside the 
privacy of the proband and relatives. Further, logistics and implementation of 
such an approach can be problematic for many clinics (Sturm, 2016). In spite of 
this, there is evidence that direct contact from healthcare workers may improve 
uptake of testing and be an acceptable approach for many (Sturm, 2016). Many 
of the challenges described above may be overcome or improved upon by 
utilising direct contact or at the very least direct support from the team (van der 
Roest et al., 2009).  
 
Pre- and post-test genetic counselling should consider comprehension of results, 
interpretation of uncertainty and reflection on the personal impact for the proband 
and their family. These issues can be used as a framework to provide structure 
for pre- and post-test genetic counselling. Underpinning these challenges are 
factors that may facilitate good communication. Risk perception impacts health 
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behaviour, therefore explicit discussion of risk, inheritance and the potential 
outcomes of testing should form part of the discussion. Given uncertain or 
secondary results may occur, explicit discussion of these will prepare patients 
and encourage resilience should they occur (Newson et al., 2016). Consideration 
of personal and familial implications to family members will allow the proband to 
consider their family and how results might impact them. In addition, where 
possible, results being made available in a timely manner may impact on test 
comprehension (Reiff et al., 2012). 
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Figure 1.18 Supporting family communication about genetics [from (Burns 
et al., 2018)] 
Figure legend: The key challenges and key solutions for supporting family 
communication about genetics.  
Key challenges
Key solutions
Uncertainty
Secondary findings
Personal and family factors
Careful variant interpretation
Genetic counselling and 
specialised clinics
Consideration of personal and 
family context
Provision of resources
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1.6 Hypothesis and Aims 
 
There is significant benefit in making a genetic diagnosis in a family with inherited 
heart disease. We aim to improve the clinical application of genetic testing in the 
care of inherited heart disease families. Collectively, projects from this PhD 
address aspects of the current state of clinical practice. 
 
The hypotheses underlying this PhD are that: 
1. More comprehensive genetic testing leads to more complex genetic results 
without improving the clinical utility; 
2. The known and accepted clinical heterogeneity of inherited heart diseases is 
due to outdated diagnostic criteria that encompass many sub-types of disease. 
Using genotype to sub-classify disease groups may improve our understanding 
of inherited heart diseases and allow more certainty for patients; 
3. Increased uncertainty in genetic results will impact on the recall and 
understanding of the patient as well as subsequent family communication; and  
4. Improved communication of genetic results to probands will increase 
knowledge and empowerment and translate to greater communication of genetic 
risk to family members. 
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Based on these hypotheses the specific aims of this PhD, as shown in Figure 
1.19, are to: 
 
Aim 1: Analyse genetic and phenotypic findings from a consecutive cohort of 
HCM families who have undergone comprehensive cardiac panel testing, with a 
focus on reassessing the clinical impact of multiple gene variants. 
 
Aim 2: Describe the impact of truncating variants in DSP in a large international 
cohort, to better understand the clinical and genetic aspects of this 
arrhythmogenic cardiomyopathy. 
 
Aim 3: Investigate the psychological consequences, attitudes, knowledge and 
preferences of patients with inherited diseases towards uncertain genetic results. 
 
Aim 4: Determine if a genetic counsellor-led intervention using a communication 
aid for the delivery of HCM genetic test results improves the ability and 
confidence of the proband to communicate genetic results to at-risk relatives 
compared with current clinical practice. 
 
Collectively, these hypotheses and aims focus on improving the clinical 
application of genetic testing for inherited heart disease families. 
  
CHAPTER 1 – INTRODUCTION  
 68 
 
Figure 1.19 PhD overview 
Abbreviations: HCM= hypertrophic cardiomyopathy; DSP= desmoplakin; NGS= 
next generation sequencing.
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2 Comprehensive Cardiac Panel Testing in 
Hypertrophic Cardiomyopathy Probands 
 
2.1 Introduction 
 
The findings from this Chapter are the basis of the following publication: ‘Multiple 
gene variants in hypertrophic cardiomyopathy (HCM) in the era of next-
generation sequencing’ published in August 2017 by Circulation: Cardiovascular 
Genetics. This work aims to investigate the utility, presence and clinical impact 
of rare variants identified through the use of a comprehensive next generation 
sequencing (NGS) approach. 
 
We live in a time of rapidly expanding knowledge associated with increasing 
technological and scientific change. Although the benefits to society have been 
huge, learning how best to use this ever-expanding genetic information can be 
challenging. Our ability to understand how to incorporate NGS approaches into 
sensible, effective and clinically valid inherited heart disease management 
illustrates these challenges. Work from this Chapter highlights variant 
identification rates when using an NGS approach and some key genetic 
counselling challenges associated with the clinical application of NGS. This work 
sets the platform for subsequent studies in this PhD.  
 
The uptake of genetic testing has undergone substantial growth in recent years 
and has moved into the genomics era, which is characterised by high throughput 
sequencing in an increasingly cost effective and timely manner. Consequently, a 
large proportion of inherited heart disease patients are offered comprehensive 
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genetic testing. The technology used for this testing is an NGS approach, which 
allows for sequencing of hundreds of genes simultaneously.  
 
The most common clinical genetic test incorporating this technology is known as 
‘cardiac panel testing’ whereby laboratories group and simultaneously sequence 
a number of genes that have been linked to the disease in question. For example, 
a common HCM panel may include up to 45 genes, but more commonly, patients 
undergo a general ‘cardiomyopathy’ panel that includes hundreds of genes, 
linked to a number of cardiomyopathies. Sequencing so many genes and base 
pairs simultaneously inevitably results in increased identification of rare variants. 
However, its implementation is not evidence based. For example, many of the 
genes that are sequenced have limited evidence linking them to disease. When 
rare variants are identified in these genes the clinical impact is largely unknown. 
The implications of such testing have not yet been systematically reviewed in the 
literature. We sought to investigate the outcomes of comprehensive testing for 
HCM probands for the first time, with a particular focus on the clinical impact of 
multiple rare variants. 
 
HCM is a myocardial disease characterised by left ventricular hypertrophy in the 
absence of loading conditions such as hypertension. With a prevalence of up to 
1 in 500 it is one of the most common cardiac genetic diseases (Semsarian et 
al., 2015a, Maron et al., 1995). At least 15 genes have been described in HCM, 
and to date thousands of variants have been published (Table 2.1) (Alfares et al., 
2015, Ackerman et al., 2011). Variants in 8 genes have the strongest evidence 
linking them to HCM. These include, MYBPC3 (20-30%), MYH7 (30-35%), 
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TNNT2 (10-15%) TPM1 (<5%), TNNI3 (<5%), ACTC1 (<1%), MYL2 (<1%) and 
MYL3 (<1%). More recently, limited evidence for variants in other genes including 
ACTN2, CSRP3, MYOZ2, NEXN and TNNC1 has emerged (Ackerman et al., 
2011, Alfares et al., 2015, Bagnall et al., 2014, Chiu et al., 2010).  
 
Targeted genetic testing is considered a Class 1 recommendation for a patient 
with a clinical diagnosis of HCM (Ackerman et al., 2011). Targeted testing refers 
to inclusion of only the well-established 8 “major” HCM genes and known 
phenocopies or mimics (i.e. GLA, LAMP2, PRKAG2, PLN), while comprehensive 
panels can include vast numbers of cardiac genes. An important recent study 
highlights that many genes beyond the 8 major HCM genes have poor evidence 
linking them to the disease phenotype (Walsh et al., 2017a). Importantly 
however, the most common clinical approach is to use large comprehensive 
panels due to their commercial availability. The ease of a one-size fits all 
approach that can be used for many different diseases alongside cost-
effectiveness is a key driver of this practice.  
 
Once a genetic diagnosis is established in the proband, predictive genetic testing 
can be offered to at-risk relatives, a unique opportunity to guide clinical 
surveillance recommendations (Ingles and Semsarian, 2018, Semsarian and 
Group, 2018). There are three key and significant genetic counselling challenges 
related to variant interpretation and clinical utility that must be addressed when 
considering a comprehensive genetic testing approach to clinical practice for the 
HCM proband (Figure 2.1).  
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1. The increased detection rate of ‘rare’ variants 
‘Rare’ variation is not uncommon and contributes to the biological diversity of 
human nature, both in disease and non-disease populations. Historically, the 
absence of a rare variant from a few hundred control chromosomes was 
considered evidence of a disease-causing role, however this is no longer 
sufficient (Richards et al., 2015). Classifying a variant as disease-causing now 
requires substantial additional evidence beyond absence from non-disease 
populations.  
 
2. There are many genes included in a comprehensive NGS approach to 
genetic testing with minimal evidence linking them to a disease phenotype 
Recent data highlight this is problematic in the field of inherited heart diseases 
and HCM (Walsh et al., 2017a, Hosseini et al., 2018). This results in major variant 
interpretation challenges and uncertainty around the clinical and inheritance risk 
associated with many variants. This has important implications for the patient, 
their family and the multidisciplinary team caring for them. Unpublished work from 
the NIH-funded Clinical Genome Resource (ClinGen) HCM gene curation project 
led by A/Prof Ingles has shown 66% of genes previously considered “HCM” 
genes have limited or no evidence of gene-disease association.  
 
3. Finally, with more genes being examined, the likelihood of identifying 
more than one rare variant in a single patient is increased  
The clinical impact of identifying more than one variant when using an expanded 
cardiac panel approach is largely unknown. In addition, this increases the 
complexity of discussions regarding inheritance risk.  
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We have previously shown that up to 5% of genetically tested probands will have 
compound heterozygous (2 different variants in the same gene) or double 
heterozygous (two variants in different genes) genotypes (Richard et al., 2003, 
Richard et al., 1999, Ingles et al., 2005, Van Driest et al., 2004, Olivotto et al., 
2008). Data from early studies suggest the phenotype associated with inheriting 
multiple rare variants in established HCM genes was likely more severe, in both 
animals and humans, including increased risk of sudden cardiac death (SCD) 
(Gersh et al., 2011, Tsoutsman et al., 2008b). At that time, there was discussion 
as to whether finding multiple rare variants in a person with HCM should be 
incorporated into risk assessment for SCD (Tsoutsman et al., 2008b).   
 
However, this finding was based on slow and targeted testing of a small number 
of well-established HCM genes. As a result of the current testing practice, 
multiple rare variants are identified in genes with both strong and weak evidence 
of HCM association. For example, a patient may have a rare variant in MYBPC3, 
the most well-established HCM gene, in addition to a rare variant in RBM20, a 
gene with no evidence linking it to HCM. In the current climate, variants in genes 
with spurious gene-disease association are included in the report back to the 
patient, mostly as a variant of uncertain significance (VUS). The clinical impact 
is unknown and therefore conclusions from historic studies do not necessarily 
apply.  
 
Identifying multiple uncertain variants can increase the risk of one of these 
variants being misclassified, with potential for harms to family members 
undergoing predictive genetic testing. For the proband, the clinical impact of 
CHAPTER 2 – COMPREHENSIVE CARDIAC PANEL TESTING 
 75 
identifying multiple variants only is also uncertain. Further, inheritance risk no 
longer follows the strictly autosomal dominant pattern and there are implications 
of multiple rare variants for decision-making regarding family planning (Ingles et 
al., 2005). In light of the vast cardiac gene panels that are now commonplace, 
coupled with increasingly strict variant interpretation, the landscape of HCM 
genetic testing is changing. The outcome and clinical impact of results from this 
type of testing is uncertain. We sought to analyse the genetic and phenotypic 
findings from a consecutive cohort of HCM families who have undergone 
comprehensive cardiac panel testing. This approach was used to reflect the 
clinical reality of current testing practice for the HCM proband.  
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Figure 2.1 Clinical utility and variant interpretation challenges 
Figure legend: The challenges associated with variant interpretation and 
consequently, clinical utility, from a comprehensive testing approach in the HCM 
proband. 
Abbreviations: HCM=hypertrophic cardiomyopathy. 
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Table 2.1 Hypertrophic cardiomyopathy (HCM) gene panel commonly 
considered to incorporate key genes at the time of this study 
Gene Encoded protein % of disease 
MYBPC3 Myosin binding protein C 20-30 
MYH7 β-Myosin heavy chain 30-35 
TNNT2 Cardiac muscle troponin 10-15 
TPM1 Tropomyosin <5 
TNNI3 Cardiac troponin I <5 
ACTC1 Actin, alpha cardiac muscle 1 <1 
MYL2 Myosin light chain 2 <1 
MYL3 Myosin light chain 3 <1 
TTR Transthyretin Unknown 
ACTN2 Alpha-actinin 2 Unknown 
CSRP3 Cysteine and glycine-rich protein 3 Unknown 
MYOZ2 Myozenin-2 Unknown 
NEXN Nexilin Unknown 
TNNC1 Troponin C Unknown 
PLN Phospholamban Phenocopy 
GLA Galactosidase alpha Phenocopy 
LAMP2 Lysosomal associated membrane protein 2 Phenocopy 
PRKAG2 Protein kinase AMP-activated non-catalytic subunit 
gamma 2 
Phenocopy 
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2.2 Methods 
 
2.2.1 Consecutive Patient Series 
 
Probands attending a specialised HCM centre between 2002-2016 who met 
clinical diagnostic criteria for HCM and provided a deoxyribonucleic acid (DNA) 
sample for comprehensive 45-gene panel testing were included. There were 224 
probands included in this study (Figure 2.2). This panel of 45 genes was chosen 
because it included the most commonly tested genes by commercial laboratories 
offering HCM genetic testing at the time of this study (Alfares et al., 2015). The 
proband was defined as the first affected family member who sought medical 
advice for HCM in our clinic. A clinical diagnosis was made based on a maximal 
left ventricular wall thickness ≥ 15mm in adults in the absence of a loading 
condition (Gersh et al., 2011, Elliott et al., 2014). All aspects of the study were 
performed with institutional human research ethics committee approval (X11-
0065). 
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Figure 2.2 Flowchart of proband genetic testing outcomes 
Abbreviations: HCM= hypertrophic cardiomyopathy. 
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2.2.2 Genetic Analysis 
 
Genetic analysis was conducted by our group as described in the publication 
from this thesis Chapter (Burns et al., 2017a). This work was performed by 
colleagues in the Molecular Cardiology Program. DNA was isolated from 
peripheral blood using a QIAmp DNA blood mini kit (Qiagen, Limburg, NL) (Burns 
et al., 2017a). The majority of participants (n=100) underwent genetic testing 
using the Illumina TruSightTM Cardiomyopathy Sequencing Panel, which 
enriches for 1,020 exons spanning 46 cardiomyopathy genes (TTN was 
subsequently excluded from analysis) (Figure 2.3). TTN was excluded due to the 
large number of TTN variants identified in disease and non-disease populations 
and the recognised lack of clarity surrounding the clinical impact of these 
variants.  Genomic DNA (50 ng) was enriched for target exons in strict 
accordance with the manufacturer’s protocol, and sequenced on an Illumina 
MiSeq platform (Ramaciotti Centre for Genomics, Australia). Raw sequence data 
were analysed at the Centenary Institute with alignment to the reference genome 
(hg19) using BWA software, followed by duplicate read removal using Novosort 
(Novocraft Technologies, Malaysia). The Genome analysis Tool Kit v3.3.0 was 
used to realign reads around insertions and deletions, recalibrate base quality 
scores and genotype variants. Single nucleotide variants were required to have: 
(1) a quality by depth score of at least 2.0; (2) a Fisher strand score of less than 
60; (3) a read position rank sum score greater than -8.5; (4) a mapping quality 
score of at least 35.0; and (5) a mapping quality rank sum test score of at least -
15.0. Indels were required to have: (1) a Fisher strand score of less than 200; (2) 
a quality by depth score of at least 1.8; (3) a read position rank sum score greater 
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than -20.0; and (4) an inbreeding coefficient score of at least -0.8. Variants were 
annotated using the SeattleSeq Annotation Server 
(http://snp.gs.washington.edu/SeattleSeqAnnotation138/). 
 
For 82 participants, commercial research grade exome sequencing was 
performed by our group as previously described (Bagnall et al., 2016). This was 
performed on the Illumina HiSeq 2000 platform (Macrogen). Alignment, variant 
calling and annotation was performed in the Centenary Institute. Only the 45 
cardiomyopathy genes (excluding TTN from the 46-gene panel) of the Illumina 
TruSight Cardiomyopathy Sequencing Panel were considered in this analysis. In 
addition, 39 participants underwent comprehensive genetic testing (≥45 genes) 
by commercial testing laboratories, using either massively parallel sequencing or 
Sanger sequencing based approaches and variant data from their gene report 
was included (variants with an allele frequency of <1% were reported, allowing 
equivalent variant lists to be generated). An additional 3 probands with ≥2 
variants identified despite limited Sanger sequencing of ≤7 genes were included. 
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Figure 2.3 Genetic test approach used in the study cohort 
Abbreviations: HCM= hypertrophic cardiomyopathy. 
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2.2.3 Single and Multiple Rare Variant Definitions 
 
Genetic data were analysed according to different sized cardiac gene panels, to 
reflect both comprehensive and targeted genetic testing approaches used in 
current clinical practice. Genes included in each panel are shown in Table 2.2. 
All rare variants (excluding variants in TTN and synonymous and intronic 
changes) with a minor allele frequency of ≤0.02% in the Exome Aggregation 
Consortium (ExAC) dataset; http://exac.broadinstitute.org/), and classifications 
of pathogenic/likely pathogenic and VUS were included (Lek et al., 2016).  
 
Single variants were defined as those seen only in the absence of another 
potentially pathogenic/likely pathogenic variant. Only those variants seen on their 
own in the cohort (isolated) were defined as “single” variants. Variants seen only 
in combination with another potentially pathogenic/likely pathogenic variant were 
termed “second” variants. Variants seen both in single and multiple genotypes 
were removed from this aspect of the analysis. Variant characteristics between 
single and second variants were compared. 
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2.2.4 Variant Classification 
 
Rare variants were defined as those with an allele frequency of ≤0.02%, 
regardless of their classification. It is the practice of our multidisciplinary team to 
classify variants using the American College of Medical Genetics/Association for 
Molecular Pathology (ACMG/AMP) guidelines for variant classification (Richards 
et al., 2015). However, at the time of this project clinical classifications were 
performed using in-house criteria (Appendix 1). Key determinants of 
pathogenicity included rarity (≤0.02%) or absence from the ExAC dataset, 
previous reports of the variant in 2 or more additional unrelated HCM patients 
(http://ncbi.nlm.nih.gov/pubmed and http://clinvar.com/), segregation with 
affected relatives where possible, as well as any supportive experimental data. 
Overall agreement amongst in silico tools and conservation scores was 
considered a single low-level supportive criterion (CADD [Combined Annotation-
Detection Depletion], SIFT [Sorting Intolerant From Intolerant, http://sift-
dna.org/], Polyphen-2 [Polymorphism phenotyping Ver2 
http://genetics.bwh.harvard.edu/pph2/], Polyphen- HCM 
[http://genetics.bwh.harvard.edu/hcm/]). 
 
Only variants in major HCM and phenocopy genes (i.e. 15-gene panel) were 
classified according to the above criteria, as per current guidelines on variant 
interpretation (Richards et al., 2015). Classifications included pathogenic, likely 
pathogenic and VUS. Family segregation of variants was performed where 
possible. Variants outside of the 15-gene panel were considered a VUS. 
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2.2.5 Clinical Assessment 
 
Probands and their relatives with a clinical diagnosis of HCM and genetic 
diagnosis confirming the presence of single or multiple rare variants were 
included. Clinically unaffected gene carriers were not included. An additional 30 
relatives with a clinical diagnosis of HCM and known genotype were included, 
either in the multiple or single variant gene groups. There were no more than 5 
relatives available for clinical screening from a single family. Genotype of 
relatives was based on predictive genetic testing of the variant(s) found in the 
proband. Clinical information including echocardiogram reports, history of 
syncopal episodes and SCD events as well as family history of disease was 
obtained by review of the medical record and from the Australian Genetic Heart 
Disease Registry (Ingles and Semsarian, 2013). 
 
A SCD event included sudden death, resuscitated cardiac arrest, or appropriate 
implantable cardioverter defibrillator (ICD) shock for ventricular fibrillation. A 
three-generation pedigree was collected by a cardiac genetic counsellor as per 
current clinic practice. A positive family history of HCM was defined as ≥2 
individuals in a family with clinical evidence of HCM, while a family history of SCD 
included any sudden death of a relative, at any age, with confirmed or probable 
HCM, based on pre-morbid investigations, death certificate or postmortem 
examination. 
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2.2.6 Statistical Analysis 
 
Data was analysed using Prism (version 7.0) and SPSS Statistics (version 23.0). 
Associations between variables and outcome factors were assessed using 
unpaired t-tests for continuous data and chi-square analysis for categorical data. 
A Kaplan-Meier plot with log-rank tests for significance was used to assess event-
free survival (from all cause death (not including SCD), cardiac transplant, 
resuscitated cardiac arrest or ICD shock due to ventricular fibrillation; first event 
only) between patients with single and multiple rare variants in 8 major HCM 
genes. A p-value of <0.05 was considered statistically significant. 
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2.3 Results 
 
2.3.1 Study Cohort and Variant Characteristics 
 
There were 758 HCM probands seen in our clinic and 382 had at least 45 genes 
sequenced (Figure 2.2). An additional 3 probands with ≥2 variants identified in 
spite of limited Sanger sequencing of ≤7 genes were included. Of the total group, 
224 (59%) had at least one rare variant identified and were included in this study. 
We identified 151 unique variants in the cohort (Appendix 2).  
 
2.3.2 Comprehensive versus Targeted Genetic Testing Yield 
 
Using a comprehensive cardiac gene panel of 45 genes, the yield of probands 
with pathogenic/likely pathogenic variants was 127 (33%), 126 (33%) for 15 
genes, 125 (32%) for 8 genes and 107 (28%) when considering MYBPC3 and 
MYH7 only (Table 2.2). Importantly, the number of probands with a VUS was 
greater than those with a pathogenic/likely pathogenic variant when using the 45-
gene panel; 139 (36%) VUS compared to 127 (33%) pathogenic/likely 
pathogenic. For all other panel sizes, the number of probands with a VUS was 
lower than those with a pathogenic/likely pathogenic variant; 66 (17%) for 15 
genes, 52 (14%) for 8 genes and 41 (11%) when considering MYBPC3 and 
MYH7 only (Table 2.2, Figure 2.4). 
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Table 2.2 Yield of rare variants based on different sized gene panels analysed in the study 
Panel Genes Yield of rare variants identified, n (%) 
P/LP VUS Multiple 
2-gene MYBPC3, MYH7 107 (28)  
 
41 (11)  
 
12 (3)  
 
5-gene MYBPC3, MYH7, TNNI3, TNNT2, TPM1  123 (32)  
 
47 (12)  
 
13 (3)  
 
Major HCM genes  
(8-gene)  
ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, 
TPM1  
125 (32)  
 
52 (14)  
 
14 (4)  
 
Major HCM genes & 
phenocopies* 
ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, 
TPM1, PLN‡, GLA‡, LAMP2‡, PRKAG2 ‡ 
127 (33)  
 
56 (15)  
 
15 (4)  
 
Major & minor HCM 
genes (15-gene)  
ACTC1, ACTN2, CSRP3, MYBPC3, MYH7, MYL2, MYL3, 
MYOZ2, NEXN, PLN, TNNC1, TNNI3, TNNT2, TPM1, TTR  
126 (33)  
 
66 (17)  
 
22 (6)  
 
Major & minor HCM 
genes & phenocopies† 
ACTC1, ACTN2, CSRP3, MYBPC3, MYH7, MYL2, MYL3, 
MYOZ2, NEXN, PLN ‡ , TNNC1, TNNI3, TNNT2, TPM1, 
TTR, GLA ‡ , LAMP2 ‡ , PRKAG2‡  
127 (33)  
 
70 (18)  
 
22 (6)  
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Comprehensive 
cardiomyopathy panel 
(45-genes)  
ABCC9, ACTC1, ACTN2, ANKRD1, CASQ2, CAV3, CRYAB, 
CSRP3, CTF1, DES, DSC2, DSG2, DSP, DTNA, EMD, 
FHL2, GLA, JUP, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, 
MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, NEXN, PKP2, 
PLN, PRKAG2, RBM20, RYR2, SGCD, TAZ, TCAP, 
TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTR, VCL  
127 (33)  
 
139 (36)  
 
66 (17)  
 
 
Table legend: *=the ideal HCM genetic test panel, †=typical commercial HCM panel, ‡ = phenocopy genes. VUS=variant of uncertain 
significance. 
Abbreviations: HCM= hypertrophic cardiomyopathy; P/LP= pathogenic/likely pathogenic variant; VUS= variant of uncertain 
significance. 
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Figure 2.4 Comprehensive versus targeted genetic testing yield 
Figure legend: The yield of identifying pathogenic/likely pathogenic, VUS and multiple variants dependent on the gene panel utilised. 
When considering 45 genes, the yield of probands with pathogenic/likely pathogenic variants was 127 (33%) and 107 (28%) when 
considering MYBPC3 and MYH7 only. Importantly, the number of probands with a VUS was greater than those with a P/LP variant 
with the 45-gene panel; 139 (36%) VUS compared to 127 (33%) pathogenic/likely pathogenic . 
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2.3.3 Multiple Rare Variants 
 
There were 66 (17%) probands with at least 2 rare variants when considering 45 
genes, 22 (6%) for 15 genes, 14 (4%) for 8 genes and 12 (3%) probands had at 
least 2 rare variants in MYBPC3 and MYH7 (Figure 2.4; Table 2.2). Of these, 7 
(2%) probands had three rare variants. Unlike data from the early studies, at the 
time of publication, no proband had two pathogenic/likely pathogenic variants; 
rather there were combinations of pathogenic/likely pathogenic and VUS or 
VUS/VUS. Phase of the variants was established were possible, with families 
demonstrating variants in cis (same allele) and trans (different alleles), as well as 
families with double variants in different genes (Table 2.3). 
 
Since publishing this work, one family has had one of their variants upgraded to 
likely pathogenic during a formal multidisciplinary pathogenicity meeting. Family 
BJJ had their MYH7 p.Arg807His upgraded from VUS to likely pathogenic. This 
means the prevalence of multiple rare pathogenic/likely pathogenic variants is 
0.4% in this cohort. 
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Table 2.3 Families with multiple rare variants in the 8-gene hypertrophic 
cardiomyopathy (HCM) panel 
Family Gene variants Proband Family history 
AJV MYBPC3 p.Leu994Phe 
MYH7 p.Arg652Gly 
Not index case 
Age dx: 17 
Max LVH: 17mm 
SCDE: No 
Father (index case) died 
awaiting cardiac 
transplant (Carried both 
variants)  
Two possibly affected 
relatives 
ALK MYBPC3 p.Gly5Trp 
TNNT2 p.Arg286Cys 
Index case 
Age dx: 62 
Max LVH: 20mm 
SCDE: No 
No family history of 
HCM or SCD 
ARX MYBPC3 p.Val219Leu 
MYBPC3 p.Trp1112dup 
(phase, in trans) 
Not index case 
Age dx: 17  
Max LVH:14mm 
SCDE: No 
 
Brother (index case) 
died suddenly 13 years 
(Carried both variants) 
Distant relative 
reportedly affected 
BET 
 
MYBPC3 p.Glu258Lys 
MYBPC3 p.Val727Met 
(phase, unknown) 
Index case 
Age dx: 53 
Max LVH: 22mm 
SCDE: No 
No family history of 
HCM or SCD 
 
BGK 
 
MYBPC3 p.Arg589Cys 
MYL2 p.Lys104Thr 
Index case 
Age dx: 14 
Max LVH: 26mm 
SCDE: No 
No family history of 
HCM or SCD 
 
BJJ 
 
MYH7 p.Ala797Thr 
MYH7 p.Arg807His 
Index case 
Age dx: 16 
No family history of 
HCM or SCD 
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(phase, unknown) Max LVH: 22mm 
SCDE: No 
 
 
BKZ 
 
MYBPC3 p.Ser311Thr 
MYBPC3 c.927-9G>A 
 (phase, unknown) 
Index case 
Age dx: 22 
Max LVH: 24mm 
SCDE: No 
 
Three affected relatives 
(5 possibly affected)  
Mother died 44 years 
with heart failure 
Brother SCD 16 years 
FQ 
 
MYBPC3 p.Arg724Trp 
MYBPC3 c.1624+4A>T 
(phase, unknown) 
 
Index case 
Age dx: 8 
Max LVH: 19mm 
SCDE: No 
One possibly affected 
relative 
No SCD 
 
NM 
 
MYBPC3; p.Gln969* 
MYBPC3; p.Arg668His 
(AF>0.02%; phase, in cis) 
MYH7; p.Arg1079ln 
Not index case 
Age dx: 48 
Max LVH: 19mm 
SCDE: No 
 
4 affected relatives in 
extended family 
(3 possibly affected) 
No SCD 
 
PE 
 
MYBPC3 p.Leu527Pro 
MYBPC3 c.1928-2A>G 
(phase, in trans) 
 
Index case 
Age dx: Infant 
Max LVH: 24mm 
SCDE: Aborted cardiac 
arrest 
ICD shocks for VF 
Two affected relatives 
Two possibly affected 
Maternal great uncle 
died suddenly aged 30 
years 
 
VN 
 
MYBPC3 p.Ala693Val 
MYBPC3 p.Arg817Gly 
(phase, unknown) 
 
Index case 
Age dx: 12 
Max LVH: 34mm 
SCDE: No 
No family history of 
HCM or SCD 
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WJ 
 
MYH7 p.Asp778Val 
MYH7 p.Arg1818Trp 
(phase, in trans) 
 
Not index case 
Age dx: 30 
Max LVH: 18mm 
SCDE: No 
 
One affected relative 
Brother (Index case) 
died suddenly aged 34 
years (MYH7 
p.Asp778Val only) 
 
DW 
 
MYH7 p.Ile313Phe 
MYBPC3 p.Trp792fs*41 
 
Not index case 
Age dx: 16 
Max LVH: 21mm 
SCDE: ICD shock for 
VF 
One affected relative 
Father died suddenly- 
details limited 
No pedigree available 
 
Abbreviations: Age dx= age at diagnosis; Max LVH= maximal left ventricular 
hypertrophy; SCDE= sudden cardiac death event; SCD= sudden cardiac death; 
ICD= implantable cardioverter defibrillator; VF= ventricular fibrillation. 
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2.3.4 Multiple Variant Families 
 
Inheritance and impact on phenotype of single and multiple variants appeared 
complex. Three generation pedigrees, where available, are used to illustrate and 
visualise the inheritance of the variants in the family and resulting phenotype. 
The pedigrees are presented below, separated into gene panels and absence or 
presence of family history. 
 
2.3.4.1 Families with Two Rare Variants in MYBPC3 and MYH7 
 
There were 12 families with two rare variants in MYBPC3 and MYH7. Families 
AJV, ARX, BKZ, C, DW (Pedigree unavailable), FQ, NM, PE, WJ carried two 
variants in MYBPC3 and MYH7 with documented family history of disease and 
are described in more detail below. These pedigrees illustrate the vast clinical 
heterogeneity seen both in and between families (Figure 2.5). 
 
2.3.4.1.1 Family AJV 
 
In family AJV, the proband (II:2) carried a likely pathogenic variant in MYH7 
p.Arg652Gly as well as a VUS in MYBPC3 p.Leu994Phe, his maximal wall 
thickness was 22mm, he had obstructive disease, had undergone myectomy and 
died awaiting heart transplantation. His son, (III:4) with a maximal wall thickness 
of 17mm also carried both variants.  
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2.3.4.1.2 Family ARX 
 
In family ARX, the proband (III:5) died suddenly aged 13 years with a postmortem 
maximal wall thickness of 20mm. He was found to carry a pathogenic MYBPC3 
p.Val219Leu in addition to a VUS in MYBPC3 p.Trp112dup. His brother (III:4) 
aged 19 years carried both variants with a maximal wall thickness of 14mm and 
an ICD in situ. Their younger brother (III:6) aged 15 years also carried both 
variants but to date clinical investigations had been within normal limits. Their 
mother (II:5) was found to carry the pathogenic MYBPC3 variant but had no 
clinical evidence of disease (maximal wall thickness 9mm). Their father (II:6) 
carried the MYBPC3 VUS with no clinical evidence of disease (maximal wall 
thickness 11mm). 
 
2.3.4.1.3 Family BKZ 
 
In family BKZ, the proband (III:4) presented with symptoms aged 22 years with a 
maximal wall thickness of 24mm and carried a pathogenic MYBPC3 variant 
c.927-9G>A as well as a VUS in MYBPC3 p.Ser311Thr. No family members had 
genetic testing. The proband’s father (II:4) was diagnosed with HCM and a 
paternal uncle (II:3) died suddenly with probable HCM aged 16 years playing 
soccer. 
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2.3.4.1.4 Family C 
 
In family C the proband (IV:4) carried a pathogenic MYH7 p.Arg719Gln variant 
as well as a VUS in MYBPC3 p.Arg273His. Her maximal wall thickness was 
20mm with an ICD in situ and she experienced episodes of atrial fibrillation. Her 
HCM had progressed to dilated phase of disease and she had undergone heart 
transplantation. Her brother (IV:5) died suddenly aged 16 years with probable 
HCM and her mother (III:4) died at 44 years with a maximal wall thickness of 
15mm, atrial fibrillation and heart failure. The proband’s son (V:1) was found to 
carry both variants with a maximal wall thickness of 33mm and ICD in situ. Her 
second son (V:2) carried only the MYBPC3 variant with a maximal wall thickness 
of 10mm. 
 
2.3.4.1.5 Family FQ 
 
In family FQ the proband (II:3) was diagnosed with HCM aged 8 years and has 
a MYBPC3 c.1624+4A>T pathogenic variant and p.Arg724Trp VUS. No family 
members had undergone genetic testing and the probands brother (II:2) had 
borderline echocardiograph findings.  
 
1.1.1.1.4. Family NM 
 
In family NM the proband (II:2) carried a pathogenic nonsense variant in 
MYBPC3 p.Gln969* as well as a VUS in MYH7 p.Arg1079Gln, he had a maximal 
wall thickness of 16mm and his cardiomyopathy had progressed to the dilated 
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phase. His children (ranging in age from 30-35 years) had normal 
echocardiograms but had not undergone genetic testing. His sister (II:3) carried 
both variants and had a maximal wall thickness of 21mm and an ICD in situ. Her 
daughter (III:4) aged 40 years carried both variants with no evidence of disease 
(maximal wall thickness 7mm). Her second daughter (III:5) aged 37 years carried 
neither variant with a maximal wall thickness of 9mm and her third daughter (III:6) 
aged 36 years carried only the pathogenic nonsense variant with a maximal wall 
thickness of 8mm. 
 
2.3.4.1.6 Family PE 
 
In family PE the proband (IV:2) aged 10 years had a maximal wall thickness of 
24mm, had a resuscitated cardiac arrest and had received appropriate therapy 
from his ICD for ventricular fibrillation. He carried a pathogenic splice variant in 
MYBPC3 c.1928-2A>G as well as a VUS in MYBPC3 p.Leu527Pro. His mother 
(III:4) carried only the splice variant with a maximal wall thickness of 12mm. The 
probands maternal grandfather (II:4) had a maximal wall thickness of 16mm with 
an ICD in situ. An uncle (II:1) died suddenly aged 30 years with postmortem 
reporting extensive hypertrophy of the left ventricle.  
 
2.3.4.1.7 Family WJ 
 
Finally, in family WJ, the proband (II:4) carried two VUS in MYH7 p.Arg1818Trp 
and MYH7 p.Asp778Val. Her maximal wall thickness was 18mm and she had an 
ICD in situ. Her clinically unaffected son (III:4, aged 26 years) carried only MYH7 
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p.Asp778Val with no clinical evidence of disease (maximal wall thickness 11mm).  
Her brother (II:1) died suddenly aged 34 years with cause of death identified as 
HCM and was found to carry only the MYH7 p.Asp778Val variant. A second 
brother (II:2) carried only the MYH7 p.Arg1818Trp variant with no clinical details 
available. Their mother carried only MYH7 p.Arg1818Trp and reportedly had 
normal echocardiogram screening. 
 
Amongst families with two rare variants in MYBPC3 and MYH7, three families ( 
BET, BJJ and VN) reported no family history of disease (Figure 2.6).  
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Figure 2.5 Families with two rare variants in MYBPC3 and MYH7 (2-gene panel) reporting a family history 
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Figure 2.6 Families with two rare variants in MYBPC3 and MYH7 (2-gene panel) with no reported family history
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When considering families with two rare variants in the 8-gene HCM panel 
(Families ALK and BGK) neither reported a family history of disease and no 
genetic testing was undertaken in relatives (Figure 2.7).  
 
 
Figure 2.7 Families with two rare variants in the 8-gene panel 
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2.3.5 Comparison of Variant Characteristics 
 
Of the total 151 unique variants identified, there were 107 rare variants 
identified in the 15-gene panel that were seen in isolation (“single” variants) and 
32 variants identified in combination with another variant (“second” variants). 
When compared to second variants, single variants were more likely to be in 
the 8 major HCM genes (99 [93%] versus 25 [78%], p=0.04), have lower (mean) 
allele frequency in ExAC (0.0004% versus 0.001%, p=0.03), higher mean 
CADD score (23 ± 7 versus 19 ± 6, p=0.006), be “deleterious” using Polyphen-
HCM (31/35 [89%] versus 4/9 [44%], p=0.01), be classified as pathogenic/likely 
pathogenic (66 [62%] versus 4 [13%], p<0.0001), and less likely to be novel (32 
[30%] versus 17 [53%], p=0.02) (Table 2.4). These data suggest single variants 
are different to second variants. 
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Table 2.4 Characteristics of variants seen in isolation ("single variants not seen with another variant") versus variants only 
seen in combination with causative hypertrophic cardiomyopathy (HCM) variants ("second variants not seen in isolation") 
Variable Isolated variant Second variant p-value 
n (%) 107 (71) 32 (22) - 
8 major HCM genes  99 (93) 25 (78) 0.04 
Missense variant 77 (72) 26 (81) 0.29 
Mean ExAC allele frequency  0.0004% 0.001% 0.03 
≥ 3/4 in silico tools supportive 44/77 (57) 12/26 (46) 0.30 
Polyphen-2 (n, %) 47/69 (68) 13/24 (54) 0.22 
Polyphen HCM (n, %) 31/35 (89) 4/9 (44) 0.01 
SIFT (n, %) 66/75 (88) 21/26 (81) 0.35 
GERP ≥ 2 (n, %) 101/106 (95) 28/32 (88) 0.21 
Mean CADD score 23 ± 7 19 ± 6 0.006 
Novel (n, %) 32 (30) 17 (53) 0.02 
P/LP classification (n, %) 66 (62) 4 (13) <0.0001 
Abbreviations: HCM= hypertrophic cardiomyopathy; GERP= the genomic evolutionary rate profiling score; CADD=combined 
annotation depletion dependent; P/LP= pathogenic/likely pathogenic.
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2.3.6 Impact on Clinical Phenotype 
 
To assess the impact of multiple rare variants on the clinical phenotype of 
patients, we included an additional 30 relatives with a clinical diagnosis of HCM 
in the single or multiple group depending on how many variants they carried. 
There were no phenotype differences observed between individuals with multiple 
(n=70) versus single (n=184) rare variants when considering the comprehensive 
45-gene panel (Table 2.5). However, when comparing individuals with a single 
(n=170) versus those with multiple rare variants (n=18) in the 8 major HCM 
genes, two differences were observed. Multiple variant individuals were younger 
(mean current age) (37 ± 19 versus 51 ± 17 years, p=0.001) and more likely to 
have a family history of SCD (7 [41%] versus 27 [17%], p=0.03). There were no 
differences in left ventricular wall thickness (22 ± 5 versus 23 ± 6, p=0.40) and 
sudden death events (3 [17%] versus 16 [9%], p=0.33). These phenotype 
differences strengthened when considering the 5 and 8-gene panels (Table 2.5). 
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Table 2.5 Clinical characteristics in hypertrophic cardiomyopathy (HCM) patients with multiple versus single variants  
HCM panel 45-genes 8-genes 5-genes 2-genes 
Variable Single  Multiple p-value Single Multiple p-value Single Multiple p-value Single Multiple p-value 
n 184 70 - 170 18 - 163 17 - 138 16 - 
Male (n,%) 115 (63) 42 (60) 0.714 98 (58)  14 (78) 0.098 93 (57) 13 (76) 0.122 79 (57) 12 (75) 0.172 
Mean age (years) 53 ± 18 52 ± 18 0.644 51 ± 17 37 ± 19 0.001 52 ± 17 37 ± 20 0.001 52 ± 17 35 ± 18 0.000 
Caucasian (n,%) 117 (64) 44 (63) 0.390 114 (67) 13 (72) 0.735 108 (66) 13 (76) 0.374 95 (69) 12 (75) 0.735 
LA area (mean, cm2)  26 ± 8 27 ± 7 0.661 27 ± 8 27 ± 10 0.916 27 ± 8 27 ± 10 0.946 26 ± 8 27 ± 10 0.813 
LA size (mm) 41 ± 13 44 ± 8 0.167 41 ± 13 41 ± 9 0.927 41 ± 13 42  ± 9 0.922 42 ± 12 42 ± 9 0.964 
Max LVH (mean, mm) 22 ± 6 22 ± 5 0.513 23 ± 6 22 ± 5 0.403 23 ± 6 21 ± 5 0.325 23 ± 7 22 ± 5 0.347 
SCD event (n,%) 17 (9) 6 (9) 0.868 16 (9) 3 (17) 0.332 16 (10) 3 (18) 0.396 10 (7) 3 (19) 0.138 
ICD therapy VF (n,%) 7 (4) 2 (3) 0.715 6 (4) 2 (11) 0.130 6 (4) 2 (12) 0.168 3 (2) 2 (13) 0.084 
RCA (n,%) 6 (3) 2 (3) 0.869 6 (4) 1 (6) 0.666 6 (4) 1 (6) 0.507 3 (2) 1 (6) 0.358 
SCD (n, %) 8 (4) 2 (3) 0.585 7 (4) 1 (6) 0.774 7 (4) 1 (6) 0.555 4 (3) 1 (6) 0.427 
FHx (n,%) 96 (52) 31 (44) 0.261 98 (58) 12 (67) 0.460 94 (58) 12 (71) 0.303 82 (59) 12 (75) 0.226 
FHx SCD (n,%) 26 (14) 12 (17) 0.548 27 (16) 7 (39) 0.025 27 (17) 7 (41) 0.022 21 (15) 7 (44) 0.011 
Abbreviations: LA= left atrial; LVH= left ventricular hypertrophy; SCD= sudden cardiac death; ICD=implantable cardioverter 
defibrillator; RCA=resuscitated cardiac arrest; VF= ventricular fibrillation; RCA= resuscitated cardiac arrest; FHx = family history. 
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2.3.7 Proposed Model for Cumulative Effect of Multiple Variants in 
Hypertrophic Cardiomyopathy 
 
Based on the statistically significant difference in mean age and family history of 
SCD between multiple and single variant carriers (when considering the 8-gene 
HCM panel), evaluation of all 14 pedigrees with more than one rare variant in 8 
HCM genes was conducted (Figure 2.8). Panel A shows a multiple variant family 
with a family history of SCD. The decedent carried only the VUS (MYH7 
p.Asp778Val). His brother, mother and nephew carried only one of the variants 
and had no evidence of disease. His sister carried both variants and had a clinical 
diagnosis (maximal left ventricular hypertrophy 18mm). Collectively, this may 
illustrate that alone these variants may not be sufficient to cause disease in family 
members, but cumulatively can cause HCM and perhaps in some cases a more 
severe presentation. In this example we hypothesis the addition of a second 
variant is required for family members to express disease. Similarly, the family in 
Panel B shows a single variant family whereby the proband carries a pathogenic 
MYBPC3 p.Pro955Argfs*95 variant. There is no family history of disease. His 
mother carries this variant with no phenotypic evidence of disease suggesting for 
some families a second ‘hit’ may be required. While there are many clear 
examples of many families with a single genetic cause for their disease with 
demonstrated autosomal dominant inheritance, this theory may explain an 
important sub-group and allow for better understanding of inheritance risks to 
family members.  
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Figure 2.8 Cumulative effect of multiple variants in hypertrophic cardiomyopathy (HCM) 
Figure legend: Two families where only the proband exhibits disease when one variant is present. This suggests the second variant 
may be required for phenotypic expression of disease amongst family members. 
Abbreviations: DOB= date of birth; Dx= diagnosis; SCD=sudden cardiac death; PM COD= postmortem cause of death; LVH=left 
ventricular hypertrophy; +ve = carries the variant; -ve= does not carry the variant; ICD= implantable cardioverter defibrillator. 
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2.3.8 Event-Free Survival  
 
To demonstrate the long-term impact of multiple rare variants (in the 8-gene 
panel) we used a Kaplan-Meier plot to assess event-free survival. Individuals with 
multiple rare variants in the 8-gene panel showed worse event-free survival from 
all cause death (not including SCD), cardiac arrest, cardiac transplantation and 
appropriate ICD events due to ventricular fibrillation over their lifetime compared 
to single variant patients (5/18 events versus 29/170 events, log-rank test 
p=0.008; Figure 2.9). There were 34 events in total. The number of events divided 
by single or multiple variant genotype are listed in Table 2.6  
 
 
Figure 2.9 Kaplan-Meier plot comparing event-free survival  
Figure legend: Survival from all cause death (not including SCD), cardiac 
transplant, cardiac arrest and appropriate ICD shock for ventricular fibrillation 
between single and multiple variant HCM patients (Log-Rank p=0.008). 
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Table 2.6 Major cardiovascular events and all cause death in single variant 
carriers versus multiple variant carriers (8-gene panel) 
Major cardiovascular events and all 
cause death 
Single variant carrier Multiple variant 
carrier  
n 29/170 5/18 
All cause death (not SCD) 3 0 
Sudden cardiac death 7 1 
Cardiac arrest (resuscitated) 6 1 
Cardiac transplantation 7 1 
Appropriate ICD shock for VF 6 2 
 
Abbreviations: SCD= sudden cardiac death; ICD= implantable cardioverter 
defibrillator; VF= ventricular fibrillation. 
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2.4 Discussion 
 
The results from this study have clinically significant implications for patients 
undergoing comprehensive genetic testing for HCM. In most cases, increasing 
the number of genes screened in the HCM proband does not increase the clinical 
utility of the test beyond the 8 major HCM genes. Although the incidence of 
‘multiple variant genotypes’ increases with increasing panel size, this is only 
clinically important for the patient when both variants are in the 8-gene panel. 
This is significant because current comprehensive genetic testing is more likely 
to identify rare variants. This increases the potential for multiple variant 
genotypes in any number of genes. This work will guide the clinical use of a 
comprehensive NGS approach to genetic testing for HCM patients and serves 
as a caution against the ‘more is better approach’ in the clinical setting. 
 
2.4.1 Multiple Variant Genotypes 
 
The landscape of genetic testing has changed in recent years, due largely to 
important advances in the technology itself. In a patient population that has 
undergone comprehensive genetic testing, at the time of publication we showed 
that no proband carries two pathogenic/likely pathogenic variants. However, 
since publication one family has been found to carry both a pathogenic and likely 
pathogenic variant. In spite of the very low incidence of two pathogenic/likely 
pathogenic variants we have shown the prevalence of multiple rare variants in 
important HCM genes (including pathogenic/likely pathogenic and VUS or VUS 
and VUS) is 4%. Two variants in important HCM genes are associated with 
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earlier disease onset, greater likelihood of a family history of SCD and overall 
worse event-free survival from all cause death (not including SCD), cardiac 
transplant and cardiac arrest. Importantly, this impact on phenotype was not 
observed when rare variants in less well-established genes were included in the 
analysis (beyond the 8-gene panel). This finding is clinically relevant, given we 
have shown 17% of probands have multiple variants identified using a 45-gene 
panel (Walsh et al., 2017a).  
 
Over 10 years ago, our group and others, reported experiences of multiple variant 
genotypes in HCM, noting occurrence in up to 5% with potential for increased 
disease severity (Richard et al., 1999, Richard et al., 2003, Ingles et al., 2005, 
Olivotto et al., 2008, Van Driest et al., 2004). At that time, there was an implicit 
understanding that both variants identified were causative. Since 2005, the 
landscape of HCM genetic testing has changed dramatically, and our approach 
to testing is now much broader. Because of this, our variant interpretation criteria 
require greater stringency to make causative assertions such as 
pathogenic/likely pathogenic. Typically, variants identified in sarcomere genes 
would have been considered causative if they fulfilled some basic criteria. In 
contrast, the latest guidelines for classifying variants written by the ACMG/AMP 
include many more criteria (Walsh et al., 2017a, Richards et al., 2015). 
Assessment of these often involves multidisciplinary input with a high-level of 
cardiac genetic expertise. Our finding of a much lower prevalence of multiple 
pathogenic/likely pathogenic variants when careful curation is applied provides 
important new data to this field. We show a marked increase in probands 
identified who have a VUS identified as a direct result of more comprehensive 
CHAPTER 2 – COMPREHENSIVE CARDIAC PANEL TESTING 
 113 
genetic testing. Indeed, more uncertain results were identified than clinically 
actionable results when 45 genes were sequenced.  
 
2.4.2 Clinical Impact of Multiple Variant Genotypes 
 
The occurrence of multiple causative variants is rare, especially using more 
stringent variant curation methods. A recent literature review identified one report 
of gene positive patients with two pathogenic/likely pathogenic variants in HCM 
genes was 0.4% (Fourey et al., 2017). When you define multiple variant 
genotypes to include VUS the identification of families carrying multiple rare 
variants in major HCM genes is 4% (including pathogenic/likely pathogenic and 
VUS). Despite variants having uncertain status, phenotype differences were 
observed between multiple and single variant patients when considering the 8-
gene HCM panel. These included younger age at disease onset, with multiple 
variant patients being on average 16 years younger at presentation. The existing 
literature supports this emerging hypothesis that double and compound variants 
may confer a gene dosage effect and increase disease severity in HCM (Maron 
et al., 2012a, Ingles et al., 2005, Kelly and Semsarian, 2009, Van Driest et al., 
2004). Wang et al. similarly reported a greater risk of cardiovascular death in 
multiple variant HCM patients. However, this was compared to both single and 
non-gene carrier patients (Wang et al., 2014).  
 
The publication by Fourey et al aimed to revisit the presence and clinical impact 
of multiple variants in HCM using an 8-gene HCM panel. Like our current work, 
they showed that with the inclusion of ACMG/AMP classification guidelines and 
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the use of a limited 8-gene panel, the incidence of two pathogenic/likely 
pathogenic variants was exceedingly rare at 0.4%. They conducted an extensive 
literature review and showed that of the previously reported multiple variant 
carriers (with both variants implied as disease-causing) only 5% would be 
classified as having two pathogenic/likely pathogenic variants under the current 
guidelines (Fourey et al., 2017). The authors suggested a revised prevalence of 
0.4% as shown in their original study. Calculating this prevalence from our data 
(one case with two pathogenic/likely pathogenic variants out of 224 HCM 
patients) we show the same incidence. Fourey et al also showed the clinical 
impact of multiple pathogenic/likely pathogenic variants resulted in earlier age of 
diagnosis but unlike our study did not report on overall survival or family history. 
The authors concluded there was insufficient evidence to guide clinical decision-
making in multiple variant carriers and that the use of multiple variants as a 
standalone risk factor is of concern (Fourey et al., 2017, Fatkin and Johnson, 
2017). 
 
To our knowledge, at the time the work in this Chapter was completed it was 
amongst the first to evaluate phenotype of multiple variant genotypes using a 
comprehensive panel (>8 genes). Importantly, we have shown the impact on 
clinical phenotype is only evident when using an 8-gene HCM panel and does 
not exist when using comprehensive panels. This is a realistic picture of the state 
of current clinical practice and is helpful in guiding clinical discussions with 
patients. In our cohort a positive family history of SCD was more common 
amongst patients with multiple variants, even after adjusting for family 
membership. Evaluation of the 14 pedigrees revealed that not all SCD cases 
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carried both variants. Therefore, when looking at SCD events in the patients 
themselves there were no differences between groups, suggesting multiple rare 
variants do no predispose to SCD in our population. 
 
2.4.3 Working Hypothesis 
 
A working hypothesis of the underlying genetics of multiple rare variants in 
sarcomere genes can be proposed based on our study. We suggest that a 
cumulative variant effect may lead to earlier age of disease onset and major 
cardiovascular events. Mouse models have been used to try and elucidate the 
wide variation of clinical outcomes caused by sarcomere and non-sarcomere 
mutations. One model showed that a common mutation, MYH7 p.Val606Met 
caused a mild HCM-related phenotype however in combination with other HCM 
mutations inferred more severe phenotypes in the mouse (Blankenburg et al., 
2014). Homozygous MYH7 p.Arg403Gln mice have been shown to develop 
severe dilated cardiomyopathy in the first week of life compared with 
heterozygous mice developing HCM later in life at 30-40 weeks (Fatkin et al., 
1999). In addition, while there are clear examples of single variants that cause 
severe phenotypes, overall, the clinical course for multiple sarcomere variant 
carriers appears to be more severe. Importantly, this was true even for variants 
not necessarily classified as causative. Whether the additional “second” 
uncertain variant is causative but lacking sufficient evidence to classify it as 
pathogenic or likely pathogenic, or it acts as a genetic modifier exerting a smaller 
effect in combination with another variant, remains to be determined. The 
proposed inverse relationship between variant effect size and rarity in the 
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population also lends weight to the latter hypothesis given we have shown there 
is an incrementally greater frequency of the additional “second” variants in ExAC 
(Manolio et al., 2009, McCarthy et al., 2008). Collectively, our data support a 
cumulative variant hypothesis, whereby multiple variants identified in key HCM 
genes contribute to earlier disease onset and worse survival from major 
cardiovascular events. A cumulative variant hypothesis is not a new one in 
cardiac genetics, and may explain some of the marked clinical heterogeneity that 
is characteristic of HCM (Bezzina et al., 2013). In addition, complex lifestyle and 
environmental interactions likely also play a role in the heterogeneity exhibited in 
HCM families (Ingles et al., 2017a). 
 
2.4.4 Genetic Counselling Implications 
 
The most important genetic counselling implications of these findings are the 
increased uncertainty and growing complexity of discussions required to 
communicate this information to families. With comprehensive genetic testing 
now mainstream, we demonstrate a high rate of VUS detection and in 17% there 
will be multiple variants identified. This raises an important question about 
whether we have tipped the scales to outweighing the obvious benefits of genetic 
testing (Ingles et al., 2015a).  
 
Our findings have important implications for cardiac genetic counselling of HCM 
families. First, we suggest HCM genetic testing in the first instance should be 
targeted to the 8 major HCM genes with addition of the established phenocopy 
genes (Table 2.2). These phenocopy genes include PRKAG2, LAMP2, GLA and 
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PLN (Alfares et al., 2015, Walsh et al., 2017a). Comprehensive panels should be 
considered in other circumstances, such as where a family has an atypical 
phenotype, which may point to other phenocopy or HCM-associated genes (e.g. 
DES, ACTN2). Alternatively, genetically elusive cases with a clear family history 
of disease, may be more suited to a comprehensive genetic testing approach, 
though would be ideally performed in a research setting.  
 
In a clinical setting, our findings suggest a cumulative variant effect may explain 
some clinical heterogeneity. Specifically, the identification of patients with 
multiple rare variants in major HCM genes gives rise to earlier onset disease and 
worse event-free survival from major cardiovascular events. This is true only for 
rare variants identified in the major HCM genes, but regardless of their 
classification. Though this may not change clinical management of the patient at 
present, it is important information for the treating clinician to consider in their 
discussion of risk. It is likely that inherited heart disease management may move 
towards incorporating genetic information to a greater extent in the future (Ho et 
al., 2018). It also highlights there should be careful selection of the proband to 
undergo initial HCM genetic testing ensuring all variants of interest are identified.  
 
Genetic counselling regarding risk of potential modifier (“second”) variants should 
be approached cautiously, given the marked uncertainty that segregation of 
these variants could cause to asymptomatic family members. Further, our data 
illustrate how the common practice of downgrading variants to likely 
benign/benign status due to co-occurrence with another causative variant may 
be inappropriate (Richards et al., 2015). Given our finding that these additional 
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“second” variants have some phenotype impact, we show very rare variants 
identified in sarcomere genes should be carefully reviewed.  
 
Study Limitations 
This study proposes a cumulative variant hypothesis whereby additional variants 
may impact on earlier disease onset and major cardiovascular events. However, 
the study methodology does not allow for further exploration of the potential 
mechanisms for this hypothesis to hold true. Additionally, no control or 
comparison group was examined to compare the frequency of rare variation in 
controls without HCM. Finally, the patient cohort was comprised of individuals 
attending a specialised clinic and may represent a more severe clinical course. 
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2.5 Conclusions 
 
We have shown that HCM patients with multiple causative variants are 
exceedingly rare in the setting of stringent variant curation approaches. 
Identification of patients with multiple rare variants in the 8 major HCM genes, 
whether pathogenic/likely pathogenic or VUS, has clinical implications and may 
contribute to a cumulative variant effect leading to earlier disease onset and 
worse survival from major cardiac events. Marked increase in VUS identification 
occurs when comprehensive cardiomyopathy gene panels are used, with no 
clinical benefit and should be avoided where possible to ensure the overall value 
of HCM genetic testing is maintained. Given the nuances of genetic inheritance 
in these families, multidisciplinary care in specialist centres is essential to provide 
the best possible outcomes for families with HCM. 
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3 Truncating Variants in the Desmoplakin Gene 
 
3.1 Introduction 
 
This Chapter aims to comprehensively elucidate the phenotypic impact of 
truncating variants in the desmoplakin (DSP) gene. As outlined in Chapter 1, 
increasingly, patients undergo comprehensive genetic testing and the clinical 
utility of this relies on expert interpretation of the genetic variants identified. 
Desmoplakin is a desmosomal protein involved in the structural integrity of cells 
via assembly of desmosomes and cytoskeletal linkage. Variants in this gene have 
been established as a cause of arrhythmogenic right ventricular cardiomyopathy 
(ARVC), though there are challenges in distinguishing which variants are 
causative and the resulting phenotype. In this study, we sought to investigate for 
the first time, the clinical impact of truncating variants in the desmoplakin gene in 
a large multi-centre international cohort. 
 
Truncating variants in DSP are known to cause ARVC with limited case reports 
demonstrating a dilated cardiomyopathy (DCM) phenotype. However, genotype-
phenotype correlations remain largely unknown. Literature reports of DSP 
variants suggest this specific cardiomyopathy is highly penetrant, with primarily 
left ventricular involvement and a propensity for arrhythmias (Castelletti et al., 
2017, Lopez-Ayala et al., 2014, Navarro-Manchon et al., 2011). Therefore, the 
phenotypic overlap between ARVC and DCM makes it diagnostically challenging 
for the clinician. Without large case series, the natural history and clinical course 
of DSP cardiomyopathy and whether it should be considered distinct from ARVC 
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or DCM remains largely elusive (Lopez-Ayala et al., 2014, Navarro-Manchon et 
al., 2011).  
 
To illustrate the clinical impact of this uncertainty, a case from 2015 is described 
below. At a monthly multidisciplinary meeting aimed at bringing together 
expertise in the field of genetics, cardiology and inherited heart disease, a female 
proband was presented. She had died suddenly at the age of 33 years, and a 
truncating variant in DSP was identified: DSP (NM_004415.2: c.478C>T; 
p.Arg160Ter). The cause of death at postmortem was considered “likely ARVC” 
with histological examination revealing a band-like zone of fatty infiltrate, but a 
diagnosis of DCM could not be excluded. Regarding her family history, one living 
sister was found to carry the DSP truncation and had a diagnosis of DCM with a 
reduced ejection fraction (EF) of 35%. Their mother had normal clinical 
investigations but was also found to carry the DSP truncation (Figure 3.1). When 
classifying the variant, at the time there was insufficient evidence from the 
literature to support a gene-disease association for the mixed phenotype of DCM 
and ARVC and truncating DSP variants. As a result, the variant was classified as 
uncertain and was unable to be used in family management. While new data 
support the family presentation as consistent with the emerging phenotype 
spectrum termed ‘arrhythmogenic cardiomyopathy’ (ACM), this highlights the 
need to expand the phenotype associated with truncating variants in DSP. Much 
of the data on DSP truncations has evolved from large ARVC cohorts (Bhonsale 
et al., 2015, Groeneweg et al., 2015, Kapplinger et al., 2011).   
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Figure 3.1 Clinical presentation of family found to carry truncating variant in desmoplakin (DSP) 
Figure legend: Family presented within the multidisciplinary meeting. The proband presented with sudden cardiac death. 
Abbreviations: +/- =individual is heterozygous for familial DSP variant. That is, one copy of their DSP gene carries the variant and 
one copy does not; ?/?= unknown genetic status; d.33 years= died aged 33 years; Dx= diagnosis; PM COD= postmortem cause of 
death; Echo= echocardiogram; SCD= sudden cardiac death; ARVC = arrhythmogenic right ventricular cardiomyopathy; DCM= dilated 
cardiomyopathy; ICD= implantable cardioverter defibrillator; DSP= desmoplakin; LV= left ventricle; LVEF= left ventricular ejection 
fraction; MVA= motor vehicle accident; COD= cause of death.  
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3.1.1 Arrhythmogenic Right Ventricular Cardiomyopathy 
 
ARVC is characterised by progressive loss and fibrofatty replacement of the 
ventricular myocardium (Figure 3.2, Panel A,B) (Corrado et al., 2017, Hoorntje et 
al., 2017). Phenotype characterisation of ARVC remains a challenge. Diagnosis 
of ARVC was previously based upon the identification of localised myocyte loss 
and fibrofatty replacement of the right ventricle only, however, diffuse and left 
ventricular involvement is increasingly recognised (Corrado et al., 2017, Estes, 
2009, Sen-Chowdhry et al., 2007). Current diagnosis relies on classification 
using International Task Force Criteria which includes characteristic 
electrocardiogram abnormalities (inverted t waves, epsilon waves, late 
potentials), arrhythmic, structural and/or histological abnormalities as well as 
family history information (Marcus et al., 2010b). It is now generally accepted 
there is a variable clinical course of disease which can involve a pre-clinical 
phase, overt arrhythmogenic manifestations and ventricular or biventricular 
failure (Calkins et al., 2017). In fact, with the growing recognition of the diverse 
spectrum of the ARVC phenotype there is now a move to consider the many sub-
types of the disease as ACM (Bennett et al., 2018).  
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Figure 3.2 Histopathological features and pathogenesis of arrhythmogenic 
right ventricular cardiomyopathy (ARVC) [from (Corrado et al., 2017)] 
A. Histological section of the right ventricular wall in a normal heart 
B. Right ventricular wall of a patient who died with ARVC. Myocytes appear red 
fibrous tissue appears blue and fatty tissue appears white 
C. The three major components of the desmosome: desmoplakin (which binds to 
intermediate filaments; transmembrane proteins (including desmocollin 2 and 
desmoglein 2) and linker proteins (including plakoglobin and plakophilin 2) 
D. Abnormal desmosomal proteins leading to disruption of the intercellular 
junction and myocyte detachment and death.  
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3.1.2 Desmoplakin 
 
DSP is a plakin family desmosomal protein that anchors to intermediate filaments 
such as desmin in the heart (Corrado et al., 2011, Corrado et al., 2017, Patel and 
Calkins, 2010) (Figure 3.3). Myocardial biopsy samples from patients with ARVC 
have shown intercalated disk abnormalities and loss of desmosomes (La Gerche 
et al., 2011) supporting the theory that abnormal desmosomes lead to disruption 
of intercellular junctions, myocyte detachment and cell death (Figure 3.2, Panel 
C, D) (Corrado et al., 2017). Variants in genes that encode the major 
desmosomal proteins have been found to account for 30-70% of ARVC cases 
and more than 50% of causative variants are attributed to five genes, including 
plakophilin 2 (PKP2), DSP, desmoglein 2 (DSG2) desmocollin 2 (DSC2) and 
plakoglobin (JUP) as listed in Table 3.1 (Ackerman et al., 2012, Gandjbakhch et 
al., 2018). In addition, nondesmosomal genes, most notably transmembrane 
protein 43 (TMEM43) and phospholamban (PLN) may account for up to 12% of 
cases (Groeneweg et al., 2015). The c.40_42delAGA PLN variant is an 
established founder variant in Dutch patients and the TMEM43 c.1073C>T 
variant is an established founder variant in Newfoundland (Gandjbakhch et al., 
2018, Merner et al., 2008, van der Zwaag et al., 2012).  
 
More recently, evidence for variants in alpha-t-catenin (CTNNA3), n-cadherin 
(CHD2), ryanodine receptor 2 (RYR2), sodium voltage-gated channel alpha 
subunit-5 (SCN5A,) desmin (DES) and lamin A/C (LMNA) have been linked to 
ACM more broadly, though the evidence regarding pathogenesis for these genes 
is still emerging and not clear (Gandjbakhch et al., 2018). Autosomal recessive 
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and syndromic forms of ARVC do exist, for example Carvajal syndrome is an 
autosomal recessive form of disease due to compound heterozygous variants in 
DSP with characteristic phenotypic features including woolly hair, palmoplantar 
keratoderma and ARVC (Carvajal-Huerta, 1998, Keller et al., 2012). However, 
desmosomal variants are most often inherited as an autosomal dominant trait 
with DSP the first gene to be associated with the ‘classic’ autosomal dominant 
form of disease (Rampazzo et al., 2002). The majority of ARVC genetics 
literature comes from patients carrying PKP2 variants with fewer studies 
assessing DSP and its clinical impact (Calkins et al., 2017). 
 
DSP has two isoforms produced by alternate splicing (DSP1 and DSP2). DSP1 
is thought to be the dominant cardiac isoform, with historic reports in the literature 
that DSP2 is not expressed in the heart (O'Keefe et al., 1989, Uzumcu et al., 
2006, Angst et al., 1990). There is evidence however, that specific components 
of heart muscle have detectable DSP2 expression (Uzumcu et al., 2006).  
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Table 3.1 Primary genes associated with arrhythmogenic right ventricular 
cardiomyopathy (ARVC) [adapted from (Ackerman et al., 2012, 
Gandjbakhch et al., 2018)]  
Gene Locus Protein % of disease 
PKP2 12p11 Plakophilin 2 25%-40% 
DSG2 18q12.1 Desmoglein 2 5%-10% 
DSP 6p24 Desmoplakin 2%- 12% 
DSC2 18q12.1 Desmocollin 2 2%-7% 
JUP 17q21.2 Plakoglobin < 5% 
PLN 6q22.31 Phospholamban 0-12% (Netherlands) 
CDH2 18q12.1 N-cadherin 2 ~2% 
TMEM43 3p25.1 Transmembrane 
protein 43 
<1% 
CTNNA3 10q21.3 Alpha-T-catenin < 1% 
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Figure 3.3 Architectural unit of the desmosome [from (Al-Jassar et al., 
2013)] 
Figure legend: The interaction of DSP in the desmosome. Key functional domains 
include N-terminal, central fibrous rod domain and C-terminal of DSP.  
 
3.1.3 Genetic and Phenotypic Overlap Between Arrhythmogenic Right 
Ventricular Cardiomyopathy and Dilated Cardiomyopathy 
 
There is both genetic and clinical overlap between DCM and ARVC. DCM is a 
progressive cardiomyopathy characterised by dilatation and impaired contraction 
of the left and in some cases right ventricle (Fatkin, 2012). DCM patients typically 
present with symptoms related to heart failure and arrhythmia (Fatkin, 2011). 
There are a number of underlying causes of DCM, with primary familial DCM 
accounting for approximately 30% of cases (Fatkin et al., 2014). The underlying 
genetics of DCM remains largely unexplained with over 30 genes implicated and 
a genetic test yield most commonly quoted of less than 30% (Ackerman et al., 
2012, Bozkurt et al., 2016, Fatkin, 2011, Fu and Eisen, 2018). Typically, genetic 
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testing is indicated in patients with clearly familial disease (i.e. ³ 2 affected in 
family) or in those with conduction system disease or a clearly arrhythmic 
phenotype (Minoche et al., 2018, Ackerman et al., 2012). 
 
Due to the phenotype overlap between ARVC and DCM, patients with left 
dominant ARVC have been reported in the literature misdiagnosed as DCM 
(Basso et al., 1996, Lopez-Ayala et al., 2014). It has been proposed, rather than 
being distinct clinical entities, left dominant ARVC and a DCM phenotype is better 
described as ACM (Lopez-Ayala et al., 2014, Elliott et al., 2010, Garcia-Pavia et 
al., 2011, Gray and Behr, 2016).  
 
There is limited information regarding the phenotypic expression associated with 
DSP variants, particularly beyond ‘classic ARVC’ cohorts. Based on the 
heterogeneous expression of truncating variants in DSP and lack of available 
data, we sought to characterise the clinical and genetic features of the largest 
case series of international families to date. Specifically, we aimed to; 
1. Investigate the phenotypic characteristics of truncating variants in DSP; 
2. Classify the truncating variants in DSP according to recent criteria; and 
3. Compare the location of truncating variants in DSP in cases versus controls to 
assess whether there are important gene regions.  
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3.2 Methods 
 
3.2.1 Participants 
 
An international cohort of probands shown to have truncating variants in DSP 
was assembled. Members of the Australian Cardiac Genetic Testing network 
(ACGT) were invited to contribute probands with a truncating variant in DSP.  The 
ACGT network includes cardiac genetic professionals throughout Australia. This 
network includes >90 clinicians, scientists, genetic counsellors and commercial 
testing centres, working towards a standardised cardiac genetic testing pathway. 
Members were contacted from July 2016 and invited to contribute cases until 
August 2018. The proband was defined as the first affected in the family who 
underwent genetic testing with a truncating variant in DSP identified. Cases from 
international colleagues were also sought via our collaborative networks. Patient 
data were submitted from the Stanford Inherited Diseases Group, California 
USA; the Royal Brompton Hospital clinics, London UK; and the Academic 
Medical Centre, Amsterdam. All aspects of the study were performed according 
to institutional human research ethics committee approval (X15-0112 and 
LNR/15/RPAH/147). 
 
3.2.2 Eligibility Criteria 
 
The definition of truncating variants included any variant that was likely to reduce 
or abolish the DSP protein compared with the wildtype allele. Variant types 
included in this definition were frameshift, splice, nonsense and insertion or 
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deletion variants. All variant nomenclature adhered to the Human Genome 
Variation Society sequence variant nomenclature recommendations (den 
Dunnen et al., 2016). A frameshift variant was defined as a deletion, duplication 
or insertion involving a number of base pairs not divisible by three and therefore 
disrupting the triplet reading frame of the normal protein product. Splice variants 
were defined as variants affecting the donor and acceptor splice regions (±1, 2, 
3, 4, 5) between the intron and exon boundary with the potential to disrupt 
messenger ribonucleic acid (RNA) and alter the protein product. Nonsense 
variants were defined as a premature stop codon being introduced. Deletions 
and insertions were defined as a sequence change whereby one or more 
nucleotide was not present when compared with a reference standard and 
resulting in disruption to the reading frame leading to a premature truncation. 
Probands were included irrelevant of cardiac phenotype if they carried one of the 
variants described above. There was no age limit on inclusion and both deceased 
and living probands were included in the cohort. 
 
3.2.3 Genetic Analysis 
 
Genetic testing was performed by the referring institution. This included both 
clinical grade sequencing by commercial testing laboratories or research genetic 
testing as described in Chapter 2 (Burns et al., 2017a). The technologies used 
included exome sequencing, Sanger sequencing of a targeted gene panel, and 
a comprehensive cardiac gene panel approach. 
 
Genetic variants included were sought from three sources; 
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1. Disease variants identified in the international disease cohorts; 
2. Variants submitted to ClinVar by submitters with a review status of one- star 
and above, that were classified as pathogenic or likely pathogenic (Landrum et 
al., 2016) (Queried on 5th October 2018); and 
3. Truncating DSP variants listed in the genome aggregation database (gnomAD, 
http://gnomad.broadinstitute.org/). This database contains over 120,000 exome 
sequences from unrelated disease specific cohorts (Queried on the 5th October 
2018). 
 
3.2.4 Gene Domain Analysis 
 
On the basis of the identification of key binding and functional domains, we 
investigated whether disease variants identified in our cohort localised to a 
specific domain when compared with control variants. As depicted in Figure 3.3, 
broadly speaking DSP has three known functional domains. The N-terminal of 
DSP containing alpha helical bundles that are predicted to interact with 
plakophilin and plakoglobin, the central fibrous rod domain containing recognition 
sites and a coiled coil and the C-terminal containing plectin repeats for binding 
with intermediate filaments, mainly desmin (Kapplinger et al., 2011, The UniProt, 
2017, Sen-Chowdhry et al., 2007). Using the UniProt database of protein 
sequences we categorised variants as falling into one of three domains, which 
encapsulated the functional regions described above. These included globular 1 
(G1) incorporating amino acid position 1-1056, central fibrous rod domain (CR), 
incorporating amino acid position 1057-1945 and globular 2 (G2) incorporating 
amino acid position 1946-2871. 
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3.2.5 Variant Classification 
 
Disease variants were classified using the American College of Medical Genetics 
and Genomics and Association for Molecular Pathology (ACMG/AMP) criteria for 
variant classification (Richards et al., 2015). This uses a number of strong, 
supportive and moderate level evidence to classify variants into five categories 
including pathogenic, likely pathogenic, variant of uncertain significance (VUS), 
likely benign and benign. Key determinants of pathogenicity include rarity in the 
general population (allele frequency of less than 0.1% from gnomAD) previous 
reports of study variants in phenotypically affected probands, segregation data 
amongst families and robust experimental data. The ACMG/AMP criteria 
includes a very strong evidence category (PVS1) , which can be used in certain 
genes where loss of function is a known and established mechanism of disease.  
 
Recent work by the NIH-funded Clinical Genome Resource (ClinGen), published 
recommendations for when PVS1 criteria can be used (Abou Tayoun et al., 
2018). These recommendations include addressing variant specific 
considerations by use of a decision-tree dependent on variant type and variant 
features (Abou Tayoun et al., 2018). This variant tree relies on the assumption 
that loss of function is a known mechanism of disease, however establishing this 
is more challenging.  
 
There are a number of factors to take into consideration regarding DSP and loss 
of function. A null mouse model was created which shows embryonic lethality 
and cardiac specific deletion of DSP (Gallicano et al., 1998, Garcia-Gras et al., 
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2006). The phenotype includes fibrosis, myocyte apoptosis, cardiac dysfunction 
and arrhythmias suggestive of an ARVC phenotype (Gallicano et al., 1998, 
Garcia-Gras et al., 2006). In addition, the Exome Aggregation Consortium 
(ExAC) (http://exac.broadinstitute.org/) provides a score that indicates the 
probability a gene is intolerant to loss of function (pLI). The pLI were calculated 
using >60,000 exomes, comparing the number of rare variants per gene to an 
expected number (Lek et al., 2016). Specifically, if the pLI is closer to 1, then the 
gene is considered more intolerant to loss of function variants. The pLI of DSP is 
1; suggesting DSP is extremely intolerant to loss of function. Finally, there are a 
number of pathogenic/likely pathogenic loss of function variants submitted to 
ClinVar for clinical testing by submitters with a review status of at least one star, 
suggesting an excess of loss of function variants in cases. Collectively, these 
data suggest loss of function of DSP is a plausible disease mechanism with at 
least a moderate level of evidence (Abou Tayoun et al., 2018).  
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3.2.6 Clinical Assessment 
 
Clinical cases included in the analyses were restricted to probands obtained from 
the ACGT network, Stanford Inherited Diseases Group, California USA; and the 
Royal Brompton Hospital clinics, London UK. Cases from the Academic Medical 
Centre, Amsterdam were not included in the clinical component of this analysis 
due to insufficient data at the time of thesis submission (Figure 3.4). Clinical 
information was obtained by review of the medical record and cardiac 
investigations obtained from the referring institution. Effort was made to obtain 
and review the genetic result, echocardiogram, electrocardiogram (ECG), 
cardiac magnetic resonance imaging (CMR), three-generation pedigree, 
postmortem report and correspondence from the treating geneticist and/or 
cardiologist.  
 
Diagnoses were recorded by the referring institution and included ARVC, DCM, 
Carvajal syndrome, ACM and unexplained ventricular fibrillation. A sudden 
cardiac death (SCD) event included sudden death, resuscitated cardiac arrest or 
appropriate ICD shock for ventricular fibrillation or very fast ventricular 
tachycardia. SCD as first presentation was defined as sudden death in an 
otherwise healthy individual within 1 hour after the onset of symptoms, or when 
unwitnessed, within 24 hours after the individual was last seen in good health 
(Bagnall et al., 2016, Evequoz et al., 1996). Family history of SCD was defined 
as a suspicious death in a first-degree relative aged less than 40 years. Clinical 
investigations including CMR, ECG and echocardiogram were reviewed by at 
least one cardiologist at each referring institution. All CMR volumes were indexed 
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for body surface area. Left ventricular dysfunction was defined as EF below 55%. 
Detection of cardiac myocardial fibrosis and scar was measured using the 
presence of late gadolinium enhancement on CMR. Endpoint for survival 
analysis was censored at first SCD event, death or current age for those who had 
not experienced a SCD event. 
 
3.2.7 Statistical Analysis 
 
Data were analysed using Prism (version 7.0) and SPSS Statistics (version 23.0). 
Chi square analysis was used to assess associations between variant location 
and clinical outcomes in cases versus controls. A Kaplan-Meier plot with log-rank 
tests for significance was used to assess event-free survival (SCD event, first 
event only) between patients with variants in the G1 versus other domains.  
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3.3 Results 
 
3.3.1 Genetic Analysis 
 
We identified 98 probands who carried a truncating variant in DSP (Figure 3.4). 
Of these, there were 68 unique truncating variants (Table 3.2). Two probands 
were compound heterozygous for a common truncating variant in DSP and both 
had a diagnosis of Carvajal syndrome. Excluding these compound heterozygous 
probands, there were 34 probands with >1 variant (DSP plus other gene) listed 
by the referring clinician. The study team did not classify the second variants but 
all were determined to be a VUS by the referring institutions. 
 
3.3.2 Genetic Variants 
 
We identified a total of 68 unique truncating DSP variants (Table 3.2). There were 
29 frameshift, 25 nonsense, 12 splice site and two insertion/deletions. Using the 
ACMG/AMP classification criteria, and using PVS1, five variants were classified 
as pathogenic and 62 were classified as likely pathogenic. One variant seen in 
both Carvajal syndrome probands had an allele frequency of 78, therefore was 
initially classified as a VUS. However, given Carvajal syndrome is an autosomal 
recessive form of the disease, less stringent frequency thresholds apply and it is 
likely this variant is causative in these probands. 
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Figure 3.4 Flowchart of study probands 
Figure legend: Panel A: cohort of probands included in analysis of genetic characteristics. Panel B: cohort of probands included in 
analysis of clinical characteristics. 
Abbreviations: gnomAD= genome aggregation database; ACGT= Australian Cardiac Genetic Testing network; ARVC= 
arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; DSP= desmoplakin. 
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Table 3.2 Truncating variants in desmoplakin (DSP)  
Genomic location 
(GRCh37/hg19) 
 
Likely coding 
effect 
HGVS nomenclature 
(DNA) 
 
HGVS nomenclature 
(Protein) 
 
Domain 
 
Published 
 
gnomAD 
count 
Referring 
clinical 
diagnosis 
ACMG/AMP 
criteria 
g.7542225_7542228dup 
 
Frameshift c.77_80dup p.Tyr28Alafs*66 
 
G1 N 
 
0 *Carvajal 
syndrome 
(heterozygous) 
Likely 
pathogenic 
PVS1, PM2 
g.7542233G>T Nonsense c.85G>T p.Glu29* G1 N 0 HCM Likely 
pathogenic 
PVS1, PM2 
g.7542266del Frameshift c.118del p.Met40Cysfs*8 G1 N 0 Case 1:DCM 
Case 2:HCM 
Likely 
pathogenic 
PVS1, PM2 
g.7555976C>T Nonsense c.196C>T p.Gln66* G1 N 0 CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7556030C>T Nonsense c.250C>T p.Arg84* G1 Y 0 CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7556058G>A 
 
? Splicing c.273+5G>A r.spl? 
 
G1 Y 
 
78 Case 1/2: 
*Carvajal 
syndrome 
(heterozygous) 
Autosomal 
recessive 
variant 
g.7559484C>T 
 
Nonsense c.448C>T p.Arg150* 
 
G1 N 
 
0 DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7559514C>T Nonsense c.478C>T p.Arg160* 
 
G1 Y 
 
0 Case 1/2: 
DCM 
Pathogenic 
PVS1, PM2, 
PM7 
g.7562888del Deletion c.601_?8559 p.? G1 N 0 ARVC Likely 
pathogenic 
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PVS1, PM2 
g.7562894_7562895insT Frameshift c.607_608insT p.Asp203Valfs*17 G1 N 0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7563990dup Frameshift c.748dup p.Gln250Profs*7 G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7565622C>T Nonsense c.808C>T p.Arg270* G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7565686_7565687dup Frameshift c.872_873dup p.Glu292Argfs*26 G1 N 0 Cardiocutaeno
us 
 
Likely 
pathogenic 
PVS1, PM2 
g.7565754G>A ? Splicing c.939+1G>A r.spl? 
 
G1 Y 1 Case 1: DCM 
Case 2: CM 
unspecified 
Case 3: DCM 
Pathogenic 
PVS1, PM2, 
PM7 
 
g.7566609G>C ? Splicing c.940-1G>C r.spl? 
 
G1 N 0 Cardiocutaeno
us 
 
Likely 
pathogenic 
PVS1, PM2 
g.7566715G>A ? Splicing c.1044+1G>T r.spl? 
 
G1 N 0 Case 
1,2,3,4:DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7567602_7567603del Frameshift c.1060_1061del p.Leu354Alafs*15 G1 N 0 Case1: ARVC 
Case 
2:ARVC/DCM 
Case3: ARVC 
Case 4: 
Unknown 
Likely 
pathogenic 
PVS1, PM2 
g.7568019dup Nonsense c.1146dup p.Glu383* G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7568140G>T ? Splicing c.1266+1G>T r.spl? 
 
G1 N 0 Case 1: DCM 
Case 2: ARVC 
Case 3: DCM 
Likely 
pathogenic 
PVS1, PM2 
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g.7569576_7569579del ? Splicing c.1574+3_1574+6del r.spl? 
 
G1 N 
 
0 ACM Likely 
pathogenic 
PVS1, PM2 
g.7571619A>T Nonsense c.1705A>T p.Lys569* G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7571742_7571754del Frameshift c.1828_1840del p.Ser610Metfs*22 
 
G1 N 
 
0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7571787C>T Nonsense c.1873C>T p.Gln625* 
 
G1 Y 
 
0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7571818G>T ? Splicing c.1903+1G>T r.spl? 
 
G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7572073A>G ? Splicing c.1904-2A>G r.spl? 
 
G1 N 0 CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7574319_7574320del Frameshift c.2131_2132del p.Ser711Cysfs*4 G1 Y 0 DCM Pathogenic 
PVS1, PM2, 
PM7 
g.7574367_7574368insTT Frameshift c.2179_2180insTT p.Lys727Ilefs*39 G1 N 0 Cardiocutaeno
us 
Likely 
pathogenic 
PVS1, PM2 
g.7574464_7574465insA Frameshift c.2276_2277insA p.Thr760Tyrfs*7 
 
G1 N 
 
0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7574487T>A ? Splicing c.2297+2T>A r.spl? G1 N 0 Case 1: CM 
Unspecified 
Case 2/3: 
DCM 
Case 4: CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7575542_7575548del Frameshift c.2451_2455del p.Asp81Glufs*32 G1 N 0 Cardiocutaeno
us 
Likely 
pathogenic 
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PVS1, PM2 
g.7576526G>C 
 
? Splicing c.2631_1G>C r.spl? 
 
G1 N 
 
0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7576525A>C ? Splicing c.2631-2A>C r.spl? 
 
G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g. 7576533G>A Nonsense c.2637G>A p.Trp879* G1 N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7576534dup 
 
Frameshift c.2638dup p.Asp880Glyfs*14 
 
G1 N 
 
0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7578760_7578761dup 
 
Frameshift c.3049_3050dup p.Leu1017Phefs*2 G1 Y 
 
0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7578796G>A ? Splicing c.3084+1G>A r.spl? 
 
G1 N 0 NCCM Likely 
pathogenic 
PVS1, PM2 
g.7579556C>T 
 
Nonsense c.3133C>T p.Arg1045* 
 
G1 Y 
 
0 Case 1: ARVC 
Case 2/3: 
DCM 
Likely 
pathogenic 
PVS1, PM2 
g.7579760C>T Nonsense c.3337C>T p.Arg1113* CR Y 0 Cardiocutaeno
us 
Pathogenic 
PVS1, PM2, 
PM7 
g.7579806_7579807del Frameshift c.3383_3384del p.Val1128Glyfs*5 CR N 0 CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7579888G>A Nonsense c.3465G>A p.Trp1155* CR N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7580032_7580033delins
AG 
Deletion/Inserti
on 
c.3609_3610delinsAG p.Met1203_Ser1204d
elinsIleGly 
CR N 0 DCM Likely 
pathogenic 
PVS1, PM2 
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g.7580102C>T 
 
Nonsense c.3679C>T p.Gln1227* 
 
CR N 
 
0 Case 1/2: 
ARVC 
Case 3: DCM 
Likely 
pathogenic 
PVS1, PM2 
g.7580162C>T 
 
Nonsense c.3739C>T p.Arg1247* 
 
CR N 
 
1 DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7580216G>T 
 
Nonsense c.3793G>T p.Glu1265* 
 
CR Y 
 
0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7580222C>T Nonsense c.3799C>T p.Arg1267* CR Y 0 VA Likely 
pathogenic 
PVS1, PM2 
g.7580603C>T Nonsense c.4180C>T p.Gln1394* CR Y 1 DCM Likely 
pathogenic 
PVS1, PM2 
g.7580818T>G Nonsense c.4395T>G p.Tyr1465* CR Y 0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7580846del Frameshift c.4423delA p.Thr1475Profs*9 CR N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7580900G>T 
 
Nonsense c.4477G>T p.Glu1493* 
 
CR N 
 
0 Case1: ARVC 
Case 2: DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.75781031_7581035del Frameshift c.4608_4612del p.Arg1537Glufs*5 CR N 0 Case 1/2/3: 
DCM 
Case 4: CM 
Unspecified 
Case 5: DCM 
Likely 
pathogenic 
PVS1, PM2 
g.7581134C>T 
 
Nonsense c.4711C>T p.Gln1571* 
 
CR N 
 
0 DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7581220del 
 
Frameshift c.4797delA p.Gly1600Alafs*2 
 
CR N 
 
0 Case 1: DCM 
 
Likely 
pathogenic 
PVS1, PM2 
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g.7581553dup Frameshift c.5130dup p.Glu1711Argfs*23 CR N 0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7581631_7581632del Frameshift c.5208_5209del p.Gly1737Thrfs*7 CR N 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7582914C>T Nonsense c.5419C>T p.Gln1807* CR N 0 Case 1: ARVC 
Case 2: ARVC 
Likely 
pathogenic 
PVS1, PM2 
g.7582955dup Frameshift c.5460dup p.Val1821Serfs*15 CR Y 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7583295C>T Nonsense c.5800C>T p.Arg1934* CR Y 0 DCM Likely 
pathogenic 
PVS1, PM2 
g.7583346C>T 
 
Nonsense c.5851C>T p.Arg1951* 
 
G2 Y 
 
0 ARVC Pathogenic 
PVS1, PM2, 
PM7 
g.7583831del Frameshift c.6336del p.Asn2114Lefs*2 G2 N 0 Case 1/2/3/4: 
DCM 
Case 5: CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7583951dup Frameshift c.6456dup p.Leu2153Alafs*3 G2 Y 0 ARVC Likely 
pathogenic 
PVS1, PM2 
g.7584001_7584002insTA
GATAGTCA 
 
Frameshift c.6506_6507insTAGAT
AGTCA 
p.Gln2169Hisfs*3 
 
G2 N 
 
0 DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7584182del Frameshift c.6687del p.Arg2229Serfs*32 G2 N 0 *Carvajal 
syndrome 
(heterozygous) 
Likely 
pathogenic 
PVS1, PM2 
g.7584345C>T Nonsense c.6850C>T p.Arg2284* G2 Y 0 ARVC Likely 
pathogenic 
PVS1, PM2 
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Abbreviations: G1= globular 1; CR = central fibrous rod domain; G2= globular 2; HCM= hypertrophic cardiomyopathy; DCM= dilated 
cardiomyopathy; CM= cardiomyopathy; ARVC= arrhythmogenic right ventricular cardiomyopathy; NCCM= non-compaction 
cardiomyopathy; VA= ventricular arrhythmias; VF= ventricular fibrillation; PVS1= pathogenicity very strong i.e. very strong supportive 
evidence that a variant is disease-causing; PM2/7= pathogenicity moderate i.e. moderate level of evidence that a variant is disease-
causing.  
Note: This table includes variants contributed by the Academic Medical Centre, Amsterdam. These cases were not included in the 
clinical analysis presented in this thesis.
g.7584591_7584598del 
 
Frameshift c.7096_7103del p.Leu2367Serfs*10 
 
G2 N 0 DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7585065_7585068del Frameshift c.7570_7573del p.Thr2524Argfs*11 G2 Y 0 CM 
unspecified 
Likely 
pathogenic 
PVS1, PM2 
g.7585268_7585271del Frameshift c.7773_7776del 
 
p.Ser2591Argfs*11 G2 N 11 Case 1/2: 
DCM 
 
Likely 
pathogenic 
PVS1, PM2 
g.7585572_7585575del 
 
Frameshift c.8077_8080del p.Lys2693Profs*3 
 
G2 Y 0 Case 1: DCM 
Case 2: VF 
arrest 
Likely 
pathogenic 
PVS1, PM2 
g.7585683del Frameshift c.8188del p.Gln2730Serfs*16 G2 Y 0 DCM Likely 
pathogenic 
PVS1, PM2 
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3.3.3 Genetic Variants by Key Functional Domain 
 
On the basis of the identification of key binding and functional domains, we 
investigated whether case and control variants localised to specific domains. 
There were n = 68 truncating variants identified in cases compared to n= 120 
truncating control variants identified in gnomAD. A schematic linear topology of 
DSP was created to visualise the localisation of the variants (Figure 3.5).  
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Figure 3.5 Linear topology schematic showing the 24 exons of desmoplakin (DSP) with the 2871 amino acid positions 
Figure legend: Sixty-eight unique case variants are shown in orange and 120 control variants in green. Key functional and binding 
domains are shown below including globular 1, which interacts with plakophilin and plakoglobin, the central fibrous rod domain 
containing the coiled coil and globular 2 containing plectin repeats (PR) which bind with intermediate filaments, particularly desmin. 
Abbreviations: N= N-terminal: C= C-terminal. 
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To investigate localisation of variants further, we examined whether case variants 
were statistically more common than control variants by functional domain. For 
these analysis case counts were used and pathogenic and likely pathogenic 
variants submitted to ClinVar were also included (n=168 cases from ClinVar), 
giving a total of 266 cases and 120 control variants. Each variant was allocated 
as residing in globular 1, central fibrous rod domain or globular 2 (Table 3.3). 
Case variants were significantly more likely to occur in the globular 1 domain and 
less likely to occur in globular 2 (134 [50%] versus 44 [17%], p< 0.0001) (Figure 
3.6). 
 
Table 3.3 Case and control variants by functional domain 
 Globular 1 Central fibrous 
rod domain 
Globular 2 Total 
Cases (%) 134 (50) 88 (33) 44 (17) 266 
Controls (%) 25 (21) 35 (29) 60 (50) 120 
Total 159 123 104 386 
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Figure 3.6 Case versus control variants by functional domain of 
desmoplakin (DSP) 
Figure legend: Percentage of case versus control variants by functional domain. 
Abbreviations: G1= globular 1; CR= central fibrous rod domain; G2= globular 2. 
  
G1 CR G2
0
20
40
60
80
100
Functional domain
N
um
be
r o
f v
ar
ia
nt
s 
(%
)
Cases
Controls
p< 0.0001
CHAPTER 3 – TRUNCATING VARIANTS IN THE DESMOPLAKIN GENE  
 151 
3.3.4 Event-Free Survival by Functional Domain 
 
To demonstrate the impact of DSP truncating variants by functional domain on 
clinical course amongst our clinical cases we used a Kaplan-Meier plot to assess 
event-free survival from SCD events. There were 33 events in total. Data were 
missing from two study probands. By sub-grouping the variants into G1, CR and 
G2 regions, there was a difference in event-free survival. This appears to be due 
to the favourable outcomes in those with G2 variants (20/52 versus 12/27 versus 
1/17 events, log-rank test p=0.016, Figure 3.7, Table 3.4). 
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Figure 3.7 Kaplan-Meier plot comparing event-free survival 
Figure legend: Comparing survival from SCD, resuscitated cardiac arrest and 
appropriate ICD therapy for ventricular fibrillation /ventricular tachycardia by 
globular 1, central fibrous rod domain and globular 2. 
Abbreviations: G1= globular 1; CR= central fibrous rod domain; G2= globular 2. 
 
 
Table 3.4 Sudden cardiac death event by functional domain 
Sudden cardiac 
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rod domain  
Globular 2 
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We dichotomised variant domain into C- versus N-terminal variants. C-terminal 
variants included those residing in G2 and N-terminal variants included those 
residing in G1 and CR. Overall individuals with variants in the N-terminal of DSP 
(globular 1 and the central fibrous rod domain) showed worse event-free survival 
from SCD, resuscitated cardiac arrest and appropriate ICD events due to 
ventricular fibrillation or ventricular tachycardia (32/79 events versus 1/17 events, 
log- rank test p=0.004, Figure 3.8).  
 
 
 
Figure 3.8 Kaplan-Meier plot comparing event-free survival 
Figure legend: Comparing survival from SCD, resuscitated cardiac arrest and 
appropriate ICD therapy for ventricular fibrillation and ventricular tachycardia by 
N versus C-terminal variants. 
Abbreviations: N= N-terminal; C= C-terminal. 
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3.3.5 Clinical Assessment 
 
Excluding the Dutch cohort, we identified 32 probands carrying a truncating 
variant in DSP. Diagnoses from the referring clinician (without adjudication by the 
study team) included: DCM (19 probands), ARVC (10 probands), ACM (1 
proband), Carvajal syndrome (1 proband) and unexplained ventricular fibrillation 
arrest (1 proband). The basic clinical characteristics of the cohort are 
summarised in Table 3.5. 
 
There was a high rate of ventricular arrhythmias amongst this cohort. SCD events 
occurred in n=15 (47%), with SCD in n=7, (22%), appropriate ICD shocks for 
ventricular fibrillation or ventricular tachycardia in n=3 (9%) and resuscitated 
cardiac arrest in n= 5 (16%). SCD was the presenting symptom in n=7 (22%). 
There was documented left ventricular involvement of disease (systolic 
dysfunction or dilatation) in all cases except for the proband diagnosed with 
Carvajal syndrome (Table 3.5). 
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Table 3.5 Basic clinical characteristics 
 
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM- dilated cardiomyopathy; ICD= implantable 
cardioverter defibrillator; LV= left ventricle. 
Clinical characteristic All ARVC DCM Other 
n (%) 32 10 (31) 19 (59) 3 (9) 
Male gender (n, %) 13 (41) 6 (60) 5 (26) 2 (67) 
Mean age (years) 46 ± 19 36 ± 16 52 ± 17 36 ± 25 
Mean age at diagnosis (years) 38 ± 17 33 ± 13 42 ± 17 30 ± 27 
Sudden death as first presentation (%) 7 (22) 7 (70) 0 0 
Sudden cardiac death event ever (%) 
Resuscitated cardiac arrest  
Appropriate ICD therapy 
Sudden cardiac death 
15 (47) 
5 (16) 
3 (9) 
7 (22) 
7 (70) 
0 
0 
7 (70) 
7 (37) 
4 (21) 
3 (16) 
0 
1 (33) 
1 (33) 
0 
0 
Heart Transplant (%) 3 (9) 0 3 (16) 0 
ICD in situ (%) 16 (50) 2 (20) 13 (68) 1 (33) 
LV involvement (%) 31 (97) 10 (100) 19 (100) 2 (67) 
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3.3.6 Arrhythmogenic Right Ventricular Cardiomyopathy versus Dilated 
Cardiomyopathy Diagnosis 
 
There were no significant differences between those with a diagnosis of ARVC 
versus those with a diagnosis of DCM when considering SCD event, gender, 
gene region (N versus C-terminal), age at diagnosis as well as CMR, 
echocardiogram and ECG parameters (Table 3.6). Probands with a diagnosis of 
ARVC were significantly younger (36 ± 16 versus 52 ± 17 years, p= 0.021), and 
more likely to present with SCD (7/10 [70%] versus 0/19, p< 0.0001). It is unclear 
whether selection bias contributes to this effect, whereby those who undergo 
postmortem examination including histological and microscopic examination are 
more likely to receive an ARVC diagnosis than living patients whose hearts are 
not examined under the microscope. In addition, the QRS interval was 
significantly longer in DCM probands though still within normal limits for both 
ARVC and DCM probands (95 ± 24 ms versus 80 ms, p= 0.04). Importantly, 
mean left ventricular EF as a percent, both by echocardiography and CMR was 
below 55% for both groups (46% and 35%), signifying left ventricular dysfunction 
in a significant proportion of cases. Further, though availability of CMR was 
limited (n= 14 in the DCM group and n= 2 in the ARVC group) upon review of 
available reports, there were a significant proportion of cases with late gadolinium 
enhancement suggesting cardiac fibrosis and scar by CMR. Only those probands 
whose primary diagnosis from the referring centre was either ARVC or DCM were 
included. 
 
CHAPTER 3 – TRUNCATING VARIANTS IN THE DESMOPLAKIN GENE  
 157 
Table 3.6 Clinical characteristics in arrhythmogenic right ventricular 
cardiomyopathy (ARVC) versus dilated cardiomyopathy (DCM) probands 
Clinical characteristic ARVC DCM p-value 
n 10 19 - 
Male gender (n,%) 6 (60) 5 (26) 0.11 
Mean age (years) 36 ± 16  52 ± 17 0.02 
Mean age at diagnosis (years) 33 ± 13 42 ± 17 0.12 
Sudden death as first presentation (%) 7 (70) 0 0.00 
Sudden cardiac death event ever (%) 7 (70) 7 (37) 0.13 
Heart transplantation (%) 0 3 (16) 0.53 
Gene region (N-terminal) 9 (90) 15 (79) 0.63 
CMR imaging (n= 16*) 
Indexed LV EDV (mL/m2) 63 127 ± 29 0.06 
Indexed LV ESV (mL/m2) 66 ± 37 86 ± 35 0.47 
Mean LVEF (%) 46 ± 12 35 ± 13 0.43 
Indexed RV EDV (mL/m2) 85 ± 11 90 ± 30 0.70 
Indexed RV ESV (mL/m2) - 42 ± 14 - 
Mean RV EF (%) 37 ± 25 48 ± 13 0.64 
LGE documented 1 (50) 9 (64) 0.71 
Echocardiography (n= 17 †) 
LVEDD (cm) 6 6 ± 1 0.74 
LVESD (cm) 4.6 5.4 ± 1 0.49 
Mean LVEF (%) 40 25 ± 12 0.24 
Electrocardiogram (n= 17‡ ) 
Mean HR (BPM) 79 ± 4 72 ± 16 0.19 
Mean PR Interval (ms) 170 ± 14 167 ± 52 0.87 
Mean QRS Duration (ms) 80 ± 0 95 ± 24 0.04 
TWI V1, V2 1 (50) 1 (7) 0.23 
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Abbreviations: CMR= cardiac magnetic resonance imaging; LV EDV= Left 
ventricular end diastolic volume; LV ESV= left ventricular end systolic volume; 
LVEF= left ventricular ejection fraction; RV EDV= right ventricular end diastolic 
volume; RV ESV=right ventricular end systolic volume; RVEF= right ventricular 
ejection fraction; LGE= late gadolinium enhancement; LVEDD= left ventricular 
end diastolic diameter; LVESD= left ventricular end systolic diameter; HR= 
heart rate; BPM=beats per minute; TWI= t wave inversion. 
Table legend: *=Only two CMR reports available on ARVC probands and 14 on 
DCM probands, †= Only one echocardiogram available on ARVC probands and 
16 on DCM probands, ‡ = Only one electrocardiogram available on ARVC 
probands and 16 on DCM probands .   
TWI V1, V2, V3 1 (50) 2 (13) 0.33 
TWI Beyond V3 0 7 (47) 0.49 
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3.3.7 Family History 
 
Documented family history of clinical disease amongst relatives of probands 
was evident in the majority of cases n= 22 (69%). Family history of SCD was 
defined as a suspicious death in a first-degree relative aged less than 40 years 
and n=9 (28%) probands had a family history of SCD not including SCD events 
in the proband (Table 3.7). 
 
3.3.8 Sudden Cardiac Death Cases 
 
Seven probands (22%) presented with SCD (Table 3.8). All seven received a 
postmortem diagnosis of probable or confirmed ARVC. Activity at time of death 
varied from exercise through to sleep. Case 1 was playing touch football at time 
of death. Case 2 was taking her child to the bathroom. Case 3 was discovered 
by her partner upon his return from an overnight trip and case 4 was playing 
competitive basketball. Case 5 died overnight and case 6 had been gardening. 
Case 7 was attending a party with friends. No decedent had a pre-morbid 
diagnosis of a cardiac condition. 
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Table 3.7 Family history details 
 
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy; SCD= sudden cardiac 
death.  
Family History All ARVC DCM Other 
n (%) 32 10 19 3 
Family history of clinical disease (%) 22 (69) 7 (70) 13 (68) 2 (67) 
Family history of SCD <40 years (%) 9 (28) 3 (30) 5 (26) 1 (33) 
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Table 3.8 Sudden death probands 
Patient code Sex Age at 
SCD 
(years) 
Activity at 
time of 
death 
Summary of significant postmortem findings Postmortem cause 
of death 
Case 1 F 32 Exercise Suspected ARVC, wrong appearance for healed myocarditis. Probable ARVC 
Case 2 F 35 Normal  Extensive fibrosis and fatty infiltration in the upper septum, RVOT and left 
ventricle. 
ARVC 
Case 3 F 18 Unknown Areas of myocardial fibrosis associated with fatty change/infiltration. Pattern 
of change most consistent with ARVC. 
ARVC 
Case 4 M 32 Exercise Cardiomegaly with biventricular dilatation. Patchy fibrosis shown throughout 
right and left ventricle. Features of ARVC and left ventricular predominance. 
DCM- subsequent 
ARVC diagnosis 
Case 5 M 14 Sleep Subepicardial fibrosis and fatty change within the left and right ventricular 
myocardium, showing left ventricular predominance. 
ARVC 
Case 6 M 51 Light 
activity) 
Microscopic examination of the left ventricle showed pathological features 
ARVC. 
ARVC 
Case 7 F 22 Normal Mild right ventricular dilatation associated with focal fat and fibrosis. Changes 
most consistent in the left ventricle. 
ARVC 
Abbreviations: SCD= sudden cardiac death; ARVC= arrhythmogenic right ventricular cardiomyopathy; DCM= dilated cardiomyopathy. 
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3.4 Discussion 
 
We present the largest series of cases with truncating variants in DSP. We show 
DSP truncations are associated with a highly lethal, arrhythmogenic 
cardiomyopathy where SCD may be the presenting symptom in a substantial 
proportion of cases. Left ventricular involvement and dysfunction (largely 
biventricular involvement) appear as the hallmark feature of DSP 
cardiomyopathy. Further, we highlight that truncating variants in DSP contribute 
to a phenotype best considered as an arrhythmogenic cardiomyopathy and 
should not be confined to those fulfilling ARVC or DCM criteria only. We show 
DSP variants that reside in the N-terminal domain of DSP are associated with 
worse event-free survival compared to C-terminal variants. This region of DSP is 
significantly more likely to harbour disease-causing variants compared to the C-
terminal. The results from this study have important clinical implications. 
Ultimately, sub-typing disease by genotype may contribute to evolution of a 
precision-based approach to management, treatment and screening for inherited 
heart disease families. This work contributes to greater understanding of 
truncating variants in DSP and the associated phenotype. 
 
3.4.1 Phenotypic Features of the Desmoplakin Cohort 
 
We present a cohort with a highly arrhythmic and lethal phenotype. This study 
confirms findings from other studies that indicate a high rate of SCD, ventricular 
arrhythmias and left ventricular involvement in carriers of truncating variants in 
DSP (Abou Tayoun et al., 2018, Bhonsale et al., 2015, Castelletti et al., 2017). 
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Twenty two percent (22%) of this cohort presented with SCD, 47% experienced 
a SCD event and 28% had a family history of SCD under the age of 40 years. 
When compared with published ARVC cohorts, the two largest of which include 
241 families and 276 families, these event rates are comparatively high 
(Bhonsale et al., 2015, Groeneweg et al., 2015). Bhonsale et al reported 
presentation with SCD or ventricular fibrillation in 6%, sustained ventricular 
tachycardia/ventricular fibrillation in 30% and left ventricular dysfunction in 14% 
(Bhonsale et al., 2015). They found rates of left ventricular dysfunction and 
presentation with SCD significantly higher amongst carriers of DSP variants 
(Bhonsale et al., 2015). In fact, amongst their DSP carriers, which included 15 
truncating variants and four missense variants (n=19), 21% presented with SCD 
(Bhonsale et al., 2015). Groeneweg et al reported 11% of their cohort presented 
with cardiac arrest and found identification of an ARVC associated variant did not 
affect cardiac mortality and transplantation outcomes (Groeneweg et al., 2015).  
 
Amongst large ARVC cohorts published in the literature approximately 30-40% 
of at-risk relatives receive a diagnosis of ARVC according to Task Force Criteria 
(Bhonsale et al., 2015, Groeneweg et al., 2015). We showed documented family 
history of disease was present in 69% of cases, suggesting DSP associated 
disease may be highly penetrant when compared with ARVC cohorts more 
generally. In addition, one report of three probands and 15 relatives carrying a 
nonsense variant in DSP suggested a penetrance of 83% (Lopez-Ayala et al., 
2014).  
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All but one proband had left ventricular involvement, supporting findings from the 
various case reports throughout the literature, which highlight the high level of 
left ventricular involvement in DSP as well as the potential that left ventricular 
involvement may contribute to poor arrhythmic prognosis (Castelletti et al., 2017, 
Bhonsale et al., 2015). The largest cohort of DSP ARVC probands (including both 
missense and truncating variants) similarly found left ventricular dysfunction and 
left ventricular involvement in 85% of their non-missense DSP variant carriers 
(Castelletti et al., 2017).  
 
The utility of CMR and particularly late gadolinium enhancement assessment to 
predict arrhythmic complications in ARVC and DCM is currently unknown 
(Castelletti et al., 2017, Sen-Chowdhry et al., 2007). One recent study suggests 
the presence of late gadolinium at multiple sites in patients with DCM is 
associated with increased risk of SCD events but beyond this specific 
quantification of late gadolinium enhancement does not seem important (Halliday 
et al., 2018). While we were limited to only CMR reports for some probands, of 
the 16 probands included, the presence of late gadolinium enhancement 
signifying fibrosis and scar was reported in 63%. Assessment of the left ventricle 
and imaging to evaluate for late gadolinium enhancement should be part of 
routine cardiac investigations for patients with DSP truncations, including clinical 
surveillance of family members.  
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3.4.2 Reconsidering the Phenotype as an Arrhythmogenic 
Cardiomyopathy 
 
Our findings strongly suggest the ARVC Task Force Criteria should not define 
the phenotype associated with DSP truncations. Comparison of the clinical 
characteristics of our cases support that both ARVC and DCM are likely part of 
the same disease spectrum, rather than certain variants or gene regions 
exhibiting pleiotropy whereby one gene causes more than one unrelated 
phenotype (Figure 3.9). Those with a diagnosis of ARVC were significantly more 
likely to present with SCD and younger but this may represent selection bias 
whereby those who undergo postmortem and histological examination are more 
likely to receive a diagnosis of ARVC compared with living patients whose hearts 
are not examined under the microscope. Irrespective of this, we highlight the 
phenotype associated with DSP truncations is best considered an 
arrhythmogenic cardiomyopathy. Though studies of ARVC and DSP have 
touched on the DCM/ARVC/ACM associated phenotype, it has not been explicitly 
highlighted that Task Force Criteria should not determinate gene/variant 
causation with identification of a DSP variant (Bhonsale et al., 2015, Groeneweg 
et al., 2015, Castelletti et al., 2017).   
.
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Figure 3.9 The phenotypic and genetic overlap between arrhythmogenic right ventricular cardiomyopathy (ARVC) and 
dilated cardiomyopathy (DCM) that is characteristic of desmoplakin (DSP) cardiomyopathy 
Figure legend: The genetic and phenotypic crossover between ARVC and DCM due to DSP variants. 
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; ACM= arrhythmogenic cardiomyopathy; DSP= desmoplakin, 
DCM= dilated cardiomyopathy. 
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3.4.3 Genetic Features of the Cohort 
 
We have shown truncating variants in DSP localise to the N-terminal of the gene. 
One previous study has highlighted the potential ‘hotspot’ N-terminal region in 
DSP variants. This study showed that 8/17 (47%) missense variants localised to 
the N-terminal compared to 1/28 (4%) of controls (p< 0.0008) (Kapplinger et al., 
2011). The same study concluded truncating variants were significantly more 
prevalent in ARVC cases than controls. Our study lends weight to these data and 
taken together, identification of a variant in this region should be considered 
important. The region plays a critical role in organisation and assembly of the 
desmosomal complex by binding with plakophilin and plakoglobin (Kowalczyk et 
al., 1997). Data such as these may contribute to gene and disease specific 
adaptation and use of ACMG/AMP criteria (Richards et al., 2015). For example, 
there is a moderate criterion for mutational hotspot under these guidelines and 
this work may contribute to improved use of these guidelines. 
 
DSP encodes two isoforms, DSP1 and DSP2 with DSP1 thought to be the 
dominant cardiac isoform though specific areas of the heart are thought to exhibit 
DSP2 expression (Uzumcu et al., 2006). DSP1 and 2 share common N and C-
terminal domains but differ in the central fibrous rod domain with two donor sites 
in exon 23 used to create DSP1 and DSP2, inferring variants residing in the 
three-prime end of exon 23 and subsequently exon 24 (C-terminal) may not be 
disease-causing (Angst et al., 1990, Uzumcu et al., 2006). Subsequent studies 
however have shown specific components of heart muscle have detectable 
DSP2 expression (Uzumcu et al., 2006). Specifically, amplification of DSP2 on a 
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cardiovascular cDNA panel showed DSP2 transcript was present in the left 
atrium and ventricle, intraventricular septum, and apex of the heart, inferring 
variants in this region may confer disease risk (Uzumcu et al., 2006, Sen-
Chowdhry et al., 2007). We and others have provided evidence of heterozygotes 
with variants in these regions having at least some phenotypic expression of 
disease (Rasmussen et al., 2013). It is likely DSP1 and DSP2 both have different 
but functional properties in the heart (Uzumcu et al., 2006, Rasmussen et al., 
2013). 
 
3.4.4 Clinical Utility 
 
The clinical utility and relevance of a genetic result for the patient and family relies 
on strong genotype-phenotype data. More thorough information in this context 
will provide prognostic value to patients. We present evidence that probands with 
a truncating variant in DSP may fall into a specific sub-type of disease under the 
broad umbrella of ACM as proposed in Figure 3.10. 
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Figure 3.10 Proposed model for ‘arrhythmogenic cardiomyopathy’ by molecular aetiology 
Figure legend: Proposed model for the ACM spectrum of disease largely determined by underlying molecular aetiology. 
Abbreviations: ARVC= arrhythmogenic right ventricular cardiomyopathy; DSP= desmoplakin; PLN= phospholamban; LMNA= lamin 
A/C; PKP2= plakophilin2; TMEM43=transmembrane protein 43.  
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 Study Limitations 
 
Collection of cases from international centres meant clinical data differed 
depending on the collection site. For this reason, we were unable to obtain full 
records on each proband and relied on the diagnosis by the referring clinician. 
All sites are considered specialised tertiary referral centres and therefore may 
represent more severe phenotypes. In addition, this work provides insight into 
clinical and genetic characteristics of truncating variants in DSP but did not 
include experimental data to further elucidate underlying molecular mechanisms 
of disease. Though we did not set out to achieve this aspect, it may be an 
important next step. 
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3.5 Conclusions 
 
We present the largest series of DSP truncation carriers and strongly suggest 
this be considered its own gene-specific cardiomyopathy. Our findings support 
and lend considerable strength to two key conclusions drawn from the limited 
DSP data available in the literature. DSP truncating variants contribute to a 
phenotype primarily characterised by left ventricular dysfunction and structural 
left ventricular involvement, with biventricular disease. The phenotype is severe, 
with many having SCD events. Genetically, DSP truncations appear highly 
penetrant with 69% reporting a positive family history. Further, the location of the 
truncation is important, with N-terminal variants statistically more significant in 
cases versus controls and associated with worse event-free survival from SCD 
events.  
 
Based on our findings, we suggest DSP cardiomyopathy contributes to a 
phenotype spectrum more diverse than that considered by the 2010 ARVC Task 
Force Criteria. By sub-typing disease by genotype we can foresee the ability to 
offer precision medicine based advice, treatment and therapies. 
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CHAPTER 4 
ATTITUDES, KNOWLEDGE AND 
CONSEQUENCES OF UNCERTAIN GENETIC 
FINDINGS IN HYPERTROPHIC 
CARDIOMYOPATHY 
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4 Uncertain Genetic Findings in Hypertrophic 
Cardiomyopathy 
 
4.1 Introduction 
 
Findings from this Chapter are the basis of the following publication: ‘Attitudes, 
knowledge and consequences of uncertain genetic findings in hypertrophic 
cardiomyopathy’ published in June 2017 by the European Journal of Human 
Genetics. This Chapter aims to examine the patient perspective of uncertain 
genetic findings in a population of individuals with hypertrophic cardiomyopathy 
(HCM). Up to this point, the projects in my PhD have focused on genetic test 
outcomes and the clinical and phenotypic impact of variants identified through 
comprehensive next generation sequencing (NGS) approaches. The work I have 
undertaken, including understanding the clinical impact of DSP truncating 
variants and their impact on family history (Chapter 3), has aimed to investigate 
how genes impact on clinical phenotype in more detail. Results from this work 
highlight that comprehensive genetic testing can increase the detection of 
complex genetic results and that more work is needed to elucidate the clinical 
impact and phenotype associated with many variants identified.  
 
The second half of my thesis aims to investigate and provide improvements in 
how the health care team communicate and explain this complex genetic 
information to families. As a consequence of the current status of testing, when 
a patient undergoes genetic testing for an inherited heart disease there is a high 
chance of detecting uncertain or complex genetic variants. As shown in Chapter 
2 for example, amongst a cohort of 224 HCM patients undergoing comprehensive 
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genetic testing, 36% had a variant of uncertain significance (VUS) identified 
(Burns et al., 2017a). The yield of identifying pathogenic/likely pathogenic 
variants in HCM may be as low as 30%, whilst VUS are identified in 15-40% of 
cases (Alfares et al., 2015, Ingles and Semsarian, 2013). In spite of this, there is 
limited literature about the impact of this uncertainty on the patient. The patients’ 
attitude, knowledge and any unforeseen consequences of uncertain genetic 
findings are largely understudied. In this project, we sought to investigate this 
issue.  
 
HCM genetic testing routinely encompasses numerous genes using a large 
cardiac panel approach (Mazzarotto et al., 2018). The additional sensitivity of this 
cardiac panel approach is limited and screening a large number of genes with 
little or no evidence of HCM association has resulted in a marked increase in 
detection of VUS (Burns et al., 2017a, Walsh et al., 2017a). In fact, there is 
mounting evidence that many of the genes included in large genetic test panels 
for HCM and other inherited heart disease offer limited additional sensitivity 
(Mazzarotto et al., 2018). Of even greater significance, many of the genes placed 
on these gene panels are unlikely to play a role in the disease at all. Important 
recent work showed that when investigating non-sarcomere genes commonly 
placed on clinical genetic test panels, there was no excess burden of rare 
variation in HCM patients when compared with population reference samples 
(Walsh et al., 2017a). These data support the notion that many of the genes 
placed on these panels are wrongly associated with disease. The interpretation 
of variants is therefore extremely challenging (Walsh et al., 2017a).  
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There are clinical and research arguments for returning VUS results in clinically 
relevant genes. For example, placing these suspicious variants on a report may 
prompt re-classification of the variant in the future and act as a catalyst for further 
studies to delineate the classification of the variant, such as co-segregation 
testing in other affected family members or experimental assays (Walsh et al., 
2017b). However, when a VUS is reported in a gene with limited or no evidence 
linking it to the disease phenotype, this represents a substantial workload for the 
clinical, scientific and research team charged with classifying and reporting 
variants to families. This workload is likely to have no positive impact on the 
family in clinic and can lead to misinterpretation and misdiagnosis. These variants 
take time to prepare and classify. There is the risk of misclassification, which in 
a diagnostic and clinical setting can be devastating. Finally, there is time lost in 
reporting and returning the variant to the family.  
 
Returning complex genetic results within the inherited heart disease context 
relies on specialist skills of the cardiac genetic counsellor. The proband genetic 
result is not a simple yes or no answer but falls along a continuum from a benign 
result to VUS through to pathogenic or likely pathogenic. These results should 
be considered probabilistic based on the available evidence at the time of 
classification (Ingles and Semsarian, 2014). This continuum of results requires 
expert knowledge to communicate effectively with both at-risk relatives and the 
clinician involved in clinical management of the patient. For example, when a 
variant remains uncertain, predictive genetic testing should not be performed but 
the genetic counsellor can assist with co-segregation testing in clinically affected 
individuals to provide supportive evidence for pathogenicity. Conversely, a 
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pathogenic or likely pathogenic variant enables predictive genetic testing and the 
potential release of up to 50% of relatives from life-long screening and 
management. This conversation requires careful consideration of issues 
associated with predictive testing such as any psychological impact of being a 
‘gene carrier’ and potential life insurance implications. Genetic counsellors are 
integral to the clinical discussion, family management and in the review of the 
genetic variants. Taking a lead role in review of genetic variants is an emerging 
skill of the cardiac genetic counsellor (Reuter et al., 2018).  
 
Cardiac genetic counselling can be complex, and the pre-test genetic counselling 
is an important component. The aim of pre-test counselling is to ensure the 
proband has adequate understanding of the genetic testing process and potential 
outcomes of testing. The outcomes of testing, including the potential for 
uncertainty and consequent implications for the patient and their family, are 
particularly important in the current testing environment. Broadly speaking, pre-
test counselling involves eliciting the family history, obtaining informed consent, 
ensuring adequate understanding of the test implications and outcomes 
(including an uncertain result), education and support. On top of this however, 
inherited heart disease families may be undergoing significant life events such 
as the sudden death of a relative. These issues require recognition, 
acknowledgement and the potential need for referral onto clinical psychological 
support. In addition, there is the potential for reclassification of variants and 
incidental or secondary findings. These possibilities need to form a component 
of the genetic counselling consultation. Specialist skills to account for this unique 
context are paramount (Figure 4.1).  
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Few studies focus on the patient perspective regarding uncertain variants, and 
those that do are often based in the paediatric and cancer settings. While 
generally most participants report a positive attitude towards receiving uncertain 
results from genetic testing (Facio et al., 2013, Middleton et al., 2016), one recent 
study examining the attitudes of nearly 7000 health professionals, genomic 
researchers and the public, highlighted a disconnect between the view of those 
handling results from testing versus those being tested (Middleton et al., 2016). 
This is particularly important given the background of increased psychosocial 
difficulties relating to a clinical diagnosis of an inherited heart disease. 
Psychosocial issues including poor health-related quality of life, increased 
anxiety, and even the presence of posttraumatic stress symptoms in sub-groups 
of patients are well documented in the literature (Cox et al., 1997, Hamang et al., 
2010, Ingles et al., 2013, Ingles and Semsarian, 2013). With this in consideration, 
understanding how patients undergoing comprehensive genetic testing deal with 
uncertainty is key. 
 
Given the unique challenges HCM patients face and the increasing yield of 
uncertain genetic results, we sought to explore the attitudes, preferences, recall 
and psychosocial consequences of uncertain genetic results. The ultimate 
objective of this work is to guide pre-test genetic counselling around intrinsic 
genetic uncertainty. 
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Figure 4.1 Pre-test genetic counselling for the inherited heart disease 
patient 
Figure legend: The process of pre-test genetic counselling from taking the family 
history through to provision of psychological support.  
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4.2 Methods 
 
4.2.1 Participants 
 
HCM probands attending a multidisciplinary specialised HCM clinic in Sydney, 
Australia who underwent genetic testing and had either (1) a pathogenic or likely 
pathogenic HCM variant, (2) a VUS or, (3) no variant identified, were eligible for 
inclusion in this study. Pathogenic and likely pathogenic variants were defined as 
variants with a high probability of affecting protein function and therefore of 
causing disease. In families where a pathogenic and likely pathogenic variant 
was identified, predictive genetic testing of asymptomatic relatives was offered. 
A VUS was defined as a variant without sufficient evidence to determine 
pathogenicity and was not used for predictive genetic testing. Variants were 
classified prior to this study, as performed routinely in our group (Burns et al., 
2017a).  
 
Eligibility criteria included sufficient English skills, aged 18 years and above and 
a genetic result disclosed since 1st January 2014. A purposive sampling method 
was employed, whereby eligible probands were invited based on a range of 
demographics and characteristics. A focus was made on recruiting those 
individuals with uninformative gene results (VUS or no variant identified). Using 
this approach, we recruited n= 19 probands. All aspects of the study were 
performed with institutional human research ethics committee approval (X11-
0352 and HREC/11/RPAH/555). 
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4.2.2 Study Design 
 
A qualitative interview study design was used to explore a number of factors 
across the different result scenarios. The interview schedule explored individual 
experiences of dealing with genetic uncertainty, knowledge and recall of complex 
genetic information and attitudes, preferences and psychosocial consequences 
of an uncertain genetic result. This interview schedule was informed and 
developed based on the candidate and the multidisciplinary teams clinical 
expertise in cardiac genetic counselling. Semi-structured interviews were 
conducted face-to-face (n=1) or by phone (n=18), as preferred by the participant. 
Interviews were conducted by the PhD candidate in her role as a PhD candidate, 
though note the considerable experience in working with families as a cardiac 
genetic counsellor which may have influenced the interviews and thematic 
analysis. An interview schedule informed by the relevant literature and reviewed 
by the multidisciplinary team provided consistency between interviews and was 
reviewed and amended to include emerging themes in the first stage of thematic 
analysis (Table 1.1). Interviews were conducted between May 2016 and August 
2016. The preliminary findings and framework development were discussed 
amongst four cardiac genetic counsellors throughout the data collection process 
(CB, CSp, LY and JI). Interviews continued until thematic saturation was reached 
(Figure 4.2).   
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Table 4.1 Abbreviated interview schedule  
Overarching theme Example question/probe 
Individual experiences with 
genetic testing and results 
 
How would you describe your initial reaction when 
you first received your genetic result? 
Was there anything you found confusing about the 
process? 
What would you say is the main benefit of your 
genetic test result? 
Is testing available to other family members? 
Knowledge and recall of complex 
genetic information 
 
In your own words, can you tell me what your gene 
result was, and what it means for you? 
How have you explained your result to somebody 
who knows nothing about genetics? 
In your own words, what does it mean for your 
family? 
Communication Who have you told in your family about your genetic 
result? 
In your own words, how did you tell them? 
Was there anything difficult about this? 
What helped you with this communication process? 
Psychological consequences of 
genetic results 
 
Has the genetic result impacted your day to day life? 
How has the genetic result made you feel about your 
current and future health? 
Information preferences regarding 
results disclosure 
 
Hypothetical scenarios were read out to probands 
with a number of questions related to these 
scenarios. Scenarios included: 
1) Uncertain result in an uncertain gene 
2) Uncertain result in a valid gene 
3) Incidental actionable finding 
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Figure 4.2 Flow chart of study methodology 
  
Literature review 
Multidisciplinary team meetings 
Interview schedule developed 
Pilot interviews conducted 
Interview schedule reviewed and amended to include 
emerging themes 
Interviews conducted 
Transcribed audio-recordings de-identified  
Transcripts coded using framework analysis process 
Themes discussed amongst multidisciplinary team 
Each transcript reviewed by CB with 58% double 
coded and 16% coded by a third coder 
Framework refined in iterative process 
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4.2.3 Genetic Counselling and Testing 
 
Probands underwent genetic testing and counselling in different settings. The 
majority (14 probands) had research or commercial based testing through the 
multidisciplinary genetic heart disease clinic at Royal Prince Alfred Hospital, 
incorporating the expertise of cardiologists and cardiac genetic counsellors 
(Ingles and Semsarian, 2014). The remainder (5 probands) had genetic testing 
ordered by a clinical genetics department, and were seen by clinical geneticists 
and general genetic counsellors in an outpatient hospital setting. 
 
The genetic testing process in the multidisciplinary specialised clinic was as 
follows (Figure 4.3). All probands underwent genetic counselling. Pre-test genetic 
counselling included documentation of the family history, discussion of the 
process of genetic testing, the potential outcomes and results of testing, and the 
implications of results for the proband and their family. Results disclosure and 
post-test counselling was usually in the clinic setting, but occasionally over the 
phone, and each participant received a letter outlining their result. The decision 
to use research or commercial-based genetic testing was contingent on the 
residential address of the patient (some health districts will pay for testing) 
otherwise samples were tested in a research setting. For probands who 
underwent research testing, the genetic counselling process was no different to 
those undergoing commercial genetic testing, with the exception that it may have 
taken longer for the gene report to be generated and the additional knowledge 
they contributed to improving our overall understanding of disease. Research 
based testing included clinical interpretation of variants in genes with unequivocal 
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evidence of disease association only. Probands consented that any information 
of clinical relevance to them be returned and genetic counselling would be 
performed by experienced cardiac genetic counsellors.  
 
4.2.4 Analysis 
 
Transcribed audio-recordings were de-identified and coded using a framework 
analysis process. Each transcript was reviewed by the primary researcher (CB). 
Initial themes were discussed amongst the multidisciplinary team. The data were 
coded according to the framework agreed upon by the multidisciplinary team. 
Each transcript was reviewed by CB with 11 (58%) double coded by an additional 
cardiac genetic counsellor. A further three transcripts (16%) were reviewed by a 
third cardiac genetic counsellor. The framework was refined in an iterative 
process during subsequent data collection and analysis. The data were 
summarised with supporting quotes in an excel spreadsheet. 
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Figure 4.3 Process of cardiac genetic counselling 
Abbreviations: HCM=hypertrophic cardiomyopathy.
Proband diagnosed with HCM 
Research 
genetic testing  
(n=14) 
Commercial 
genetic testing 
(n=5) 
Pre-test genetic counselling 
 
•  Family history 
•  Test process 
•  Test implications 
•  Consent 
Post-test genetic counselling 
 
•  Result disclosure 
•  Clinical implications 
•  Family screening 
•  Letter 
•  Only variants 
in known 
genes returned 
•  Testing 
process may 
take longer 
•  Results 
confirmed in 
clinical 
laboratory 		
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4.3 Results 
 
4.3.1 Proband Characteristics 
 
There were 19 HCM probands who completed interviews (Figure 4.4). Eleven 
(58%) were male, with a mean age of 54 ± 13 years and 8 (42%) had university 
level education or higher. Fifteen probands (79%) had gene results considered 
to be uninformative, including 9 (47%) VUS and 6 (32%) had no variant identified 
(Table 1.2). We purposively enriched our sample for those with uninformative 
results and continued recruitment until we were satisfied thematic saturation was 
complete. The majority of probands completed genetic testing as part of a 
research program (74%). The mean time since the result was disclosed for 
research probands was 1.3 years compared to 1.8 years for those who 
underwent clinical genetic testing. The mean age at diagnosis of probands was 
42 ± 16 years. Nine (47%) probands had a family history of HCM and one had a 
personal history of resuscitated cardiac arrest.  
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Figure 4.4 Flowchart of probands approached and recruited to this study  
Approached 
n=30 
Consent obtained 
n=19/21 (90%) 
Likely pathogenic/
pathogenic 
n=4 
Variant of uncertain 
significance 
n=9 
No variant identified 
n=6 
No response 
n=9 
Declined 
n=2 
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Table 4.2 Characteristics of probands 
 
Characteristic Cohort (%) 
n 19 
Male gender (%) 11 (58) 
Caucasian ethnicity (%) 14 (74P) 
Mean age (years) ± standard deviation 54 ± 13 
Result classification 
Pathogenic/likely pathogenic 
Variant of uncertain clinical significance  
No variant identified 
 
4 (21) 
9 (47) 
6 (32) 
Research result 14 (74) 
Median time since blood drawn (years) 3 (1-14) 
Time since result returned (years) 1 (1-2) 
Family history of HCM 9 (47) 
Education level 
Postgraduate 
University 
Diploma 
High school 
Year 10 or below 
 
4 (21) 
4 (21) 
6 (32) 
2 (11) 
3 (16) 
Interview duration (minutes) ± standard deviation 20 ± 11 
 
Abbreviations: HCM=hypertrophic cardiomyopathy.  
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4.3.2 Overview of Results 
 
There were three key themes that emerged during the interviews. These will be 
further explored under the subheadings: 
 
1. Individual experiences with HCM genetic testing and results 
2. Knowledge and recall of complex genetic information 
3. Communication and the value of information 
 
Those with uninformative results reported unique issues that are explored 
separately under a 4th heading: 
 
4. Variants of uncertain significance  
 
More generally, the impact of HCM genetic testing was highly dependent on the 
context, time and place that testing and disclosure of results took place. This was 
particularly apparent amongst probands with an uninformative result performed 
in a research setting, where genetic testing blended into ‘everything else’ 
regarding their diagnosis. Of those probands approached for interview with 
uninformative results, four had no recollection of having genetic testing, in spite 
of genetic counselling. Further, it appeared that although most had adequate 
conceptualisation of results, translation into meaningful action (such as screening 
or genetic counselling) by relatives was minimal. Recall and understanding of 
results was poorest amongst those probands who received uninformative results.  
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4.3.2.1 Individual Experiences with Genetic Testing and Results 
 
4.3.2.1.1 Context, Time and Place 
 
The impact of genetic testing was highly dependent on the context, time and 
place. Often probands referred to the ‘[traumatic shock]’ of diagnosis and genetic 
testing, which followed many years later, had a comparatively smaller impact. 
Probands often recounted the story of their diagnosis when asked about their 
experience with genetic testing. 
 
“I'm probably saying things now in a calmer, more reasoned way than I did at the 
time. I can remember, you know, telling family when I first got picked up, prior to 
genetic testing and being quite, I suppose traumatised, certainly” P4, Male (51 
years), VUS 	
“I think because I was diagnosed with it quite a few years ago, so anything around 
hypertrophic cardiomyopathy I've accepted” P9, Female (31 years), No variant 
identified 
 
4.3.2.1.2 Perceived Value of Genetic Testing 
 
Probands’ perceptions regarding the value of genetic testing varied. Many of 
those with uninformative results viewed genetics as an altruistic contribution to 
research rather than a test, which may have personal and familial implications. 
This highlighted a need for genetics professionals to even further emphasise the 
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familial aspect of testing when probands are undergoing research based testing. 
Given the large proportion of probands having their genetic testing performed as 
part of research, it is unclear whether this is a theme unique to research probands 
or to anyone in general undergoing HCM genetic testing.  
 
“I guess the real reason comes right down to it is, I know that, you know, genetics 
studies we always need, we always need volunteers and we always need more 
data and the more the data the better” P8, Male (56 years), VUS 
 
“And it was the suggestion that this would be a great opportunity to help … and I 
thought, you know… it wasn't a big deal” P14, Male  (55 years), Likely 
pathogenic 
 
Those with informative results were more likely to consider children and future 
generations when reflecting on the value of genetic testing. This group were able 
to identify the more tangible benefits to future generations, compared to those 
with uninformative results. One proband with an uninformative result seemed 
only to consider the impact to children important had the results been informative. 
 
“I suppose that for my kids it would be now, um if they chose to have children 
and get them genetic tested” P1, Female (47 years), Pathogenic 
 
“Yeah, so the finding out, finding out was just, "Oh, ok", confirmation and that 
just, um, you know, doubly reassures the need for my children to have to be 
checked out” P14, Male (55 years), Likely pathogenic 
CHAPTER 4 – UNCERTAIN GENETIC FINDINGS IN HCM  
 192 
 “I was a bit hesitant because, obviously the implications for my children if I was 
found to have one that was actually mapped that they could identify it was a gene 
issue” P11, Female (60 years) no variant identified 
 
4.3.2.1.3 Sense of Self Removed from Genetic Results 
 
Familial or personal implications of genetic test results were often not considered 
by probands. This appeared to be the case more often for those with 
uninformative results, although was problematic for some probands with 
informative results. At the time of blood collection, probands would undergo pre-
test genetic counselling to explain the process of genetic testing, the potential 
outcomes and impact for their family. If they decided to go ahead with testing, 
whether research or commercial, they would sign a consent form. However, the 
importance of the familial implications of testing eluded many and they recalled 
the simple blood collection procedure as the process of genetic testing. 
 
“Genetics side of it, um, there wasn't a lot to remember because I only had to 
give blood” P10, Male (63 years), VUS 
 
“Oh well I thought it was, I just think it's a great thing you guys are doing so if I 
could help I'm all for it, if I'm asked to provide any more blood tests or anything 
else I'm happy to oblige” P16, Male (59 years), VUS 
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“Because I was asked would I be interested and these are some of the reasons 
why, um for you to consider… which was helping research and that sort of thing, 
I thought I would help out” P14, Male (55 years), Likely pathogenic 
 
4.3.2.1.4 Perceived Certainty in Diagnosis and Finding an Answer 
 
The idea that genetic testing would provide an answer and clarity regarding an 
individual’s diagnosis was raised by a number of probands. No proband reflected 
on the potential for genetic testing to remain unresolved. A positive gene result 
was seen as a confirmation of their clinical diagnosis and an explanation for 
familial inheritance.  
 
“I was pretty pleased really, that there was a gene that had been, isolated and 
found to explain my cardiac condition and also I was pleased because it meant 
both my mum and I then had, you know, an answer for why, for why we get these, 
um, palpitations.” P3, Female (26 years), Likely pathogenic 
 
“Suggested ah, that genetic testing, well, that the blood test would, 100% affirm 
what happened” P14, Male (55 years), Likely pathogenic 
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4.3.2.2 Knowledge and Recall of Complex Genetic Information 
 
Overall, the knowledge and recall of the result was dependent on the result 
classification, person and the context. Amongst the group there was generally 
sufficient conceptualisation, particularly for those where a causative variant was 
identified.  
 
“Ah, so I guess, so, the main thing I would say is that the gene that was isolated 
which, which I can't actually remember the exact transcription of it, it's PK, ah, 
hold on, I don't even have it... Well I guess the main thing is that I recall from it 
was that it was an autosomal dominant pathway sort of, and so that with my 
children- and the main thing that really stuck in my mind was that my children 
would have a 50:50 chance of getting the gene” P3, Female (26 years), Likely 
pathogenic 
 
However, discrepancies became apparent at an individual level, with limited 
understanding of the implications for at-risk relatives by some probands. It 
appeared those with uninformative results were less clear in their 
conceptualisation and recall of genetic results. Further, the idea that their 
uninformative result was able to rule out possible diagnoses, highlighted poor 
understanding and confusion. 
 
“At least hopefully you can rule some things out” P15, Female (52 years), No 
variant identified 
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“I don't exactly understand what you mean by genetics” P19, Male (57 years), 
VUS 
 
“I think it goes a long way to sort of settling in your mind what I've got” P7, Female 
(72 years), VUS 
 
4.3.2.2.1 Lack of Confidence in Genetics Understanding 
 
Throughout many of the interviews probands sought validation of their 
knowledge, asking questions during and after the interview. This highlighted the 
importance of information and resources, and ensuring probands feel adequately 
equipped and supported to pass the appropriate knowledge on to at-risk 
relatives. 
 
“Would it be an idea to send my latest genetic result to her so she can have it in 
case she needs it, you know, take it to her doctor?” P7, Female (72 years), VUS 
 
“So, and again, this is my understanding versus being open to you correcting me 
if I've not got it right” P4, Male (52 years), VUS 
 
“So, from what I've sort of answered in the interview here do you consider that 
I've got a reasonably good understanding of, of what I've been through in terms 
of testing?” P4, Male (52 years), VUS 
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4.3.2.3 Communication 
 
When asked about informing relatives of the genetic risk or result in the family, 
communication appeared to be generally good though this did not always 
translate to meaningful action by relatives such as clinical screening or referral 
to genetics services where appropriate. It appeared effective communication 
might be problematic for some, and the explanation by the proband about what 
at-risk relatives had been told was often vague. For those with a causative variant 
identified, this did seem to be less of an issue. 
 
“Yeah I don't think I've actually, I haven't mentioned it to anybody” P15, Female 
(52 years), no variant identified 
 
“Many years ago, I did contact them to say, blah, blah, blah. Yeah, so they're… I 
mean, it's not a secret” P16, Male (59 years), VUS 
 
“I was thinking, um, maybe I'd sort of get my sisters to start going down once 
every 2 years” P13, Male (37 years), no variant identified 
 
“Ah, no, I have a very supportive family and, and actually my, I've had my father 
and my mother and my husband, all three of the key people in my life come to 
cardiac appointments with me” P3, Female (26 years), Likely pathogenic 
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4.3.2.3.1 The Value of Information 
 
Throughout many of the interviews, the importance of periodic contact with the 
team alongside resources to assist with understanding and communication was 
raised. 
 
“So that would probably be my only comment on that and maybe, you know, I 
probably would've liked a little bit more detail perhaps if that was possible” P11, 
Female (60 years) No variant identified 
 
“It was very helpful because, absolutely, because, as you heard, I’m not good at 
remembering the gene, so I have had to refer to my letter on a few occasions” 
P3, Female (26 years), Likely pathogenic 
 
“Something saying here's the facts, here's the implications, here's some 
suggestions and recommendations" P14, Male (55 years), Likely pathogenic 
 
4.3.2.4 Variants of Uncertain Significance 
 
Those with an uncertain variant may require additional information when 
receiving results and pre-test counselling should carefully consider the potential 
of unveiling uncertain genetic variants. This group often perceived they might 
have a different type of HCM, and their recall and conceptualisation of results 
appeared poorer.  
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“Right, and it's a bit that way I guess with, with myself, we don't know what has 
caused the HOCM, to a certain degree I suspect it hasn't, just because mine is 
so minor, do you get what I mean?” P8, Male (55 years), VUS 
 
“Yes, it did because it was just so unusual for want of a better word right now, I 
can't think of one, it was horrific in a way because, ‘[Oh my god, my heart is really 
bad now]" P7, Female (72 years), VUS 
 
“Look I think I'm a little bit still on the fence because of the, the fact that I, although 
I fit into the characteristics as I understand it, there's still not a clear link … please 
offer the contrary if I'm not, but some, some people that have been picked up 
with HCM because it's such a wide variety, have a more definite, have a more 
definite understanding of it because of the testing that has been done in their 
situation” P4, Male (52 years), VUS 
 
4.3.3 Framework for Improving Communication to the Proband 
 
Based on themes collated from this data, key target areas for improving the 
genetic counselling process have been identified. These key areas and a genetic 
counselling approach for addressing them have been surmised based on 
discussions with the multidisciplinary team after review of transcripts and data 
from this project. By targeting these key areas and paying particular attention to 
the potential for uncertainty during genetic counselling, the information provided 
to the proband may be improved. Improving this information and the process by 
which it is delivered may result in improved understanding and comprehension 
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of genetic results. Improved understanding by the proband may contribute to 
improved screening action by relatives. Screening of at-risk relatives is one of 
the key outcomes of genetic counselling for inherited heart disease patients. A 
framework to guide this process that aims to ensure sufficient conceptualisation 
of genetic test results and empower the proband to communicate risk to relatives 
has been developed (Figure 4.5). 
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Figure 4.5 Framework for improving communication to the proband 
Figure legend: Areas to address for improved communication with the proband based on themes identified from this work. 
Theme from this data Key target area to be 
addressed 
Outcome 
Key questions for the genetic 
counsellor 
Individual experiences with 
genetic testing and results 
Context, time and place of testing Is the proband adequately informed of the 
key aspects and implications of testing ? 
Perceived value of genetic testing Does the proband have realistic 
expectations of testing outcomes? 
Sense of self and implications of 
testing 
Irrelevant of result or research/clinical 
context, does the proband understand the 
personal and familial implications of testing 
outcomes? 
Certainty in diagnosis and finding an 
answer 
Does the proband have realistic 
expectations of the certainty a genetic test 
can provide? 
Knowledge and recall of 
complex genetic information 
Knowledge, recall and 
conceptualisation discrepancies 
Can the proband conceptualise the result 
with enough confidence that translates to 
meaningful communication with relatives? 
Lack of confidence in genetics 
understanding 
Has the proband been offered the 
opportunity to ask questions and seek 
validation? 
Communication and the value 
of information 
Relatives informed Does the proband feel equipped to pass 
on the appropriate level of information to 
relatives to allow them to take meaningful 
action such as clinical screening or 
cascade genetic testing? 
The importance of information Has the proband been provided with 
resources to assist in family 
communication? 
Has a family letter been provided? 
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4.4 Discussion 
 
We have shown that recall and understanding of genetic information in many 
cases was poor. A number of probands expected genetic testing would provide 
clarity with regard to their disease and were unprepared for additional 
uncertainty. Many held an altruistic view of their participation in genetic testing 
(research or clinical), failing to fully appreciate the familial implications of their 
results. In others, particularly those with an uncertain genetic result, genetic 
knowledge was poor. In some probands, the uncertain results affirmed a belief 
that they had something ‘different’ to HCM, or which they incorrectly perceived to 
be reassuring for the inheritance risk of relatives. Whilst these issues were not 
problematic for every proband, the key utility of genetic testing in HCM is for 
identification of at risk relatives. Therefore, clear communication between the 
proband and at-risk relatives is a critical step in this pathway. Currently, this is 
not adequately addressed in current practice. 
 
Theories of health behaviour and stress can guide the application of genetic 
testing and pre-test genetic counselling. The transactional model of stress and 
coping and the theory of planned behaviour, for example, can provide a 
framework for health behaviours, stress and coping outcomes. These theories 
suggest an individuals’ ability to cope, their intention to undergo genetic testing 
and the impact of genetic results are based on a number of subjective and 
internal judgments and determinants of behaviour. These may be influenced by 
internal factors including personal characteristics and coping style but also 
external factors such as perceived resources to deal with the health threat or a 
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perceived sense of control. There are points within this framework that may 
provide target areas for pre-test genetic counselling (Figure 4.6). Specifically, 
ability to cope may be influenced by a patients’ need for certainty, information 
seeking preferences and sense of control over health outcomes (Lazarus, 1993, 
Ajzen, 1991, Gooding et al., 2006). Based on these models, interventions 
focused on reducing uncertainty can improve the patients’ sense of control and 
perceived benefit from genetic counselling (Lipinski et al., 2006). Relief from 
uncertainty is often cited as the primary benefit in the uptake of testing across a 
number of genetic testing contexts, an interesting consideration given the 
uncertainty inherent to the practice (Croyle et al., 1995, Gooding et al., 2006, 
Press et al., 2001). This certainty and the idea of tangible treatment options are 
not always achievable and this incorrect perception of the test highlights the need 
for careful genetic counselling outlining the potential for uncertainty and the 
limitations of testing.  
 
The patient perspective regarding uncertain genetic findings is currently 
understudied. This is particularly true in the inherited heart disease context. To 
date, the focus has largely been around what laboratories and clinicians would 
prefer to see on a report, with little attention to how the patient will respond to this 
information. A study exploring the informed consent process amongst individuals 
with a Mendelian disease undergoing exome/genome research testing, 
concluded this group might be less likely to adequately consider their risk due to 
their strong desire to find an answer and help advance research (Bergner et al., 
2014). Given the value of genetic testing for many people is to reduce 
uncertainty, understanding the impact of uncertain results and therefore ensuring 
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informed consent is guided by appropriate research and theory is vital (Fanos, 
2012). The current practice (which does vary between laboratories) often 
includes reporting of VUS and should be carefully considered. Uncertain variants 
that are highly suspicious, and where additional segregation studies may help to 
clarify its role, are an exception. However, where it cannot be avoided, measures 
to better prepare patients and ensure correct understanding need to be 
implemented.   
 
We have highlighted a number of conceptualisation issues relating to the gene 
result. Many probands value the perceived certainty a genetic test offers, in spite 
of increasingly uncertain and complex results. Further, some assign incorrect 
meaning to a result, particularly where it is an uncertain or uninformative result. 
In addition, the familial implications, although understood at a superficial level are 
often not translated into meaningful action by relatives. Having adequate recall 
of the outcome of genetic testing, whether it be positive, no variant identified or 
VUS, is a critical first step in ensuring appropriate information is communicated 
to at-risk relatives. In the general genetics literature, various studies have 
demonstrated issues with recall and personal interpretation regarding genetic 
results, leading to families inaccurately understanding their meaning (Kiedrowski 
et al., 2016, Turbitt et al., 2015). Indeed, poor understanding has been shown to 
impact on communication of risk to at-risk relatives (Daly et al., 2016, O'Neill et 
al., 2009). The consent process and pre-test expectations are therefore important 
considerations when examining a patients ability to cope with uncertain results 
(Meiser et al., 2016). The need for additional information or support could provide 
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important targets for interventions to improve pre-test genetic counselling in this 
setting. 
 
Given the research probands were predominantly from a highly educated 
background, it could be speculated they represent a highly literate and engaged 
patient population. Our findings may therefore be an overestimate of the true 
level of recall and understanding of HCM genetic test results amongst the HCM 
population. Health disparities between high and low socioeconomic status 
patients are well known (Korda et al., 2007, van Doorslaer et al., 2006) and 
genetics is likely an area that could increase these disparities (Ingles et al., 
2015b). Methods to better support patient understanding and decision-making, 
tailored to the needs of all patients is therefore likely to be of even greater 
importance. 
 
To address these issues, it does not appear that a “one-size fits all” approach 
applies. The need for a personalised and evidence-based consent and 
communication process is clear. Where informational needs of patients and their 
families are not fully met, particularly for families who receive uncertain results, 
additional genetic counselling or information would be beneficial (Reiff et al., 
2012), and providing appropriate support, genetic counselling and resources are 
effective in improving comprehension (Kiedrowski et al., 2016, Reiff et al., 2012, 
Jez et al., 2015). The lack of confidence probands demonstrated regarding their 
genetic knowledge, highlights our current practice is falling short. As a result of 
this work, we have developed a framework to guide more effective cardiac 
genetic counselling. Key ‘target’ areas identified have been translated into ‘areas 
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to be addressed’ and followed by the proposed outcome. It is hoped this 
framework will guide genetic counsellors, or be used in the development of 
resources, to allow more effective communication and genetic counselling. 
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Figure 4.6 Theories of health behaviour and stress 
A) Schematic of the Ajzen theory of planned behaviour [Adapted from (Ajzen, 1991)] 
B) Schematic of the Lazarus transactional model of stress and coping [Adapted from (Lazarus, 1993)] 
Boxes highlighted in green represent areas for genetic counselling intervention to appropriately prepare patients. 
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Study Limitations 
This was a small cohort of individuals from a tertiary referral centre with a 
predominately high education background. In addition, the majority of 
participants were Caucasian and male and these demographics may further 
impact result comprehension and communication patterns. The results may not 
be generalisable to a broader genetic testing context. However, given recall and 
understanding was overall poor amongst many probands in this highly educated 
cohort, we anticipate results from this study may have underestimated the 
problem, and in fact, this may be more problematic in the general genetic testing 
population. In addition, we have used a qualitative study design. This research 
project was intended to be exploratory and though we reached saturation after 
19 interviews, deducing finite conclusions from this research about the 
understanding and recall of all inherited heart disease patients was not the 
purpose of this research question. Based on themes identified from the data we 
have developed a useful framework that we think will contribute to improvements 
in the genetic counselling process. 
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4.5 Conclusions 
 
HCM patients undergoing genetic testing may require additional support and 
information beyond the current practice model. Information that specifically 
addresses the potential for genetic uncertainty and considers the understanding 
and comprehension of the proband is paramount. The key role of HCM genetic 
testing is for at-risk relatives, and therefore effective communication with the 
family is vital. Further, inclusion of some uncertain variants on gene reports 
should be carefully considered. Efforts to ensure the proband is sufficiently 
empowered to communicate effectively with at-risk relatives should be 
considered and we have developed a framework aimed at addressing these key 
areas.
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5 Evaluating a Custom Designed Aid to Improve 
Communication of Genetic Results in Families with 
Hypertrophic Cardiomyopathy: A Randomised 
Controlled Trial 
 
5.1 Introduction 
 
The protocol for this randomised controlled trial forms the basis of the following 
publication: ‘Evaluating a custom designed aid to improve communication of 
genetic results in families with hypertrophic cardiomyopathy: study protocol for a 
randomised controlled trial’ accepted in December 2018 by BMJ Open. 
 
In this Chapter we present data on a prospective randomised controlled trial. The 
aim of the trial was to investigate the impact of a genetic counsellor led 
intervention to return proband gene results using a custom designed 
communication aid. The Chapter is the culmination of work from Chapter two, 
three and four. Research I have undertaken up to this point has highlighted areas 
where greater knowledge is required to improve the clinical application of 
genomics in the cardiac clinic. These areas in need of better evidence and 
research span the genetic testing and counselling process from the choice of 
genes tested (Chapter two), to our limited understanding of how genetic variants 
contribute to disease (Chapter two and three). In Chapter four we have shown 
that patient understanding of complex genetic results can be poor, and 
subsequently developed a framework for improving this process. In this current 
work, we focused on clinical translation of our findings. Specifically, we focused 
on trying to improve the way in which we convey genetic information to the patient 
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with hypertrophic cardiomyopathy (HCM). We incorporated information learnt 
from the work throughout this PhD, previous research and our clinical experience.  
 
Genetic testing in the era of genomics brings unique challenges for the genetic 
counselling of families. In the setting of HCM, genetic testing of the proband 
(index case) can provide invaluable information by allowing at-risk relatives the 
opportunity to undergo predictive genetic testing to look for the presence or 
absence of the family-specific variants (Ingles et al., 2015a, Ingles et al., 2018). 
The first step is often the most challenging, requiring identification of a variant for 
which there is sufficient evidence of causation.  
 
The genetic result for the proband is increasingly complex and may result in 
uncertainty for the patient. This uncertainty is highlighted by work from Chapter 
two, where we have shown the chance of identifying a variant of uncertain 
significance (VUS) using a 45-gene panel is 36% (Burns et al., 2017a). In 
addition, it is now recognised that prior to variant classification, the evidence for 
the gene-disease association should be clearly established, in contrast to the 
current trend to report all variants identified in the gene report (Strande et al., 
2017). 
 
Genetic counselling is a critical aspect of the process, not just for genetic testing 
and explaining uncertain and complex results, but also for understanding 
inheritance risks, characterisation of the family history, information and emotional 
support (Burns et al., 2018, Ingles and Semsarian, 2018). In the clinic setting, 
pre- and post-test genetic counselling should include discussion of inheritance 
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risks and clinical screening guidelines for at-risk relatives (Semsarian and Ingles, 
2017, Burns et al., 2018). This allows asymptomatic at-risk relatives to make 
proactive, informed decisions regarding their risk of developing disease, 
including family planning decisions (Ingles and Semsarian, 2018).  
 
How a patient understands and communicates this genetic information to their 
at-risk relatives is critical to ensuring families get the most value out of genetic 
testing. This task of communication relies on the proband in the family. Current 
Australian practice and privacy laws dictate that in most cases the health care 
provider does not contact relatives to disclose risk information. Therefore, it 
follows that in order to communicate genetic results or risk information the 
proband must have adequate understanding of the information they have 
received from their healthcare provider. Several studies indicate this may be 
problematic, and some individuals may not retain or understand the information 
presented to them (Burns et al., 2018, Burns et al., 2016b, Burns et al., 2017b, 
Young et al., 2017, Patenaude et al., 2013).  
 
Current literature estimates between 20-40% of relatives remain unaware of 
relevant genetic information and do not act on information even when they have 
reportedly been informed of their risk (Burns et al., 2016b, Christiaans et al., 
2008, Gaff et al., 2007). We have shown (Chapter four) some of the barriers that 
can negatively impact on family communication. In a qualitative study of HCM 
patients undergoing comprehensive genetic testing, many patients report 
uncertain results to be conveyed less amongst families (Burns et al., 2017b). The 
general genetics literature highlights that risk perception and understanding of 
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results though varied, can be poor, inaccurate and incomplete (Patenaude et al., 
2013, Young et al., 2017).  
 
There is evidence for the effectiveness of a genetic counsellor in addressing 
some of these communication and knowledge barriers (Fiallos et al., 2017, 
Forrest et al., 2003, Forrest et al., 2008). There are key points within the genetic 
counselling process to support families to communicate genetic results (Figure 
5.1). One key area for intervention is during the post-test genetic counselling 
session. Genetic and risk information can be difficult to understand and explain 
clearly. As a consequence, the patient may not gain sufficient knowledge and 
lack confidence to convey key messages to at-risk relatives (Burns et al., 2017b). 
Further, it is recognised patients deliberate on the appropriate time to 
communicate genetic information and make decisions regarding which relatives 
the information is pertinent to, regardless of the recommendation of professionals 
(Burns et al., 2016b, Montgomery et al., 2013, Seymour et al., 2010). Few 
resources exist that aim to facilitate effective communication to at-risk relatives. 
We therefore hypothesised that improving knowledge of an HCM genetic result 
would have a positive impact on communication to at-risk relatives.
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Figure 5.1 Genetic counselling process and key intervention points for supporting family communication about genetics 
Figure legend: There are key points within the genetic counselling process to support families to communicate genetic results. 
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In conjunction with genetic counselling, resources such as communication aids, 
or family letters, may provide additional support to this process, though more data 
is needed regarding efficacy (Forrest et al., 2008, Hodgson et al., 2016, Seymour 
et al., 2010, Suthers et al., 2006). Decision or communication aids are tools 
specifically designed to support patients with decision making and unmet 
information needs. There is evidence for the effectiveness of an aid with regard 
to improved knowledge and accuracy of risk perceptions (Stacey et al., 2017, 
Vavolizza et al., 2015, Wakefield et al., 2007). Further, most health information 
is written which may not be the most effective health communication method. 
Communication and decision aids provide a format to include visual elements 
that may improve comprehension, recall and comfort with the information, 
particularly when health literacy may be an issue.  
 
Overall, the literature highlights that probands require additional support to 
understand and communicate genetic results. The rationale for this study is the 
critical gap in supporting patients’ comprehension and subsequent 
communication with at-risk relatives. Though genetic counsellors are specifically 
trained in delivering genetic information, information needs of patients are not 
always met and communication amongst at-risk relatives can be suboptimal. As 
genetic test results become increasingly complex and availability of testing 
increases, an evidence-based approach to supporting patients to communicate 
genetic knowledge and inheritance risk should be explored.  
 
The aim of this study was to determine if a genetic counsellor led intervention 
using a communication aid for the delivery of HCM genetic test results improves 
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the ability and confidence of the proband to communicate genetic results to at-
risk relatives compared with current clinical practice.  
 
1. The primary outcome was the ability and confidence of the proband to 
communicate genetic results to at-risk relatives (over 18 years), measured at two 
weeks post-intervention. 
 
2. Secondary outcomes included genetic knowledge; satisfaction with services; 
patient reported outcomes of genetic counselling; and psychological adaptation 
to genetic information, measured at two weeks post-intervention.  
 
3. In order to assess longer term communication; we are in the process of 
conducting phone calls at one, three and six months. Data collection is currently 
ongoing (expected completion May 2019) and the telephone script for these 
phone calls is included in Appendix 3. 
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5.2 Methods 
 
5.2.1 Trial Design 
 
This was a prospective randomised controlled trial. The trial was registered with 
the Australian New Zealand Clinical Trials Registry: ACTRN12617000706370. 
The methods are reported in accordance with the SPIRIT statement, which 
provides recommendations for a minimum set of scientific, ethical and 
administrative elements that should be addressed in a clinical trial protocol (Chan 
et al., 2013). Consecutive HCM patients were invited to participate when notified 
during their genetic counselling intake call that their genetic result was ready to 
be returned. Once verbal consent was obtained they were randomised to receive 
their genetic result via the intervention or control arm of the study (Figure 5.2). 
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Figure 5.2 Flow chart of study design 
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5.2.2 Study Setting 
 
This trial was carried out in a specialised multidisciplinary HCM clinic. The clinic 
incorporates the expertise of specialist cardiologists and cardiac genetic 
counsellors (Ingles et al., 2008, Ingles et al., 2011). Patients with HCM attending 
these clinics at Royal Prince Alfred Hospital were invited to attend.  
 
5.2.3 Eligibility Criteria 
 
HCM probands with a genetic result ready for return were eligible. Probands were 
aged 18 years or older, with sufficient written English skills. Genetic testing was 
performed as part of a research study, or commercial laboratory, as previously 
published and described in Chapter two (Bagnall et al., 2016, Burns et al., 
2017a). All identified variants were classified in the same manner, using the 
American College of Medical Genetics and Genomics and Association for 
Molecular Pathology (ACMG/AMP) criteria for variant classification (Richards et 
al., 2015). Recruitment commenced in November 2017 and ended in November 
2018. Invitation to participate occurred during the genetic counselling pre-clinic 
intake phone call conducted as normal clinical process, and probands indicated 
verbally if they were interested in participating. Informed written consent was 
obtained by the cardiac genetic counsellor present at the probands’ clinic 
consultation. The participant information statement and consent form for this 
study can be found in Appendices 4 and 5. 
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5.2.4 Randomisation 
 
A randomised list was prepared using the Excel (Microsoft Office) “Random” 
function and study probands who verbally agreed to participate were allocated 
the next number on the random list. This number was linked to either control or 
intervention. A researcher not involved in the study, or familiar with the clinic 
patients, performed the randomisation to ensure allocation concealment.  
 
5.2.5 Sample Size and Power Calculations 
 
Prior to commencement of the study, sample size calculations were performed 
using the results from our published feasibility study (Smagarinsky et al., 2017). 
The primary outcome of this trial was the ability and confidence of the proband 
to communicate genetic results to at-risk relatives. Data from the feasibility study 
indicated 75% of probands communicated genetic results to at-risk relatives. 
Assuming the control group communicates in 50% of cases, at a significance 
level of 5% and 80% statistical power, a sample size of n=21 was required per 
group. We planned to recruit additional probands with the aim of reducing the 
impact of drop-out and incomplete survey data on endpoints.  
 
5.2.6 Development of the Custom Communication Aid 
 
We developed a communication aid to assist with the delivery of genetic results 
to the proband and to support family communication. A full copy of the 
communication aid can be found in Appendix 6. This work was primarily 
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conducted by Yana Smararinsky (Master of Genetic Counselling student). My 
role was to assist with supervision, assist with development of the communication 
aid content, assist with data analysis and assist with manuscript preparation and 
edits. This work relates to the published pilot study reported by (Smagarinsky et 
al., 2017). This pilot data demonstrated feasibility and acceptability of the 
communication aid. 
 
Development of the communication aid was a multistep process and on the basis 
of meeting outcomes, literature review and empirical evidence from the 
multidisciplinary team. The aid addresses:  
1. Genetic test basic background information; 
2. Possible outcomes of genetic testing; 
3. Overview of the process involved in classification of a genetic variant;  
4. Implications for at-risk relatives including family screening 
recommendations. 
 
Development of the content involved review of the literature alongside 
multidisciplinary meetings involving a team of experts with over 15 years’ 
experience in providing genetic counselling and cardiac care to inherited heart 
disease patients. Content comprised of the most important components of 
practice for returning genetic results according to the specialised multidisciplinary 
team, literature and with guidance from communication aids in different genetic 
fields. Visual representation frameworks recommended by the International 
Patient Decision Aid Standards were used to guide visual representation of the 
content (Trevena et al., 2013). The culmination of this work resulted in the first 
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stage of the aid, which was an A4 booklet used in the pilot study to assess 
feasibility (Smagarinsky et al., 2017). An iterative pilot and revision process were 
then completed with 13 study probands. Analyses of results from this pilot study 
were incorporated into content revisions and a professional graphic designer was 
employed to assist with preparation of the final communication aid for use in this 
current study. 
 
5.2.7 Control Arm 
 
Those in the control arm of the study received their result via current clinical 
practice. There are currently no evidence-based guidelines for return of 
comprehensive genetic test results in the multidisciplinary clinic setting. Current 
clinical practice typically involves return of a genetic result either by the 
cardiologist or genetic counsellor. All three genetic counsellors included in the 
multidisciplinary team at the time of this study were involved in return of results. 
Return of the result is usually performed following clinical cardiology review, 
which is often the primary purpose of the consult. In the majority of cases a 
genetic counsellor is present (Figure 5.3). 
 
5.2.8 Intervention Arm 
 
Those randomised to the intervention arm were allocated a separate 
appointment time after clinical review with their cardiologist. In this appointment 
they saw the cardiac genetic counsellor who returned their genetic result using 
the communication aid (Figure 5.3). Two of the three genetic counsellors included 
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in the multidisciplinary team returned results to probands randomised to the 
intervention arm of the study.  
 
The communication aid covers the process of genetic testing from diagnosis of 
HCM, through to the implications of a genetic result for at-risk relatives (Figure 
5.4). There is a section in the aid under ‘Results’, which goes through the 
meaning of each category of genetic result. These include an indeterminate 
result (no variant identified), VUS and a pathogenic/likely pathogenic result 
(Figure 5.5). Importantly, specific recommendations for each family member are 
provided (Figure 5.6). 
  
CHAPTER 5 – RANDOMISED CONTROLLED TRIAL 
  224 
 
Figure 5.3 Overview of study protocol for control and intervention arm  
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Figure 5.4 Genetic testing step by step 
Abbreviations: HCM=hypertrophic cardiomyopathy.
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Figure 5.5 Example page from communication aid: what is my genetic result? 
Abbreviations: HCM=hypertrophic cardiomyopathy.  
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Figure 5.6 Example page from communication aid: clinical screening guidelines for family members 
Abbreviations: HCM= hypertrophic cardiomyopathy. 
Sharing this booklet with family members is encouraged.
If you’re a family member reading this booklet, hopefully you will find  
some details below that apply directly to you.
All first-degree relatives of someone with HCM are recommended to have  
clinical screening to check for signs of HCM. This includes children,  
brothers/sisters and parents.
Clinical screening involves: echocardiogram (ultrasound of the heart) electrocardiogram  
(or ECG, an electrical trace of the heart rhythm), and physical examination with a cardiologist.
First name Relation Age
Clinical 
Screening
Genetic testing 
possibilities
My family  
summary
23Communicating HCM Genetic Test Results Communication Aid Version 1, 29 February 2016
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5.2.9 Data Collection and Outcomes 
 
Both the primary and secondary outcomes were measured at a single time point 
(two weeks post-intervention) using a survey comprised of a number of 
previously published and validated scales (Appendix 7). A number of 
demographic questions were asked within the survey. The survey was available 
online via Qualtrics (https://www.qualtrics.com/) with a direct link sent to 
probands. For those who preferred a hard copy it was posted with a return 
envelope. Evidence regarding the most appropriate time between genetic result 
disclosure and family communication is lacking. However, given the risk of 
arrhythmia and sudden cardiac death (SCD) in the inherited heart disease 
context, two-weeks post result disclosure was considered by the study team to 
be an appropriate time point (Vavolizza et al., 2015). Return of the survey was 
followed up on a fortnightly basis. 
 
5.2.10 Primary Outcome 
 
The primary outcome of this trial was the ability and confidence of the proband 
to communicate genetic results to at-risk relatives (over 18 years). This included 
half siblings when the lineage of HCM in the family was not known. This was 
measured at a single time point, and collected two weeks after return of genetic 
results. Ability and confidence were assessed by two measures and then 
combined into a binary outcome. The certainty sub-scale of the Psychological 
Adaptation to Genetic Information (PAGIS) scale was used to measure 
confidence with genetic knowledge (Read et al., 2005). This sub-scale measures 
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the patients’ perception and confidence in their genetic knowledge and the items 
from this sub-scale are listed in Table 5.1. Subsequent ability to pass this 
information on was measured by the percentage of at-risk relatives (over 18 
years) informed of genetic results by the proband. This percentage was 
calculated by counting the living first-degree relatives informed of their risk, and 
dividing by the total number of living first-degree relatives (over 18 years). We 
then averaged the scores from both measures to determine a final score. The 
final score was converted to a binary outcome of “fair” versus “poor” ability and 
confidence to communicate genetic results to at-risk relatives. Fair 
communication was considered an average score of 75% and over and poor 
communication was an average score of less than 75%. We came to this cut-off 
by a combination approach. First, we reviewed the literature focused on 
communication of genetic information and determined that communication rates 
fall between 60-80% but more often below 75%. In addition, we reviewed data 
from our previous studies in the field that showed similar rates of non-
communication (Burns et al., 2016b). This outcome was specifically designed for 
this study. The calculations used to determine this cut-off are illustrated in Table 
5.2.  
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Table 5.1 Items from the psychological adaptation to genetic information 
(PAGIS) certainty sub-scale incorporated into the primary outcome 
  
Example questions 
1. I understand how I came to have hypertrophic cardiomyopathy 
2. I understand the health risks my relatives face because of hypertrophic cardiomyopathy 
3. I feel certain that I understand the meaning of having hypertrophic cardiomyopathy 
4. I understand the chances I have of passing hypertrophic cardiomyopathy along to my 
children 
5. I feel that I can explain to other people what having hypertrophic cardiomyopathy means 
6. I feel confused because I have been given different explanations of what having hypertrophic 
cardiomyopathy means 
CHAPTER 5 – RANDOMISED CONTROLLED TRIAL 
  231 
Table 5.2 Demonstration of primary outcome measure conversion to binary 
outcome 
 
 
Abbreviations: PAGIS= psychological adaptation to genetic information. 
  
Measures incorporated: 
Certainty sub-scale from PAGIS (measuring confidence) 
Adult first-degree relatives informed of genetic risk (measuring ability) 
Calculation examples 
Example 1: 
Certainty score from PAGIS sub-scale = 18/36= 0.5 
Relatives informed of risk = 3/6= 0.5 
= (0.5 + 0.5 = 1) / 2= 0.5 
= 50% 
Therefore, this participant falls into the “poor” communication category of the primary outcome 
Example 2:  
Certainty score from PAGIS sub-scale = 30/36= 0.83 
Relatives informed of risk = 7/8= 0.88 
(0.88+ 0.83) / 2= 0.86 
= 86% 
Therefore, this participant falls into the “fair” communication category of the primary outcome 
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Factors that influence communication of genetic results to at-risk relatives are 
multidimensional. For this reason, we chose this combination approach to more 
broadly reflect the communication process. Many studies rely on single and linear 
measures of communication such as contact by relatives with genetics 
departments or self-reported communication with at-risk relatives only. To 
overcome this, we aimed to incorporate a multidimensional approach that 
included the probands confidence regarding their knowledge of genetics 
alongside the ability linked to this knowledge. We aimed to determine consistency 
between the probands confidence with genetic information against their self-
reported percentage of immediate family members informed. 
 
The certainty sub-scale of the PAGIS scale was used to measure confidence with 
genetic knowledge as described above (Read et al., 2005). Guided by grounded 
theory in patient perspectives of genetic counselling and the Roy Adaptation to 
Genetic Information Model, the 26-item PAGIS scale allows for evaluation of the 
efficacy of genetic counselling (Kasparian et al., 2007, Read et al., 2005). The 
scale aims to incorporate the multidimensional adaptation to genetic information 
and comprises five domains which include; a) non-intrusiveness, b) support c) 
self-worth, d) certainty and e) self-efficacy (Read et al., 2005). Evidence for the 
utility of this scale has been published and illustrates its potential use for 
assessing genetic counselling interventions (Read et al., 2005).  
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5.2.11 Secondary Outcomes 
 
The survey was comprised of three additional scales to assess secondary 
outcomes, a number of questions regarding communication with relatives, as well 
as a number of demographic questions.  
 
Genetic knowledge was assessed using an amended version of the Breast 
Cancer Genetic Counselling Knowledge Questionnaire (Erblich et al., 2005, 
Kasparian et al., 2007). This scale was originally developed to assess knowledge 
of information typically included in genetic counselling for inherited cancer. The 
original scale was a 27-item questionnaire including statements regarding 
genetics like ‘50% (half) of your genetic information was passed down from your 
mother’. Probands were asked if the statement was true or false. Items in the 
original scale were derived from detailed content analysis of breast cancer 
genetic counselling sessions. The original scale demonstrated a high content 
validity with Cronbach’s α = 0.92. The authors cite demonstrated ability to 
discriminate between patients before and after genetic counselling sessions 
(Erblich et al., 2005). We have amended questions to reflect the HCM context 
and 10 items were included.  
 
Satisfaction with services received was assessed using the widely utilised 
Satisfaction with Genetic Counselling Scale (SGCS) (Shiloh et al., 1990). The 
original survey was designed to assess three dimensions of patient satisfaction: 
instrumental, affective and procedural (Kasparian et al., 2007, Shiloh et al., 
1990). We used an amended version of the 12-item short form of the survey. We 
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amended the scale by reducing it to nine questions therefore removing the 
procedural dimension to the scale (three questions). The authors of the scale 
advocate a flexible approach and we felt this met the needs of our study best 
(Shiloh et al., 1990). 
 
The genetic counselling outcome scale (GCOS-24) was used to assess patient 
reported outcomes of genetic counselling (McAllister et al., 2011). The survey 
was designed to be used pre- and post-genetic counselling, though we have used 
it in the post-counselling setting to compare the control and intervention groups. 
The authors of this scale used the construct of empowerment to summarise the 
patient derived benefits from genetic counselling. They  suggest a high score is 
indicative of patients feeling empowered with the information received in a 
genetic counselling session (McAllister et al., 2011). 
 
5.2.12 Data Management 
 
All data from the survey was entered into Microsoft Excel. Patient identifiers were 
removed with study codes allocated. A second senior researcher and supervisor 
oversaw data storage and analysis. Data was stored in accordance with the 
Sydney Local Health District Ethics Review Committee and Centenary Institute.  
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5.2.13 Data Analysis 
 
Data was analysed using Prism (version 7.0) and SPSS (version 23.0). We 
compared the primary outcome as a binary measure between the intervention 
and control group. We used chi-square analyses using p<0.05 for statistical 
significance. For assessment of secondary outcomes, we were guided by 
published scoring protocols for the validated scales to score genetic knowledge, 
satisfaction with services and genetic counselling outcomes. Mean scores for 
each scale were compared between the intervention and control group and 
comparisons between groups were analysed using unpaired t-tests for 
continuous data and chi-square analysis for categorical data. Sub-group analysis 
was performed; specifically, we compared outcomes in the study groups stratified 
by the gene result [informative (pathogenic/likely pathogenic)] and [uninformative 
(uncertain or indeterminate)]. We also stratified probands by the presence or 
absence of a family history of disease.  
 
5.2.14 Ethics and Dissemination 
 
All aspects of the study were performed according to institutional human research 
ethics committee approval. This study was approved by and was performed in 
strict accordance with the Sydney Local Health District Ethics Review Committee 
(X16-0030). Results from this trial are in the process of being prepared as a 
manuscript for publication.  
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5.3 Results 
 
5.3.1 Cohort Characteristics 
 
We approached 57 eligible HCM probands with a genetic result ready to be 
returned. This included informative results (pathogenic/likely pathogenic) and 
uninformative results (VUS and indeterminate). Of those 57 probands, four were 
deemed ineligible due to insufficient English language skills and three declined. 
Fifty probands provided verbal consent to be randomised to the study, reaching 
n=23 in the control arm and n=27 in the intervention arm. After randomisation, 
three probands cancelled their clinic appointment. An additional five probands 
had insufficient data in their surveys to be included in analysis. This included 
three probands from the intervention arm and two probands from the control arm 
of the study. Therefore, in total there were 20 probands in the control arm and 22 
in the intervention arm (Figure 5.7). 
 
The basic clinical and demographic characteristics of the probands included in 
the study are documented in Table 5.3. There were no statistically significant 
differences between probands in the control versus the intervention arms of this 
randomised controlled trial. Fifty percent (50%) of probands in the intervention 
arm and 50% of probands in the control arm had pathogenic/likely pathogenic 
variants identified. These figures accurately reflect the clinical yield of HCM 
genetic testing from the literature (Ho et al., 2018).   
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Figure 5.7 Flowchart of randomised controlled trial study probands 
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Table 5.3 Clinical characteristics in control versus intervention group 
 Control Intervention p-value 
n 20 22 - 
Male gender (%) 18 (90)  16 (73) 0.24 
Current age (years) 50 ± 15 52 ± 16 0.61 
Caucasian ethnicity (%) 14 (70) 19 (86) 0.27 
Comorbidities present (%)  6 (30) 4 (18) 0.48 
Pathogenic/likely pathogenic result (%) 10 (50) 11(50) 1 
ICD in situ (%) 9 (45) 6 (23) 0.23 
SCD event (%) 1 (5) 2 (9) 1 
FHx clinical disease  6 (30) 10 (45) 0.30 
FHx SCD 3 (15) 3 (14) 1 
Number Living first-degree relatives (> 18) 3.5 ± 2 4.5 ± 2 0.10 
 
Abbreviations: ICD= implantable cardioverter defibrillator; FHx=family history; SCD= sudden cardiac death. 
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5.3.2 Primary Outcome 
 
The a priori primary outcome measure was an average score measuring the 
ability and confidence of the proband to communicate genetic results to at-risk 
relatives. This incorporated the certainty sub-scale from PAGIS and the number 
of first-degree relatives (over 18 years) informed of their genetic test result. This 
was a binary score. It included “fair” communication that was an average score 
of ≥75% and “poor” communication was a score less than 75%. Though more 
than half of the probands in the intervention group demonstrated “fair” 
communication (≥75%) there was no statistically significant difference between 
the two groups (13/22 [59%] versus 10/20 [50%], p= 0.26) (Figure 5.8).We 
compared the mean primary outcome score as a continuous variable and found 
no significant differences between the control and intervention groups (72 ± 4 
versus 73 ± 4 years, p= 0.88). 
 
 
 
 
 
 
 
 
 
Figure 5.8 Fair versus poor communication 
Figure legend: The percentage of probands with “fair” versus “poor” 
communication in the control and intervention groups.  
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5.3.3 Secondary Outcomes 
5.3.3.1 Genetic Knowledge  
 
The mean score for genetic knowledge amongst the total group was 6/10 (60%). 
Across the survey items, there were 107/420 ‘don’t know’ responses that were 
scored as incorrect. Though probands in the intervention group had higher 
knowledge scores, these were not statistically different (7 ± 3 versus 6 ± 3, p= 
0.11) (Figure 5.9). When considering the genetic knowledge score as a pass or 
fail, i.e. a score of less than 50% was considered a “fail” and a score of ³ 50% a 
“pass”. Though more of the intervention group received a pass for genetic 
knowledge this did not reach statistical significance (19/22 [86%] versus 12/20 
[60%], p= 0.05) (Figure 5.10). The items from this questionnaire and percentage 
answered correctly by the control and intervention group are illustrated in Figure 
5.11. 
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Figure 5.9 T-test of genetic knowledge scores 
Figure legend: Genetic knowledge scores (maximum score of 10) between 
probands in the control and intervention groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Genetic knowledge score as a binary outcome 
Figure legend: Percentage of probands receiving a pass or fail for genetic 
knowledge compared between the control and intervention groups. 
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Figure 5.11 Percentage of probands who gave correct answers for genetic knowledge items 
Figure legend: Items from the genetic knowledge score answered correctly by control and intervention groups. 
Abbreviations: HCM= hypertrophic cardiomyopathy; DNA= deoxyribonucleic acid. 
0 20 40 60 80 100
A variant of uncertain significance (VUS) may or may not be the cause of HCM
An indeterminante genetic test result (no gene variants found) means HCM is not inherited in their family
An individual who has a sister or brother with an HCM-causing gene variant has a 1 in 4 (25%) chance of also having the variant
If a parent has an HCM-causing gene variant (pathogenic variant), each child has a 1 in 2 (50%) chance of inheriting the variant
There is more than one gene in humans, which if damaged, can cause HCM
An inherited HCM-causing gene variant is present in the DNA in every cell of the body
Genetic testing is the only way of finding out if someone has HCM
Each daughter and son has the same chance of developing HCM if one parent has HCM
25% (one quarter) of your genetic information was passed down from your father
50% (half) of your genetic information was passed down from your mother
Percent answered correctly
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5.3.3.2 Psychological Adaptation to Genetic Information 
 
Overall, the mean total PAGIS score was 114 ± 16 (maximum score of 156) with 
higher total scores indicating more positive psychological adaption amongst the 
group. When comparing the mean total score between the intervention and 
control groups there were no statistically significant differences (115 ± 16 versus 
112 ± 15, p= 0.48).  
 
The mean total scores for the sub-scales included: non-intrusiveness 4.1 ± 0.8 
(maximum weighted score of 6), support 4.5 ± 0.8 (maximum weighted score of 
6), self-worth 4.4 ± 1.3 (maximum weighted score of 6) and self-efficacy 4.2 ± 1 
(maximum weighted score of 6). The mean score for certainty was 4.4 ± 0.5 
(maximum weighted score of 6), which was incorporated into the primary 
outcome calculation as described above. We compared the sub-scale scores 
between the intervention and control groups and there were no statistically 
significant differences (Figure 5.12). 
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Figure 5.12 Psychological adaptation to genetic information (PAGIS) sub-
scale scores 
Figure legend: Sub-scale scores from the PAGIS scale compared between 
control and intervention groups. 
Abbreviations: PAGIS= psychological adaptation to genetic information. 
 
5.3.3.3 Satisfaction with Services 
 
Overall, all probands reported high levels of satisfaction with the process to return 
their genetic result. This was indicated by a mean total satisfaction score of 33 ± 
5 (maximum score of 36). Higher scores indicate higher levels of satisfaction. For 
the instrumental and affective components of this scale, mean scores were 11 ± 
2 (maximum score of 12) and 11 ± 2 (maximum score of 12) respectively. Single 
item scores (maximum score of 4) relating to expectations fulfilled (3.8 ± 0.6), 
satisfaction with information (3.7± 0.5) and overall satisfaction (3.6. ± 0.6) all 
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reflected high levels of satisfaction. When comparing the mean total score 
between the intervention and control groups there were no statistically significant 
differences (33 ± 6 versus 33 ± 4, p= 0.91). We compared the instrumental (11 ± 
2 versus 11 ± 1, p=0.90) and affective (11 ± 2 versus 11 ± 1, p=0.76) components 
between the intervention and control groups and there were no statistically 
significant differences. 
  
5.3.3.4 Patient Reported Outcomes of Genetic Counselling 
 
The mean GCOS-24 score was 119 ± 15 (scores range from 24 to 168) which 
indicates good patient empowerment with higher scores indicating higher levels 
of empowerment (McAllister et al., 2011). When comparing the mean score 
between the intervention and control groups there were no statistically significant 
differences (120 ± 15 versus 119 ± 16, p= 0.72). Mean scores for each item on 
the GCOS-24 scale are presented in Figure 5.13. Probands in the intervention 
group were more likely to understand the reasons their doctor referred them to 
the cardiac genetic service when compared with probands in the control group 
(6.7± 0.5 versus 5.6 ± 1.0, p= 0.01). 
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Figure 5.13 Mean genetic counselling outcome scale (GCOS-24) item scores 
Figure legend: Mean scores per item (maximum score of seven) between control and intervention groups from the GCOS-24 scale. 
Abbreviations: GCOS-24= genetic counselling outcome scale.
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5.3.4 Communication with At-Risk Relatives amongst the Cohort 
 
The mean percentage (total number of at-risk first-degree relatives informed 
divided by total number of at-risk first-degree relatives) informed of a genetic test 
result amongst probands was 71% (range: 0-100). This indicates 29% of at-risk 
relatives were not informed of a genetic result. The mean percentage of total at-
risk first-degree relatives informed of their diagnosis of HCM was 83% (range: 0-
100), indicating 17% were not informed. We reviewed communication between 
those with informative genetic results (pathogenic/likely pathogenic variants 
identified) and uninformative results (VUS/indeterminate). In those with 
informative results 85% of their relatives were informed of an HCM diagnosis 
(range: 25-100) and 73% (range: 0-100) were informed of a genetic result. In 
probands with uninformative results (VUS/indeterminate) 81% of their relatives 
were informed of an HCM diagnosis (range: 0-100) and 69% (range: 0-100) were 
informed of a genetic result (Figure 5.14). Communication amongst relatives 
appeared consistent across the two groups though statistical tests were not 
performed as the figures reported are percentages.  
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Figure 5.14 Communication of genetic results and hypertrophic cardiomyopathy (HCM) diagnosis amongst probands 
Figure legend: Panel A: percentage of first-degree relatives informed of the genetic result by pathogenic/likely pathogenic versus 
indeterminate/VUS genetic results. Panel B: percentage of first-degree relatives informed of the HCM diagnosis by pathogenic/likely 
pathogenic versus indeterminate/VUS results. 
Abbreviations: P/LP= pathogenic/likely pathogenic; VUS= variant of uncertain significance. 
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5.3.4.1 Sub-Group Analyses 
 
We conducted sub-group analyses by dividing probands into those who received 
informative (pathogenic/likely pathogenic) and uninformative 
(VUS/indeterminate) genetic test results. In addition, we divided probands into 
those with and without a family history of HCM. We did this to review differences 
between the control and intervention groups stratified by sub-groups.  The data 
from this sub-group analysis is shown in Table 5.6. There were no differences 
between the intervention and control groups in the sub-group analyses. 
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Table 5.4 Sub-group analyses of primary and secondary outcomes 
 Informative genetic results Uninformative genetic results Family history  No family history  
 Control Interv p-value Control Interv p-value Control Interv p-value Control Interv p-value 
n 10 11 - 10 11 - 6 10 - 14 12 - 
Age (Years) 43 ± 15 49 ± 15 0.33 57 ± 10 55 ± 17 0.79 46 ± 17 56 ± 14 0.23 51 ± 14 49 ± 18 0.71 
Male gender (%) 9 (90) 5 (45) 0.06 9 (90) 11(100) 0.47 6 (100) 6 (60) 0.23 12 (86) 10 (83) 1 
“Fair communication” (%) 6 (60) 7 (64) 1 4 (40) 6 (55) 0.67 4 (67) 6 (60) 1 6 (43) 7 (58) 0.43 
Mean total genetic 
knowledge score 
6.8 ± 2.5 7.4 ± 2.1 0.58 4.4 ± 2.5 6.5 ± 2.8 0.09 6.8 ± 2.5 7.1 ± 2.1 0.83 5.1 ± 2.6 6.8 ± 2.8 0.14 
Mean total PAGIS score 113 ± 12 121 ± 16 0.22 111 ± 18 109 ± 16 0.89 117 ± 13 121 ± 15 0.61 109 ± 16 111 ± 17 0.87 
Mean total GCOS-24 score 118 ± 17 125 ± 17 0.34 119 ± 15 115 ± 11 0.51 121 ± 18 123 ± 16 0.84 117 ± 15 118 ± 13 0.93 
Mean total satisfaction 
score 
35 ± 3 33 ± 8 0.50 32 ± 4 34 ± 3 0.37 36 ± 0 32 ± 9 0.31 32 ± 4 34 ± 3 0.19 
 
Abbreviations: Interv= intervention; PAGIS= psychological adaptation to genetic information scale; GCOS-24= genetic counselling 
outcome scale. 
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5.4 Discussion 
 
We describe a randomised controlled trial that investigated the impact of a 
genetic counsellor led intervention to return proband gene results using a custom 
designed communication aid. The a priori primary outcome measure for this 
study was to assess the ability and confidence of the proband to communicate 
genetic results to at-risk relatives. Though this did not show statistical 
significance when compared between the intervention and control group, we 
highlight some important findings. First, the majority of probands in the 
intervention group did demonstrate “fair” communication as measured by the 
primary outcome. Further, genetic knowledge scores were consistently higher 
amongst the intervention group. In addition, and of great clinical importance, we 
highlight that up to 29% of at-risk relatives remain uninformed about a genetic 
result in their family. Further, up to 17% of at-risk relatives remain uninformed of 
the HCM diagnosis itself. This is in spite of return of results in a specialised 
multidisciplinary clinic with expertise including experienced cardiac genetic 
counsellors and cardiologists.  
 
This work highlights further research is needed that aims to address the critical 
gap in supporting families to communicate genetic information. Uninformed 
relatives are unable to make proactive decisions regarding their own risk 
management. 
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5.4.1 Family Communication  
 
When asked about family communication, most patients report families should 
communicate risk amongst themselves with varying levels of support from their 
healthcare providers (Forrest et al., 2003, Healey et al., 2017, Young et al., 
2017). In addition, there is evidence for the effectiveness of genetic counselling 
to assist with this process (Fiallos et al., 2017, Forrest et al., 2008, Healey et al., 
2017). In spite of this, the literature consistently demonstrates family 
communication about genetics falls somewhere between 60-80% with a 
significant number of at-risk relatives remaining uninformed about their genetic 
risk (Healey et al., 2017, Gaff et al., 2007). At present, the biggest benefit of an 
informative genetic result is the opportunity for clinical and genetic screening 
amongst at-risk relatives (Burns et al., 2018, Ingles et al., 2018, Ingles and 
Semsarian, 2018). 
 
Many factors have been identified that influence family communication about 
genetic risk. These include complicated family dynamics, guilt, ethnicity, anxiety 
and gender (Barsevick et al., 2008, Burns et al., 2016b, Christiaans et al., 2008, 
Claes et al., 2003). In addition, the literature and clinical experience highlights 
loss of contact and geographically distant relatives are a commonly cited and 
significant issue (Healey et al., 2017, Young et al., 2017). Importantly, much of 
this literature comes from the inherited cancer context. Inherited heart disease 
has the unique risk of SCD, which should be considered when discussing 
communication of risk. Initial discussions surrounding a diagnosis of an inherited 
heart disease are often focused on clinical management of the proband 
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themselves but should highlight the importance of family screening adherence 
(Burns et al., 2018, Hudson et al., 2018).  
 
5.4.2 Measuring Improvements in Family Communication 
 
Studies focused on the inherited heart disease patient population aimed at 
addressing family communication show varying results. One recent study 
amongst HCM probands found 80% of first-degree relatives were informed of 
their genetic risk with probands acknowledging the unique process of 
communication for each family but perceiving disclosure of risk information as 
‘imperative’ (Hudson et al., 2018). In addition, we have conducted a study in long 
QT syndrome patients that demonstrated 10% of probands had not disclosed 
relevant risk information to at least one first-degree relative (Burns et al., 2016b).  
 
Evaluating genetic counselling interventions, particularly related to family 
communication is difficult. This may account for some of the ambiguity around 
the best practice approach. There is little agreement about suitable outcome 
measures to assess the effectiveness of a particular genetic counselling 
intervention (McAllister et al., 2011, Payne et al., 2008). Here, we aimed to 
address the issue commonly referred to as passive non-disclosure, whereby 
relatives intend to disclose and communicate relevant information and do not 
actively choose non-disclosure. In spite of this however, communication still does 
not occur (Gaff et al., 2005). One contributing factor may be the information 
provided to probands and their knowledge of the appropriate information to 
disclose (Eijzenga et al., 2018, Healey et al., 2017, Bish et al., 2002, Burns et al., 
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2016b, Jacobs et al., 2015). Therefore, we aimed for our communication aid to 
improve knowledge and the information provided regarding family screening. In 
spite of the time spent with probands during the study, positive satisfaction and 
outcome scores, good confidence with genetic knowledge alongside a 
reasonable mean genetic knowledge score (60%), up to 17-29% of first-degree 
relatives amongst this cohort remain uninformed of their risk.  
 
5.4.3 Uptake of Clinical Screening and Adherence to Guidelines 
 
We reported ability and confidence of the proband to communicate genetic 
results to at-risk relatives as a surrogate endpoint for the clinically relevant 
endpoint, which is actual adherence to screening advice by at-risk relatives. 
Beyond communication of genetic risk information, uptake of screening and 
adherence to guidelines is a related but perhaps more complex issue. The 
proportion of relatives who undergo screening and genetic testing vary 
considerably. We have previously demonstrated that uptake of predictive genetic 
testing amongst long QT syndrome patients was 60% (Burns et al., 2016b). A 
report of a randomised controlled trial aimed at assessing the impact of a genetic 
counselling intervention on communication to at-risk relatives used the primary 
outcome as the difference between at-risk relatives who contacted genetic 
services for information and or genetic testing (Hodgson et al., 2016). Audit of 
the genetic files in this study found that 25% of the intervention group and 20% 
of the control group made contact with services. This primary outcome measure 
was not significantly different between the two groups but demonstrates the 
difficulty in finding an appropriate measurement of communication and uptake of 
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screening, and the low adherence to recommendations amongst relatives 
(Hodgson et al., 2016).  
 
5.4.4 Future Research  
 
The need to improve the way in which we return results from genetic testing that 
supports family communication as well as adherence to screening guidelines 
should be a focus of future research. Our study demonstrated overall satisfaction 
with services, positive outcomes from genetic counselling, and good 
psychological adaptation to genetic information. In addition, there were trends in 
our data that indicate the intervention improved genetic knowledge. This is 
supported in the literature as having a positive influence on family communication 
(Burns et al., 2018, Burns et al., 2016b, Burns et al., 2017b, Young et al., 2017, 
Patenaude et al., 2013). Further we showed more probands in the intervention 
group reported “fair” communication compared to the controls, indicating there 
may have been some improvement due to the communication aid. 
 
As part of this study, data collection is ongoing, specifically the longer-term 
outcome measure aimed at investigating the clinically relevant adherence to 
screening by at-risk relatives. Though this is a self-report measure by the 
proband, phone calls are being conducted to assess actual family member 
uptake of screening and genetic testing (Appendix 3 ). In addition, we are 
considering development of an electronic version of the communication aid for 
wider use amongst our multidisciplinary clinic patients, that may increase the 
ease with which it can be passed onto at-risk relatives. We plan to continue using 
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the communication aid with evaluation and refinement to proceed within the 
multidisciplinary clinic model, and explore ways we can show an objective 
improvement in outcomes. 
 
While essentially all outcomes in the study were non-significant, there are some 
key points to highlight. First, it is likely this study was underpowered. Though we 
completed power calculations and recruited n= 50 probands (an additional n=9 
probands), the final numbers in the control and intervention group were small. 
Given the variability and intricacies of family communication it is likely a larger 
study is needed to account for the heterogeneity in response. Second, design of 
our intervention may have addressed the wrong aspect of family communication 
about genetics. As described above, family communication about genetics is 
complex and multifaceted, and in choosing to target ability and confidence as 
important contributors to family communication we may have missed the 
appropriate target. 
 
Interpretation of these results and the literature, highlights the complexity, 
intricacies and personal and family dynamics that may play a significant role 
beyond knowledge in the process of family communication. A more tailored 
approach, addressing individual family needs may be required to more directly 
influence the process of family communication about genetics. Finally, outcome 
measures to assess the effectiveness of a genetic counselling intervention are 
extremely variable, with limited agreement and a lack of consistency. Few studies 
exist that show statistically significant improvements in a pre-determined 
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outcome such as family communication about genetics (Hodgson et al., 2016, 
Eijzenga et al., 2018).  
 
Nonetheless, overall satisfaction and outcome scores were good. Particularly, 
genetic knowledge scores were consistently higher in the intervention group 
across all sub-scales indicating genetic knowledge was facilitated by use of the 
communication aid. In addition, the cardiac genetic counsellors using the 
communication aid found the aid to be clinically useful and commented that it 
facilitated the communication of genetic results to probands. In fact, it was 
identified that returning genetic results without use of the communication aid felt 
as though it were lacking after commencement of this study. Though data were 
not collected systematically, questions raised by the probands during the genetic 
counselling sessions with the communication aid reflected both a positive 
experience and firm grasp of the information provided for probands themselves. 
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Study Limitations 
 
Several factors may have limited the results from this study. First, power 
calculations may have underestimated the numbers required to achieve 
statistical significance. This is likely due to the marked heterogeneity in 
responses, which we intended to mitigate against by additional recruitment 
however study drop-out and incomplete survey completion was higher than 
expected. Another key limitation of this study is relying on self-reported measures 
of family communication by the proband. Further, the majority of probands in this 
study were male which may impact communication patterns amongst families. 
Finally, the most important limitation is adequate outcome measures to assess 
genetic counselling interventions aimed at addressing family communication 
about genetics. 
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5.5 Conclusions 
 
We highlight that in spite of satisfaction with services and the information 
provided, family communication about genetics remains a multifaceted and ill-
defined area of study. Complex family dynamics, interpersonal family 
relationships and the probands own beliefs about whom they should 
communicate with all contribute to family communication about genetics as an 
immensely complex issue. These issues are not necessarily dealt with in the 
clinic and likely have an important impact on family communication. Ideally, 
interventions, that address family communication, may need to specifically 
address these more complex issues in greater detail.
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6 Summary and Conclusions 
 
6.1 Summary and Future Directions 
 
While the difficulties associated with the clinical application of next generation 
sequencing (NGS) approaches can be substantial, overwhelmingly, the 
technology holds great potential to improve outcomes and risk management for 
both patients and their families. This PhD thesis focused on three critical 
challenges associated with the clinical utility of NGS technologies. These include 
understanding how underlying genetic aetiology contributes to the clinical 
phenotype of disease and the impact of uncertain and complex NGS results on 
the patient. Finally, research into evidence-based approaches for improving 
current and future methods for returning complex genetic results to improve 
family communication about genetics. The candidate performing these studies is 
a cardiac genetic counsellor trained with specialist skills in the communication of 
genetic information and adaptation to this information for families. Having spent 
five years discussing the process, implications and results of cardiac genetic 
testing with patients and their families, this clinical experience has directly 
informed research questions within this thesis. Ultimately, this thesis aimed to 
contribute to improved clinical utility of genetic testing for inherited heart disease 
families.  
 
Inherited heart diseases include structural cardiomyopathies and primary 
arrhythmogenic conditions and are an important cause life-threatening 
ventricular arrhythmias and sudden cardiac death (SCD) in the young (Ho et al., 
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2018, Bagnall et al., 2016, Priori et al., 2013). Beyond the clinical impact of an 
inherited heart disease diagnosis, there can be substantial burden on the patient, 
family and community in terms of life years lost, significant psychosocial morbidity 
and life-long interaction with medical services (Ingles et al., 2008, Ingles et al., 
2012, Ingles et al., 2013, Ingles and Semsarian, 2013, Stecker et al., 2014). 
Further, these conditions are most often inherited as an autosomal dominant trait, 
with a 50% risk to first-degree relatives underlying the need for relatives to be 
well informed of their risk. 
 
Identifying the pathogenic or likely pathogenic variant can be a powerful tool for 
families. Most notably, it allows for identification of at-risk relatives, providing 
direction and clarity around the appropriate screening approach. Beyond this 
benefit, the identification of genotype may guide management, confirm diagnosis 
and predict outcomes in a certain sub-set of patients (Girolami et al., 2018, Ingles 
et al., 2018, Mazzanti et al., 2018). Importantly, it allows for family planning 
options, such as pre-implantation genetic diagnosis and critically, plays an 
important role in families with an experience of SCD where genetic testing can 
elucidate the cause of death in up to 30% of previously unsolved cases (Bagnall 
et al., 2016).  
 
In the future, knowledge of the underlying genetic aetiology is likely to provide 
even greater benefit to inherited heart disease families. Research into novel 
therapeutic targets and development of gene therapy and gene editing 
techniques may further revolutionise the field (Ross et al., 2017, Dainis and 
Ashley, 2018, Rossidis et al., 2018). All of these potential advances however, 
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rely on a firm understanding of the underlying genetic aetiology of disease, strong 
disease and gene associations and critically, appropriate classification and 
interpretation of the genes and variants identified. By performing more 
comprehensive genetic testing, the ultimate hope is there can be improved 
understanding of the genetic causes of disease, moving us to a precision 
medicine approach to managing these families (Girolami et al., 2018, Gray et al., 
2018b, Ingles et al., 2018, Mazzarotto et al., 2018, Yang et al., 2018). 
 
The most common genetic test ordered for the inherited heart disease patient is 
a comprehensive cardiac gene panel (Rehm, 2013). This involves sequencing of 
hundreds of genes under the broad umbrella of inherited cardiomyopathies or 
primary arrhythmogenic conditions. Theoretically, once a pathogenic/likely 
pathogenic genetic result is identified, the proband can benefit from diagnostic, 
management and family planning outcomes. In addition, at-risk relatives should 
be informed of the appropriate clinical screening and management to follow. 
Relatives who undergo predictive genetic testing and found not to carry the 
pathogenic/likely pathogenic variant are released from ongoing medical 
evaluation, incurring no additional costs of screening or unnecessary worry. 
 
In reality however, rapid advances in test availability and the technology itself, 
means that clinical application of NGS has moved quickly with limited evidence-
based consultation and review regarding genes tested, classification criteria, test 
implementation and uptake. As a result, numerous challenges that impede the 
clinical utility of the technology have become apparent. Most notably, these 
include issues with historic variant and gene classification approaches. Overall, 
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emerging data highlight inappropriate classification of genes and variants as 
disease-causing based on limited and ill-defined evidence (Furqan et al., 2017, 
Harrison et al., 2017, Hosseini et al., 2018, Ingles et al., 2018, Mazzarotto et al., 
2018). Additionally, to take full advantage of the hundreds of genes and variants 
implicated in inherited heart disease, more sophisticated data regarding 
genotype-phenotype correlations will contribute to the ability to better sub-type 
inherited heart disease by genotype. This will foster development of inherited 
heart disease management as we move in to the precision medicine era. Finally, 
an increased focus on translational research and the patient perspective have 
emphasised the need for patient experiences and needs to be incorporated into 
the clinical application of medical technologies.  
 
There are important initiatives, research and guidelines beginning to emerge 
regarding standardised and improved classification of variants and the need for 
stringent gene and disease evidence. However, there remains significant gaps in 
the literature and evidence that hinder the clinical utility of NGS technologies. In 
particular, research regarding the patient experience, and data that directly 
reflects the current clinical reality, is missing from the current evidence base. 
 
This thesis aimed to address critical challenges that directly impact the clinical 
utility of NGS approaches for inherited heart disease patients and their families. 
As the patient moves along the clinical genetic testing pathway there are three 
key areas for improvement addressed in the current work. First, regarding 
interpretation of results themselves and particularly improved understanding of 
the phenotype associated with rare variants identified by an NGS approach to 
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testing. Second, once the patient receives their result, the impact of NGS results, 
particularly uncertain results, on patients. Finally, we aimed to address the 
significant gap in current knowledge regarding the best approach for returning 
complex genetic results to the patient. The ultimate goal is improved knowledge 
of the impact of genetic variants, as well as improved patient understanding and 
family communication about genetics. Figure 6.1 summarises the key findings 
from this thesis and contributions of this PhD in helping to fill gaps in the field
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Figure 6.1 Summary of PhD study outcomes 
Abbreviations: HCM= hypertrophic cardiomyopathy; DSP= desmoplakin, NGS= next generation sequencing. 
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6.1.1 Genotype-Phenotype Correlations 
 
Identification of the pathogenic/likely pathogenic variant in the proband holds 
significant diagnostic, therapeutic and prognostic implications for inherited heart 
disease families. As one of the most critical challenges of inherited heart disease 
genetic testing, genotype-phenotype correlations and insight into the clinical 
impact of rare variants identified by NGS formed the focus of two studies of this 
PhD (Chapter two and three). Important recent research has highlighted a 
number of problems with current gene and disease curation approaches (Furqan 
et al., 2017, Harrison et al., 2017, Hosseini et al., 2018, Ingles et al., 2018, 
Mazzarotto et al., 2018). Previously accepted approaches to variant classification 
have largely been dismissed. In addition, focus has been placed on cardiac 
panels with the example of Brugada syndrome (BrS) an excellent illustration of 
how many of the previously established gene and disease associations no longer 
meet the clinically accepted level of evidence (Gray et al., 2018b, Hosseini et al., 
2018). As a result of these issues, establishing correlations between genetic 
variants and phenotype using the currently accepted and ever evolving 
ACMG/AMP guidelines is crucial. In particular, understanding the clinical impact 
and phenotype associated with variants identified using an NGS cardiac panel 
approach is essential to improving the clinical utility of technologies available in 
the clinic.  
 
In Chapter two and three we aimed to address some of these issues by 
investigating the clinical impact of rare variants identified from current genetic 
test practices for inherited heart diseases. By understanding in greater detail, the 
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clinical impact of rare variants, such as multiple rare variants in HCM in Chapter 
two, and truncating variants in Desmoplakin (DSP) in DCM/ARVC in Chapter 
three, we aimed to contribute to diagnosis and predictive testing, with future 
potential to guide therapies and inform prognosis.  
 
The first study of this PhD (Chapter two) sought to investigate the presence and 
clinical impact of rare variants identified in HCM probands undergoing 
comprehensive cardiac panel testing. At the time of the study, and in current 
practice, a comprehensive cardiac gene panel is the most commonly used 
genetic test for the HCM proband (Rehm, 2013, Alfares et al., 2015, Ingles et al., 
2018). In Chapter three we describe the impact of truncating variants in DSP in 
a large international cohort, to better understand the clinical and genetic aspects 
of DSP associated cardiomyopathy. 
 
In Chapter two and three, we addressed three critical clinical interpretation and 
genetic counselling issues that arise using a comprehensive cardiac gene panel 
approach: 
1. The increased detection rate of rare variants using cardiac panels; 
2. The clinical utility of large cardiac gene panels with many genes included 
having minimal evidence linking them to disease; 
3. The clinical impact of multiple rare variants.  
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6.1.1.1 The Increased Detection Rate of Rare Variants using Cardiac Panels 
and the Clinical Utility of Large Cardiac Gene Panels 
 
The first key result from Chapter two was that when sequencing genes beyond 
the 8-gene HCM panel, the identification of pathogenic/likely pathogenic variants 
did not increase beyond 32% but the identification of variants of uncertain 
significance increased significantly from 13% to 36%. This result supports the 
growing body of evidence highlighting many genes included on inherited heart 
disease panels have limited evidence of a pathogenic role in disease. Therefore, 
adding them to panels does not increase the diagnostic yield of the genetic test 
(Gray et al., 2018b, Hosseini et al., 2018, Ingles et al., 2018, Mazzarotto et al., 
2018, Shah et al., 2018). Further, returning such a high number of uncertain 
variants are likely to impact the recall and understanding of genetic results for 
the patient as addressed in Chapter 4 (Burns et al., 2017b). As we highlight in 
Chapter 2, the results apply to the clinical environment where results are 
returned to probands and their families with the view for use in clinical 
management and screening. Research testing inevitably involves sequencing 
hundreds of genes as well as exome and genome approaches with the potential 
to identify new candidate genes and provide further insight into genotype-
phenotype correlations (Bagnall et al., 2018). 
 
There is scope for further research to improve the clinical utility of large cardiac 
gene panels. This approach to testing grew out of the commercial interests of 
diagnostic laboratories, whereby a one-size fits all approach that included a large 
panel for ‘cardiomyopathies’ or ‘arrhythmogenic conditions’ represented a cost-
effective and ‘user-friendly’ test platform for consumers and the companies 
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themselves. Systematic evaluation of genetic results and rare variant 
identification as a result of current clinical approaches to inherited heart disease 
genetic testing is needed. Initiatives such as ClinGen (NIH-funded Clinical 
Genome Resource), have focused on combining field specific expertise to create 
standardised approaches to gene and variant curation on a larger scale (Rehm 
et al., 2015, Harrison et al., 2018). The strength of our study lies in the ability to 
investigate long-term clinical outcomes of patients who receive various gene 
results. In addition, our study reflects a realistic clinical scenario for inherited 
heart disease patients undergoing genetic testing.  
 
6.1.1.2 Understanding how Genetic Variants Influence Phenotype 
 
Findings from Chapter two and three provide insight into how gene variants 
contribute to disease. In Chapter two we provide strong evidence that multiple 
rare variants in an 8-gene HCM panel were associated with earlier disease onset, 
greater likelihood of family history of SCD and overall worse event-free survival 
from all cause death, cardiac transplant and cardiac arrest (Burns et al., 2017a). 
Of critical importance, worse outcomes were not observed when rare variants in 
less well-established genes were included in the analysis (beyond the 8-gene 
panel). This result contributes to clinical and family screening implications for 
inherited heart disease patients undergoing genetic testing. If a proband 
diagnosed with HCM were found to carry both a rare variant in MYBPC3 along 
with a rare variant in LDB3 (minimal evidence of gene-disease association for 
HCM), our results indicate there is less likely to be increased severity in 
phenotype or family history based on the presence of the second variant (Burns 
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et al., 2017a). This impacts the predictive genetic testing and genetic counselling 
advice provided to families. Inheritance in a family like this is likely to follow an 
autosomal dominant pattern, with no need to offer testing for the LDB3 variant. 
Seventeen percent (17%) of probands had multiple rare variants identified when 
considering a comprehensive 45-gene panel, highlighting that these results have 
important implications for a large proportion of probands. These findings 
represent a significant contribution to the field. They have direct genetic 
counselling implications that should guide discussions around inheritance and 
risk.  
 
In addition, identification of multiple rare variants when considering important 
HCM genes was 4%, including both causative and uncertain variants. 
Historically, it was reported multiple variants in HCM are seen in approximately 
5% of tested probands and might contribute to a more severe phenotype (Alfares 
et al., 2015, Ingles et al., 2018) however the landscape of genetic testing and 
how we classify and interpret variants has changed considerably since then. Our 
data support this literature, that highlights multiple variants in strong evidence 
HCM genes such as MYBPC3, and MYH7 has an effect on phenotype severity 
(Van Driest et al., 2004, Ingles et al., 2005). As a result, inheritance discussions 
and genetic counselling in these families becomes more complex. As indicated 
in our study, only 0.4% probands had two pathogenic/likely pathogenic variants. 
Therefore, for families with one pathogenic/likely pathogenic variant and one 
variant of uncertain significance (VUS), discussions regarding predictive genetic 
testing can be challenging. For example, there is an argument to offer predictive 
testing for both variants given the second variant, albeit of uncertain significance, 
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contributes to worse outcomes when seen in combination with another variant. 
The effect of this variant on its own however is unknown. The clinical impact for 
at-risk relatives found to carry only the VUS is unknown, as is the risk to their 
children, and clinical screening should continue as per expert clinical guideline 
recommendations.  
 
The second study of this PhD (Chapter three) evolved from a clinical scenario 
encountered in our multidisciplinary genetic heart disease clinic. When trying to 
classify a truncating variant in DSP the group felt at that time there was 
insufficient evidence from the literature to support the mixed phenotypic 
presentation including SCD, dilated cardiomyopathy and arrhythmogenic right 
ventricular cardiomyopathy (ARVC). The DSP variant was classified as a VUS 
and unable to be used in family management.  
 
Only limited reports of DSP variants, and specifically truncating variants in DSP 
have been reported in the literature. Most arise from large ARVC cohorts, 
whereby the study design does not allow for systematic evaluation of genotype-
phenotype correlations in DSP associated disease specifically (Lopez-Ayala et 
al., 2014, Bhonsale et al., 2015, Groeneweg et al., 2015). The study reported in 
Chapter three is the largest series of DSP truncation carriers in the literature. 
The study sought to comprehensively elucidate the phenotypic impact of 
truncating variants in the DSP gene. 
 
The data presented in Chapter three provides strong evidence that truncating 
variants in DSP should be considered its own gene-specific arrhythmogenic 
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cardiomyopathy. Probands with a truncating variant in the DSP gene have a 
phenotype characterised by left ventricular dysfunction and structural left 
ventricular involvement, compared with ‘classic’ ARVC patients whereby the right 
ventricle is primarily affected and in whom biventricular disease is not always 
evident (Lopez-Ayala et al., 2014, Bhonsale et al., 2015, Groeneweg et al., 2015). 
Although this cohort included mainly patients referred from tertiary centres we do 
show the phenotype associated with DSP truncating variants is likely severe. 
Importantly 22% of our cohort presented with SCD, 47% had SCD events, and a 
family history of SCD was present in 28% of the cohort. 
 
We provide new data that advance our understanding of the phenotype spectrum 
associated with DSP truncations, but also show that the location of the variant in 
DSP matters in terms of clinical outcomes. Using a large international cohort of 
variants, we found causative variants were significantly more common in the N-
terminal domain when compared with controls. Further, variants residing in this 
region were associated with worse event-free survival for probands. Notably, the 
cohort presented was not restricted to an ARVC diagnosis. Diagnoses from the 
referring clinician included ARVC, dilated cardiomyopathy and unexplained 
ventricular fibrillation. This data highlights that ARVC Task Force criteria should 
not define the phenotype associated with this disease as previously thought 
(Bhonsale et al., 2015, Castelletti et al., 2017, Groeneweg et al., 2015, Lopez-
Ayala et al., 2014).  
 
We show truncating variants in DSP contribute to the emerging arrhythmogenic 
cardiomyopathy phenotype spectrum and even more specifically DSP associated 
CHAPTER 6 – SUMMARY AND CONCLUSIONS 
  274 
cardiomyopathy (Gandjbakhch et al., 2018, Bennett et al., 2018). Increasingly, 
there is recognition that underlying genotype should guide phenotype 
characterisation. The example of long QT syndrome (LQTS) can be used to 
illustrate how genotype may guide clinical decision-making. Individuals carrying 
variants in KCNH2 (LQTS2) and SCN5A (LQTS3) with QTc intervals over 500ms 
are considered at greater risk than those carrying a KCNQ1 variant (LQTS1) for 
example (Mazzanti et al., 2018). Further, mexiletine has been shown to reduce 
arrhythmic risk in SCN5A carriers (Mazzanti et al., 2016). Additional examples 
are illustrated by probands diagnosed with conduction system disease, whereby 
routine management includes insertion of a pacemaker capable of treating 
bradyarrhythmia’s associated with the conduction system. In these individual’s, 
identification of an SCN5A or LMNA variant however, changes the management 
decision to insertion of an implantable cardioverter defibrillator, capable of 
shocking the heart out of dangerous ventricular arrhythmias. There is robust 
evidence to suggest these gene carriers are at increased risk of ventricular 
arrhythmia and SCD unlike those with conduction system disease in the absence 
of SCN5A or LMNA variants (Brodt et al., 2013, Ackerman et al., 2012). 
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6.1.2 The Impact of a Comprehensive Next Generation Sequencing 
Approach to Testing on the Patient 
 
Very few studies exist that report the patient experience of complex results from 
a comprehensive NGS approach to testing for inherited heart diseases. 
Summarising the available literature, that is drawn primarily from inherited cancer 
and paediatric settings, whilst patients theoretically seek all results from NGS 
testing, most enter the genetic testing process hoping for certainty, that a genetic 
test in many cases, cannot provide (Lazarus, 1993, Ajzen, 1991, Gooding et al., 
2006). Further, poor understanding of a genetic test result has been shown to 
have a negative impact on family communication about genetics (Daly et al., 
2016, O'Neill et al., 2009). The consent process and pre-test genetic counselling, 
are therefore important considerations when examining a patients’ ability to cope 
and to adequately conceptualise uncertain and complex genetic test results 
(Meiser et al., 2016).  
 
At present, the primary benefit of genetic testing lies in the opportunities it 
provides for family screening (Ingles et al., 2018, Ingles and Semsarian, 2018, 
Burns et al., 2018). Upon identification of a pathogenic/likely pathogenic variant, 
predictive genetic testing, whereby at-risk relatives can test for the presence or 
absence of the causative variant becomes available. For those found not to carry 
the variant, they are released from ongoing screening and their children are not 
at risk. For those found to carry the variant, clinical screening is recommended, 
to identify individuals with phenotypic evidence of disease, and whom may be at 
increased risk of SCD (Ingles et al., 2018, Ingles and Semsarian, 2018). As a 
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consequence of the current approach to testing, and the gaps in knowledge 
regarding how gene variants contribute to disease, there is a high chance of 
detecting a VUS (Alfares et al., 2015, Burns et al., 2017a). This uncertain result 
should not signify the patients’ disease is not inherited and does not exclude at-
risk relatives from risk or the recommendation for clinical screening.  
 
Based on clinical experience and the limited literature that does exist, we 
hypothesised that patients receiving complex or uncertain results may have 
inaccurate understanding of their genetic result. Subsequently, this poor 
understanding contributes to poor family communication about genetics. As 
reported in Chapter 4, we chose to perform an exploratory, qualitative study to 
explore the attitudes, preferences, recall and any psychosocial consequences of 
uncertain genetic results amongst HCM probands (Burns et al., 2017b). This was 
an important study, given the high prevalence of uncertain results returned to 
patients as shown in Chapter 2 (Alfares et al., 2015, Burns et al., 2017a, Gray et 
al., 2018b, Hosseini et al., 2018, Yang et al., 2018). It is paramount that we 
adequately prepare patients regarding the potential outcomes from genetic 
testing during the pre- and post-test genetic counselling process. 
 
We identified a number of themes from the qualitative interviews we conducted 
in Chapter 4. Themes identified included knowledge and recall of complex 
genetic information, individual experiences with HCM genetic testing as well as 
the process of communication and the importance of the provision of information. 
Importantly, we purposively recruited individuals with uncertain results and 
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identified unique themes related to recall and communication amongst this group 
of probands. 
 
The key result from this study was that HCM probands undergoing genetic testing 
require additional support and information beyond the current practice model 
employed in the multidisciplinary specialist clinic setting (Burns et al., 2017b). 
Amongst the probands interviewed, individuals who received an uncertain 
genetic result showed poor recall and understanding of genetic information. 
Many were ill-prepared for the potential for uncertainty and those with uncertain 
results perceived their result to be reassuring regarding the inheritance risk to 
relatives. Potentially the most clinically relevant finding was that in spite of cases 
where family communication about genetics did occur, there was not good 
evidence for meaningful screening action by relatives. This reflects findings from 
the currently available literature, which shows a need for more effective and 
evidence-based approaches to improve family communication about genetics 
(Smagarinsky et al., 2017, Young et al., 2017, Burns et al., 2018). 
 
The greatest benefit from genetic testing at present is the ability to determine 
relatives at risk of inherited heart disease and to release those found not to be at 
risk from ongoing screening and management (Ingles and Semsarian, 2018). 
This has economic, psychological and medical implications (Ingles et al., 2012, 
Ingles and Semsarian, 2018, Hendriks et al., 2008). Our work, and the work of 
others, highlights two key issues. First, communication does not occur between 
probands and their relatives in many scenarios. Second, when it does occur, 
meaningful action such as adherence to screening guidelines or uptake of 
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predictive genetic testing amongst relatives is poor. The results presented in 
Chapter four highlight that further research is needed regarding the way in which 
results from NGS genetic testing are returned to patients in the clinic. In Chapter 
five, we aimed to address this issue, however beyond this, evidence-based pre- 
and post-test genetic counselling which considers results from studies such as 
those presented in Chapter two, three and four is essential. 
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6.1.3 Improving the Current and Future Process for Returning Complex 
Genetic Results 
 
There are gaps that span the genetic testing and counselling process with 
uncertainty created at many points, both for patients and for the multidisciplinary 
team caring for them. From the choice of genes tested (Chapter two), to our 
evolving understanding of how genes contribute to disease (Chapter two and 
three). In Chapter four we showed that uncertain and complex results might 
impact patient understanding and family communication about genetics. The 
findings in Chapter five are the culmination of work from Chapter two, three 
and four. Research I have undertaken up to this point has emphasised the 
complexity of genetic results for patients with inherited heart diseases. In 
Chapter five, we focused on translating findings from our previous research into 
a resource to help patients (Smagarinsky et al., 2017). We developed a study 
protocol for a randomised controlled trial of a custom designed aid for improving 
the ability and confidence of the proband to communicate genetic results to at-
risk relatives. We compared results between the intervention group and those 
receiving genetic results as per current clinical practice in the multidisciplinary 
clinic.  
 
Overall, the literature highlights family communication about genetic risk is 
complex (Gaff et al., 2005, Gaff et al., 2007, Hodgson et al., 2016). Many factors 
have been identified which influence family communication about genetic risk. 
These include family dynamics, guilt, anxiety and gender as well as emotional 
and geographic distance between relatives (Barsevick et al., 2008, Burns et al., 
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2016b, Christiaans et al., 2008, Claes et al., 2003, Healey et al., 2017). 
Importantly, the general consensus is that probands are in favour of informing 
their family about genetic risk, however a significant proportion of relatives remain 
uninformed (Hudson et al., 2018, Healey et al., 2017, Burns et al., 2016b, Burns 
et al., 2018).  
 
We hypothesised that improving the ability and confidence of a proband with 
HCM to communicate genetic results would have a positive impact on 
communication with at-risk relatives. We sought to address passive non-
disclosure, whereby relatives do not actively choose not to inform relatives, but 
rather may not be adequately equipped to do so (Gaff et al., 2005). Our a priori 
primary outcome measure in assessing the communication aid was the ability 
and confidence of the proband to communicate genetic information to at-risk 
relatives. Though we did not see a statistically significant difference, the majority 
of probands in the intervention group demonstrated “fair” communication when 
compared to controls. In addition, genetic knowledge scores were consistently 
higher amongst those probands randomised to the intervention when compared 
to normal clinical practice, although this did not reach statistical significance. 
Secondary outcomes assessed indicated positive outcomes for those in the 
intervention group, including satisfaction with services, outcomes from genetic 
counselling and genetic knowledge scores. 
 
The overall results from this study highlight the opportunities and challenges for 
genetic counselling, specifically related to return of genetic results and supporting 
families to communicate with their at-risk relatives. Determining the appropriate 
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outcome measure to assess when conducting genetic counselling intervention 
research is problematic (Payne et al., 2008, McAllister et al., 2011). This may 
contribute to the lack of consistency and consensus regarding the best practice 
approach to supporting family communication about genetic risk.  
 
A key finding from our study was that 29% of at-risk relatives were not informed 
of a genetic result. In addition, 17% of relatives were not informed that there was 
a diagnosis of a familial disease in the family. This was in spite of the genetic 
result disclosure occurring in a specialised multidisciplinary clinic equipped to 
deal with the complexity of inherited heart disease families. This work is in line 
with similar studies, which highlights a critical gap in communication amongst 
relatives. Beyond the communication process itself, uptake and adherence to 
screening guidelines has also shown to be problematic (Christiaans et al., 2008, 
Christiaans et al., 2009, Burns et al., 2016b, Hodgson et al., 2016). Though there 
is considerable variation, key results from our studies and the literature, highlight 
that use of a genetic counsellor, alongside a communication resource, should, to 
some extent, assist with the process of family communication. Collectively, the 
issue of family communication and screening represent an important area for 
future research into potential ways in which we can improve our current practice.  
 
After completion of this study we plan to evaluate the communication aid in more 
detail as it likely represents an important and useful contribution to our current 
clinical approach. We are currently conducting longer term follow up in this cohort 
of patients to systematically review communication and uptake of actual 
screening and genetic testing amongst relatives. 
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6.2 Clinical Significance and Translation 
 
This PhD has identified that in spite of the many opportunities of NGS testing, 
there are significant challenges to overcome to ensure we foster clinical 
translation of NGS technologies into clinical practice. Overall, the main clinical 
significance of this work is contribution to improved clinical application of NGS 
technologies for patients undergoing genetic testing for inherited heart diseases. 
The results of this PhD have the potential to impact clinical practice for inherited 
heart disease patients and their families. The studies evolved from common 
scenarios the inherited heart disease patient encounters as they undergo the 
process of genetic testing in the clinic.  
 
As described in Chapter two and three, accurate gene and disease association 
as well as strong evidence for genes included on cardiac panels is essential. 
Results from Chapter two and three should guide clinical interpretation and 
application of results from NGS technology for those ordering genetic testing in 
inherited heart disease patients. Data from these studies complement and 
support large scale initiatives and findings from international efforts such as 
ClinGen, which ultimately aim to improve variant and gene curation efforts. 
 
Based on the high prevalence of uncertain and complex results, data regarding 
the patient perspective of these results is essential in guiding improvements to 
the way in which we conduct genetic counselling and return complex results from 
an NGS approach. We aimed to provide the patient perspective in Chapter 4 and 
this work highlights the need to improve our current approach to returning genetic 
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results to probands. We developed a framework for improving communication to 
the proband which can be used by multidisciplinary teams ordering genetic 
testing in the clinic setting. The culmination of findings from Chapter two, three 
and four informed a clinical study to improve outcomes for our patients. In 
Chapter five we designed a randomised controlled trial to assess the use of a 
custom designed communication aid to improve the return of result process. The 
ultimate goal of this research was to facilitate better understanding of genetic 
results with the view to improving communication. Results from this trial highlight 
important focus areas for future research.  
 
The overarching message throughout this thesis is that the capabilities of NGS 
technologies have surpassed our knowledge of how best to implement clinical 
application of the tests and results generated. As the field evolves, the patient 
and their families, as well as approaches that increase the chance of returning 
clinically meaningful results to families should be paramount. By accurately 
investigating and attributing genotype-phenotype correlations, exploring the 
patient perspective, and examining approaches that may improve the process of 
returning results, this PhD has contributed to a better understanding of the 
challenges associated with clinical application of NGS for families with inherited 
heart diseases. 
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6.3 Conclusions 
 
In conclusion, genetics holds significant potential for families with inherited heart 
diseases in terms of diagnosis, management and family screening. Increasingly, 
improved understanding of genetic information is contributing to the evolution of 
precision medicine whereby management decisions and family screening may 
be tailored to an individual patient depending on their genotype. However, there 
are critical issues to address in order to improve the clinical application and utility 
of NGS technologies in the clinic. My work, as presented in this PhD, directly 
addresses a number of these issues including genotype-phenotype correlations, 
the patient perspective and investigations into how we might improve current 
practice. As a cardiac genetic counsellor, I have unique insight into the impact of 
these challenges on the patient and their family. The ultimate goal of the work 
from this PhD is to maximise the clinical utility of NGS technologies for families 
with inherited heart diseases seen in the clinic
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AGNES GINGES CENTRE FOR MOLECULAR CARDIOLOGY 
VARIANT ASSESSMENT & ASSERTION CRITERIA 
 
 
In our laboratory, variant assessment and determination of pathogenicity involved a multidisciplinary 
team composed of clinicians, clinical geneticists, genetic counsellors, research fellows, and lab 
technicians. Current guidelines from the American College of Medical Genetics and Genomics 
(ACMG).1,2 were modified to develop a more focused criteria applicable to the observed phenotype 
and correlation with specific genes. The clinical significance of variants was assessed using a 
systematic approach including, but not limited to: 
 
• Search of existing data to help determine likelihood of pathogenicity (e.g., literature, 
population databases, communication with collaborators)  
• Clinical and genetic evaluation of family members to determine if the variant segregates with 
disease 
• Interpretation of experimental data including in vivo and/or in vitro models 
• Revision of conservation and computational predictions by multiple in silico tools 
 
Determination of variant pathogenicity was discussed at formal meetings and the evidence was 
weighted to reach an overall conclusion. Classification of variants was assigned using a five-tier 
terminology system (pathogenic, likely pathogenic, uncertain significance, likely benign, benign). All 
variant classifications are reviewed as new guidelines and/or additional information becomes 
available. 
 
 
 
 
 
 
 
 
 
 
1. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE. ACMG recommendations for 
standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008 Apr;10(4):294-300. 
 
2. Bahcall OG. Genetic testing: ACMG guides on the interpretation of sequence variants. Nat Rev Genet. 2015 Apr 9. 
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 A2 
 
 
BENIGN LIKELY BENIGN UNCERTAIN SIGNIFICANCE 
 
LIKELY PATHOGENIC 
 
PATHOGENIC 
 
- Predicted null variant where LOF is 
known mechanism of disease 
 
- Well-characterised pathogenic 
mutation 
 
- De novo variant (paternity confirmed) 
 
- Strong segregation with disease 
 
- Very rare or absent in general 
population 
 
- Moderate segregation with disease 
 
- A different amino acid substitution at 
same location has been well 
characterised as pathogenic in the 
same disease 
 
- Functional evidence 
 
- Suspected de novo (paternity not 
confirmed) 
 
- Reputable source reports as 
pathogenic 
 
 
- Limited or conflicting data 
 
 
- Observed in population at 
frequency higher than expected 
disease 
 
- Not a conserved region 
 
- Multiple lines of computational tools 
predict no impact on gene 
 
- Lack of segregation in informative 
family members 
 
- Found in case where there is an 
alternate genetic  cause 
 
 
- Frequency >5% in general 
population 
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Appendix 2 Chapter 2 Unique variants identified in HCM cohort 
 
MYBPC3 rare variants 
Gene Genomic location cDNA variation 
Amino acid 
variation Function Classification Probands 
MYBPC3 Chr11(GRCh37):g.47374186C>A c.13G>T p.Gly5Trp Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47374173C>T c.25+1G>A p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47372920del c.162delG p.Lys54Asnfs*13 Frameshift Pathogenic 1 
MYBPC3 
Chr11(GRCh37):g.47372895_47372905d
el 
c.177_187delAGAGGGCAC
AC p.Glu60Alafs*49 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47371628C>T c.442G>A p.Gly148Arg Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47371366G>A c.613C>T p.Gln205* Nonsense Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47370092C>G c.655G>C p.Val219Leu Missense Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47369975C>T c.772G>A p.Glu258Lys Missense Pathogenic 3 
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MYBPC3 Chr11(GRCh37):47369411C>T c.818G>A p.Arg273His Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47368189GAA>G c.913_914delTT p.Phe305Profs*27 Frameshift Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47367917A>T c.931T>A p.Ser311Thr Missense 
Uncertain 
Significance  1 
MYBPC3 Chr11(GRCh37):g.47367930C>T c.927-9G>A p.? Splice Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47367758C>T c.1090G>A p.Ala364Thr Missense 
Likely 
Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364621G>T c.1302C>A p.Tyr434* Nonsense Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364570A>G c.1351+2T>C p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364478CA>C c.1359delT p.Val454Cysfs*12 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364409C>T c.1429G>A p.Val477Ile Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47364296C>T c.1458-1G>A p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364270G>C c.1483C>G p.Arg495Gly Missense 
Likely 
Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47364249G>A c.1504C>T p.Arg502Trp Missense Pathogenic 13 
MYBPC3 Chr11:(GRCh37):g. 47364248C>T c.1505G>A p.Arg502Gln Missense Pathogenic 1 
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MYBPC3 Chr11(GRCh37):g.47364173A>G c.1580T>C p.Leu527Pro Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47364129C>G c.1624G>C p.Glu542Gln Missense  Pathogenic 5  
MYBPC3 Chr11(GRCh37):g.47364125T>A c.1624+4A>T p.? Splice Pathogenic 3 
MYBPC3 Chr11(GRCh37):g.47363567G>A c.1765C>T p.Arg589Cys Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):47362747dup c.1838dupA p.Asp613Glufs*25 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):47361343T>C c.1928-2A>G p.? Splice Pathogenic 4 
MYBPC3 Chr11(GRCh37):g.47361239G>A c.2030C>T p.Pro677Leu Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47360945G>A c.2078C>T p.Ala693Val Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47360940C>CTGGG c.2079_2082dupCCCA p.la695Profs*14 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47360209G>A c.2170C>T 
p. 
Arg724Trp Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47360200C>T c.2179G>A p.Val727Met Missense 
Uncertain 
Significance 1 
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MYBPC3 Chr11(GRCh37):g.47360145T>C c.2234A>G p.Asp745Gly Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47360071C>T c.2308G>A p.Asp770Asn Missense 
Likely 
Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47360070C>T c.2308+1G>A p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47359347T>C c. 2309-2A>G p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47359280A>AC c.2373dupG p.Trp792Valfs*41 Frameshift Pathogenic 8 
MYBPC3 Chr11(GRCh37):g.47359115C>T c.2429G>A p.Arg810His Missense 
Likely 
Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47359095G>C c.2449C>G 
 
p.Arg817Gly Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47359019T>TA c.2524dupT p.Tyr842Leufs*41 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47359011G>T c.2533C>A p.Arg845Ser Missense Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47359001G>T c.2543C>A p.Ala848Glu Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):47357561 c.2604-2605delTCinsA p.Ser871Alafs*8 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47357429GC>G c.2735_2736delGC p.Gly912Valfs*138 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47356762T>A c.2738-2A>T p.? Splice Pathogenic 1 
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MYBPC3 Chr11(GRCh37):g.47356716ATG>A c.2780_2781delCA p.Thr927Ilefs*123 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47356671G>A c.2827C>T p.Arg943* Nonsense Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47356632CAG>C c.2864_2865delCT p.Pro955Argfs*95 Frameshift Pathogenic 7 
MYBPC3 Chr11(GRCh37)g.47356593 c.2905C>T p.Gln969* Nonsense Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47355487G>A c.2980C>T p.Leu994Phe Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47355293C>T c.3005G>A p.Arg1002Gln Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47355233C>T c.3065G>A p.Arg1022His Missense 
Uncertain 
Significance 1 
MYBPC3 
Chr11(GRCh37):g.47355108_47355110d
el c.3188_3190delTTG p.Val1063del Indel 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47355103C>T c.3190+5G>A p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37)g.47354883dupG c.3192dupC p.Lys1065Glnfs*12 Frameshift Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47354798C>A c.3277G>T p.Gly1093Cys Missense 
Uncertain 
Significance 1 
MYBPC3 
Chr11(GRCh37):g.47354743A>C 
 
c.3330+2T>G 
 p.? Splice Pathogenic 1 
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MYBPC3 
Chr11(GRCh37)g.47354518_47354520du
p c.3335_3337dupGG p.Trp1112dup Indel 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47354364C>T c.3490+1G>A p.? Splice Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47354145A>G c.3599T>C p.Leu1200Pro Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47354139C>T c.3605G>A p.Cys1202Tyr Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47354126AC>A c.3617delA p.Gly1206Valfs*31 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47354119TG>T c.3624delC p.Lys1209Serfs*28 Frameshift Pathogenic 2 
MYBPC3 Chr11(GRCh37):g.47353795C>A c.3642G>T p.Trp1214Cys Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37):g.47353740G>A c.3697C>T p.Gln1233* Nonsense Pathogenic 3 
MYBPC3 Chr11(GRCh37):g.47353737C>T c.3700G>A p.Gly1234Arg Missense 
Uncertain 
Significance 1 
MYBPC3 Chr11(GRCh37)g.47353723CAG>C c.3712_3713delCT p.Leu1238Glyfs*3 Frameshift Pathogenic 1 
MYBPC3 Chr11(GRCh37):g.47353686A>G c.3751T>C p.Tyr1251His Missense 
Uncertain 
Significance 1 
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MYH7 rare variants 
Gene Genomic location cDNA variation 
Amino acid 
variation Function Classification Probands 
MYH7 Chr14(GRCh37):23884311 c.5452C>T p.Arg1818Trp Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23884476C>T c.5287G>A p.Ala1763Thr Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37:g.23884651AC>A c.5222_5223delTG 
p.Val1741Glyfs*
11 Frameshift 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23884861G>A c.5134C>T p.Arg1712Trp Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23885041C>A c.4954G>T p.Asp1652Tyr Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23887453C>T c.4135G>A p.Ala1379Thr Missense Pathogenic 4 
MYH7 Chr14(GRCh37):g.23887464T>C c.4124A>G p.Tyr1375Cys Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23887513G>A c.4075C>T p.Arg1359Cys Missense 
Uncertain 
Significance 1 
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MYH7 Chr14(GRCh37):g.23887522C>T c.4066G>A p.Glu1356Lys Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23889188C>A c.3592G>T p.Asp1198Tyr Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23890178T>C c.3325A>G p.Lys1109Glu Missense Likely Pathogenic 1 
MYH7 Chr14 (GRCh37)g.23891398C>T c.3236G>A p.Arg1079Gln Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23892791T>C c.3064A>G p.Lys1022Glu Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23893268C>T c.2770G>A p.Glu924Lys Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23893300 c.2738T>C p.Ile913Thr Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):23893357T>C c.2681A>G p.Glu894Gly Missense Pathogenic 6 
MYH7 Chr14(GRCh37):g.23894048C>T c.2609G>A p.Arg870His Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23894079T>C c.2578A>G p.Lys860Glu Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23894118T>C c.2539A>G p.Lys847Glu Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23894494C>T c.2420G>A 
p. 
Arg807His Missense 
Uncertain 
Significance 1 
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MYH7 Chr14(GRCh37):g.23894525C>T c.2389G>A p.Ala797Thr Missense Likely Pathogenic 2 
MYH7 Chr14(GRCh37):23894581 c.2333A>T p.Asp778Val Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23894965G>T c.2225C>A p.Ala742Glu Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23894969C>A c.2221G>T p.Gly741Trp Missense Pathogenic 3 
MYH7 Chr14(GRCh37):g.23894983A>G c.2207T>C p.Ile736Thr Missense Pathogenic 2 
MYH7 Chr14(GRCh37):g.23895023G>A c.2167C>T p.Arg723Cys Missense Pathogenic 3 
MYH7 Chr14(GRCh37):23895179C>T c.2156G>A p.Arg719Gln Missense Pathogenic 2 
MYH7 Chr14(GRCh37):g.23895180G>A c.2155C>T p.Arg719Trp Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23895242A>G c.2093T>C p.Val698Ala Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23896042C>T c.1988G>A p.Arg663His Missense Pathogenic 5 
MYH7 Chr14(GRCh37):g.23896451T>C c.1954A>G p.Arg652Gly Missense Likely Pathogenic 2 
MYH7 Chr14(GRCh37):g.23896866C>T c.1816G>A p.Val606Met Missense Pathogenic 3 
MYH7 Chr14(GRCh37):g.23896955T>C c.1727A>G p.His576Arg Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23898201A>G c.1370T>C p.Ile457Thr Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23898247G>A c.1324C>T p.Arg442Cys Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23898487C>T c.1208G>A p.Arg403Gln Missense Pathogenic 1 
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MYH7 Chr14(GRCh37):g.23898488G>A c.1207C>T p.Arg403Trp Missense Pathogenic 1 
MYH7 Chr14(GRCh37):g.23899071T>C c.1051A>G p.Lys351Glu Missense Likely Pathogenic 1 
MYH7 Chr14(GRCh37):g.23899816T>G c.952A>C p.Thr318Pro Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g.23899831T>A c.937A>T p.Ile313Phe Missense 
Uncertain 
Significance 1 
MYH7 Chr14(GRCh37):g23900998C>T c.611G>A p.Arg204His Missense 
Uncertain 
Significance 1 
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TNNT2 rare variants 
Gene Genomic location cDNA variation 
Amino acid 
variation Function Classification Probands 
TNNT2 Chr1(GRCh37):g.201334766A>T c.236T>A p.Ile79Asn Missense Pathogenic 1 
TNNT2 Chr1(GRCh37):g.201334425C>T c.275G>A p.Arg92Gln Missense Pathogenic 2 
TNNT2 Chr1(GRCh37):g.201334389G>A c.311C>T p.Ala104Val Missense Likely Pathogenic 1 
TNNT2 Chr1(GRCh37):g.201333435G>T c.450C>A p.Asn150Lys Missense 
Uncertain 
Significance 1 
TNNT2 
Chr1(GRCh37):g.201332505_201332507
del c.487_489delGAG p.Glu163del Indel Pathogenic 2 
TNNT2 Chr1(GRCh37):g.201331078C>A c.652G>T p.Val218Leu Missense 
Uncertain 
Significance 1 
TNNT2 Chr1(GRCh37):g.201328372C>T c.833G>C p.Arg278Pro Missense Likely Pathogenic 1 
TNNT2 Chr1(GRCh37):g.201328372C>T c.833G>A p.Arg278His Missense 
Uncertain 
Significance 1 
TNNT2 Chr1(GRCh37):g.201328349G>A c.856C>T p.Arg286Cys Missense 
Uncertain 
Significance 1 
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Rare variants in CSRP3,ACTN2,TNNi3,ACTC1,MYL2, MYL3,TPM1,NEXN,PLN.MYL2 and TTR 
Gene Genomic location cDNA variation 
Amino acid 
variation Function Classification Probands 
CSRP3 Chr11(GRCh37):g.19213903G>C c.93C>G p.His31Gln Missense 
Uncertain 
Significance 1 
CSRP3 Chr11(GRCh37):19209758T>C c.206A>G P.Lys69Arg Missense 
Uncertain 
Significance 1 
CSRP3 Chr11(GRCh37):19207854del c.322delA p.Ser108Profs*100 Frameshift 
Uncertain 
Significance 1 
CSRP3 Chr11(GRCh37):g.19206571G>A c.436C>T p.Arg146Cys Missense 
Uncertain 
Significance 2 
CSRP3 Chr11(GRCh37):g.19206570C>T c.437G>A p.Arg146His Missense 
Uncertain 
Significance 1 
CSRP3 Chr11(GRCh37):g.19204291A>C c.511T>G p.Cys171Gly Missense 
Uncertain 
Significance 1 
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ACTN2 Chr1(GRCh37):g.236902708G>A c.983G>A p.Arg328Gln Missense 
Uncertain 
Significance 1 
ACTN2 Chr1(GRCh37):g.236906281G>A c.1193G>A p.Arg398His Missense 
Uncertain 
Significance 1 
ACTN2 Chr1(GRCh37):g.236908039C>T c.1369C>T p.Arg457Cys Missense 
Uncertain 
Significance 1 
ACTN2 Chr1(GRCh37):g.236914861A>C c.1748A>C p.Glu583Ala Missense 
Uncertain 
Significance 1 
ACTN2 Chr1(GRCh37):g.236917290A>G c.1883A>G p.Glu628Gly Missense 
Uncertain 
Significance 1 
TNNI3 Chr9(GRCh37):g.55666111C>G c.370G>C p.Glu124Gln Missense Likely Pathogenic 1 
TNNI3 Chr19(GRCh37):g.55665514G>A c.433C>T p.Arg145Trp Missense Pathogenic 1 
TNNI3 Chr19(GRCh37):g.55665507A>G c.440T>C p.Val147Ala Missense 
Uncertain 
Significance 1 
TNNI3 Chr19(GRCh37):g.55665462C>T c.485G>A p.Arg162Gln Missense Likely Pathogenic 3 
TNNI3 Chr19(GRCh37):g.55663286C>T c.550-1C>T p.? Splice 
Uncertain 
Significance 1 
TNNI3 Chr19(GRCh37):g.55663224C>T c.611G>A p.Arg204Hi Missense Likely Pathogenic 1 
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ACTC1 Chr15(GRCh37):g.35085622T>C c.278A>G p.Tyr93Cys Missense 
Uncertain 
Significance 1 
ACTC1 Chr15(GRCh37):g.35083455T>A c.850A>T p.Ile284Phe Missense 
Uncertain 
Significance 1 
ACTC1 Chr15(GRCh37):g.35083337G>A  c.968C>T p.Ala323Val Missense 
Uncertain 
Significance 1 
MYL2 Chr12(GRCh37):g.111356937C>T c.64G>A p.Glu22Lys Missense Likely Pathogenic 1 
MYL2 Chr12(GRCh37):g.111351092T> c.311A>C p.Lys104Thr Missense 
Uncertain 
Significance 1 
MYL3 Chr3(GRCh37):g.46902455A>G c.152T>C p.Ile51Thr Missense 
Uncertain 
Significance 1 
MYL3 Chr3(GRCh37):g.46900985C>T c.461G>A p.Arg154His Missense Likely Pathogenic 1 
MYL3 Chr3(GRCh37):g.46900983G>C c.463C>G p.His155Asp Missense 
Uncertain 
Significance 1 
TPM1 Chr15(GRCh37):g.63353123C>T c.548C>T p.Ala183Val Missense Likely Pathogenic 3 
TPM1 Chr15(GRCh37):g.63353922G>A c.574G>A p.Glu192Lys Missense Likely Pathogenic 1 
TPM1 Chr15(GRCh37):g.63353983A>T c.635A>T p.Glu212Val Missense 
Uncertain 
Significance 1 
APPENDIX 2 
 
 A17 
NEXN Chr1(GRCh37):g.78395007G>A c.871G>A p.Glu291Lys Missense 
Uncertain 
Significance 1 
NEXN Chr1(GRCh37):g.78398976G>C c.871G>C p.Asp291His Missense 
Uncertain 
Significance 1 
PLN Chr6(GRCh37):g.118880137T>C c.53T>C p.Ile18Thr Missense 
Uncertain 
Significance 1 
PLN Chr6(GRCh37):g.118880200T>G c.116T>G p.Leu39* Nonsense Pathogenic 1 
TTR Chr18(GRCh37):g.29172958G>A c.169G>A p.Ala57Thr Missense 
Uncertain 
Significance 1 
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CODE:   
RESULT CLASSIFICATION:  
DATE OF PHONE CALL:   
INTERVENTION /CONTROL:  
DATE OF RESULT RETURN:   
DATE OF THIS PHONE CALL:  
ONE/THREE or SIX MONTHS:  
 
Hello, this is (Insert Name) from the Centenary Institute, may I please speak 
to (Participant name)? 
 
I am phoning (as we discussed back in (insert month of intervention) to follow 
up with you after you received your genetic result as part of our research into 
communicating genetic results. This is your (one month, three month, six 
month) follow up phone call. I was hoping to get some additional information 
from you regarding your gene result. Do you have 10 minutes or so to do this 
now- or I can arrange a more appropriate time? 
 
SECTION 1: 3-generation pedigree documented – Have this 
documented prior to phone call. Confirm during phone call. (Can print 
progeny pedigree) 
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SECTION 2 
Who in the family have you told about the following: (List 
names/details): 
Your diagnosis of HCM? 
 
 
 
 
 
 
 
 
About your genetic result? 
 
 
 
 
 
 
 
 
Who in the family has had an echo/ecg/Cardiology review- Outcome? 
(Assess against guidelines)? 
 
 
 
 
 
 
 
 
 
Who in the family has had genetic testing- Outcome? 
 
 
 
 
 
 
 
Who in the family is awaiting an appointment- with whom? 
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SECTION 3: 
 
Total number of first degree relatives informed of diagnosis =  / 
 
 
 
 
 
Total number of first degree relatives informed of genetic test outcome= / 
 
 
 
 
Total number of first degree relatives who have had cardiology review= / 
 
 
 
 
 
Total number of first degree relatives who have had genetic review= / 
 
 
 
 
 
Total number of first degree relatives awaiting review= / 
 
 
 
 
 
Total number of first degree relatives with a positive clinical screen= / 
 
 
 
Total number of relatives with a negative clinical screen = / 
 
 
Total number of first degree relatives with a positive genetic result =  
 
Total number of first degree relatives with a negative genetic result=  
 
 
Total number of other relatives informed =  
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Communicating Hypertrophic Cardiomyopathy (HCM) 
Genetic Test Results 
 
INFORMATION FOR PARTICIPANTS 
 
 
Introduction 
 
You are invited to take part in a research study examining how we can best 
communicate genetic test results in hypertrophic cardiomyopathy (HCM). Genetic 
testing for genetic heart diseases like HCM has become increasingly complex and 
our method of explaining these results needs to evolve to meet these changing 
needs. Cardiac genetic counsellors coordinate the genetic testing process and they 
play a key role in ensuring the information you are receiving is clear and meaningful 
for you and your family. The objective of this study is to compare the effectiveness of 
an intervention aimed at improving the way we communicate genetic test result 
information with our current usual care. If you consent to the study, you will be 
randomly assigned to either the new communication intervention or to usual care. 
 
Individuals with hypertrophic cardiomyopathy are eligible to participate in this study if 
they are the first in their family to have genetic testing.  People aged 16 years or 
older are eligible to participate; however children younger than this are excluded. 
 
The study is being conducted by Dr Jodie Ingles, Prof Christopher Semsarian, Ms 
Laura Yeates and Ms Charlotte Burns from the Molecular Cardiology Research 
Program, Centenary Institute and Royal Prince Alfred Hospital Sydney.  
 
Study Procedures 
 
If you agree to participate in this study, you will be asked to complete the participant 
consent form.  You will then be randomly allocated to one of two groups, to receive 
your genetic test result.  Two weeks after your genetic test result appointment, you 
will be asked to complete a survey (either paper or online), asking about your 
understanding of genetic testing for HCM. This survey will take between 10-20 
minutes to complete.  
 
In addition, the researchers would like to phone you at one, three and six 
month intervals to follow up with you after you receive your genetic result. 
These phone calls will take approximately 10 minutes and will be conducted at 
a time that suits you.  
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Researchers will have access to your medical record to obtain information relevant 
to this study. Information about you may also be sought from the Australian Genetic 
Heart Disease Registry, if you have enrolled (www.heartregistry.org.au). 
Confidentiality of the survey responses will be paramount. Your name will be 
replaced with a unique code and only Dr Jodie Ingles will have access to the true 
identity of respondents.  
 
No additional genetic testing will be carried out as part of this study. 
 
Information collected about you will be securely stored. 
 
Benefits 
 
While we intend that this research study furthers medical knowledge and may 
improve management of genetic heart diseases in the future, it may not be of direct 
benefit to you. 
 
Voluntary Participation 
 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If 
you do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not affect your medical 
treatment or your relationship with the staff who are caring for you.  
 
Confidentiality 
 
All of the information collected from you for the study will be treated confidentially, 
and only the researchers named above will have access to it. The study results may 
be presented at a conference or in a scientific publication, but individual participants 
will not be identifiable in such a presentation. 
 
Any forms completed online, including the participant consent form and survey will 
be extremely secure to maintain participant privacy.  
 
Further Information 
 
When you have read this information, one of the investigators is available to discuss 
it with you further and answer any questions you may have.  If you would like to 
know more at any stage, please feel free to contact: 
 
Dr Jodie Ingles 
Molecular Cardiology Research Program 
Centenary Institute 
Locked Bag No 6, Newtown NSW 2042 
Ph. 02 9565 6293 
Email. j.ingles@centenary.org.au      Web. www.heartregistry.org.au   
 
This information sheet is for you to keep. 
 
 
 
Ethics Approval and Complaints 
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This study has been approved by the Ethics Review Committee (RPAH Zone) of the 
Sydney Local Health District.  Any person with concerns or complaints about the 
conduct of this study should contact the Executive Officer on 02 9515 6766 and quote 
protocol number X16-0030. 
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Communicating Hypertrophic Cardiomyopathy (HCM) Genetic 
Test Results 
 
PARTICIPANT CONSENT FORM 
 
 
 
I, ...................................................................................................................................... [name]  
 
of 
......................................................................................................................................[address]  
 
…………………………………………………………………………………………………….[email] 
 
have read and understood the Information for Participants on the abovenamed research study 
 
and have discussed the study with .............................................................................................. 
 
I have been made aware of the procedures involved in the study. 
 
I understand that my participation in this study will allow the researchers to have access to my 
medical record, including information held by the Australian Genetic Heart Disease Registry (if 
I am enrolled), and I agree to this. 
 
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
NAME:    ........................................................................................................... 
 
SIGNATURE:   ........................................................................................................... 
 
DATE:    ........................................................................................................... 
 
NAME OF WITNESS:  .................................................................................................. 
 
SIGNATURE OF WITNESS: .................................................................................................. 
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Hypertrophic Cardiomyopathy
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Genetics:  
The Basics
Definition of  
‘Gene Variant’
 
A change in a gene’s DNA code is 
called a ‘gene variant’. Some gene 
variants have no effect on the health 
of our body and are part of normal 
variation. Variants that cause serious 
mistakes in the genes (and proteins) 
in our body can lead to disease, such 
as HCM. The challenge lies in working 
out which gene variants are normal 
(‘benign’) and which are disease 
causing (‘pathogenic’).
8
Our body is made up of millions of cells.  
Each cell contains DNA, the genetic code that 
acts as the instruction manual for the body. 
It decides features such as the shape of our 
heart, the colour of our eyes and whether we 
are tall or short. Along the lengths of DNA, 
specific regions of the code are called genes. 
Humans have about 20,000 genes and we 
have 2 copies of each gene, one copy we 
inherit from our mum, the other copy from  
our dad. These genes code for proteins, 
which play an important role in the  
functioning of our bodies.
Each and every person is unique because  
we all have a number of small differences 
within our genes. We all inherit a random 
combination of differences from our parents. 
This is known as normal genetic variation.
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What is my  
genetic result?
12
Test Result The Impact for You The Impact for Your Family
Pathogenic 
(page 18)
This result is considered to be the 
definite cause of your disease.
We can look for the same variant  
in family members  
(cascade genetic testing).
Likely (probably)  
pathogenic 
(page 18)
This result is considered to be 
important and with the available 
evidence is thought to be the 
cause of HCM.
We can look for the same variant  
in family members  
(cascade genetic testing).
Variant of unknown 
significance (VUS) 
(page 20)
Currently we do not know if this 
variant is the cause of HCM or 
not. More evidence is needed.
Continue with current clinical 
screening guidelines,  
no cascade genetic testing 
options available at this time.
Benign or  
likely benign  
(page 16)
This variant is not  
the cause of HCM.
Continue with current clinical 
screening guidelines,  
no cascade genetic testing 
options available at this time.
No variant identified  
(indeterminate) 
(page 15)
No HCM variants  
have been identified.
Continue with current clinical 
screening guidelines,  
no cascade genetic testing 
options available at this time.
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How certain are we that  
a variant is the cause of HCM?
Your gene result
Benign
indeterminate
A DNA variant in   (gene) was found.
It is classified at present as   
No DNA variant was found or only benign/likely benign 
variants were found at present (indeterminate).
Does not cause HCM Causes HCM
Likely benign Uncertain
Likely  
pathogenic Pathogenic
OR
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Sharing this booklet with family members is encouraged.
If you’re a family member reading this booklet, hopefully you will find  
some details below that apply directly to you.
All first-degree relatives of someone with HCM are recommended to have  
clinical screening to check for signs of HCM. This includes children,  
brothers/sisters and parents.
Clinical screening involves: echocardiogram (ultrasound of the heart) electrocardiogram  
(or ECG, an electrical trace of the heart rhythm), and physical examination with a cardiologist.
First name Relation Age
Clinical 
Screening
Genetic testing 
possibilities
My family  
summary
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Communicating HCM Genetic Test Results 
 
 
PART 1 – Basic information 
 
Name  __________________________________________________ 
Phone  __________________________________________________ 
Email  __________________________________________________ 
Today’s Date__________________________________________________ 
 
 
 
Thank you for your participation in this study. 
 
 
 
 
Please complete the following survey and return to: 
 
Dr Jodie Ingles 
Molecular Cardiology 
Centenary Institute 
Locked Bag No 6 
Newtown NSW 2042 
Phone: 02 9565 6293 
Email: j.ingles@centenary.org.au 
 
 
  
APPENDIX 7  
 
 A47 
 
  
Communicating HCM Genetic Test Results 
Participant Survey Version 3.0 17th August 2016  Page 2 of 10 
YOUR ANSWERS ARE STRICTLY CONFIDENTIAL 
PART 1 - Basic information 
 
For each of the following questions, please tick the box that best describes your answer.  
1. How often do you see a cardiologist? 
! More than once a year 
! About once a year 
! Every 2-3 years 
! Every 3-5 years 
! Only if there is a problem 
! I do not see a cardiologist 
 
2. Have your immediate family members previously seen a cardiologist to test for 
HCM? 
! Yes, all of them 
! Yes, some of them 
! None 
! Unsure 
 
PART 2 – Socio-Demographic Information  	
1. What is the highest level of education you have completed? 
 ! University 
 ! TAFE/ College 
 ! High School 
 ! Did not finish high school 
 ! Still studying 
 
2. What is your postcode? _________ 
 
3. How would you describe your ethnicity 
 ! White/Caucasian 
 ! Aboriginal and/or Torres Strait Islander 
 ! Other, please provide details ___________________________ 
 
4. Do you have any other serious medical problems? ! Yes     ! No 
 (Example: diabetes, depression, cancer etc.) 
 Please list: 
___________________________________________________________ 
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PART 3 – Genetics Knowledge 
 
For each of the following questions, please tick the box that best describes your answer.  
Don’t take too long over your replies; your immediate response is best for this survey.   
 
 True False Don’t 
know  
1. 50% (half) of your genetic information was 
passed down from your mother. 
   
2. 25% (one quarter) of your genetic information 
was passed down from your father. 
   
3. Each daughter and son has the same chance of 
developing HCM if one parent has HCM. 
   
4. Genetic testing is the only way of finding out if 
someone has HCM. 
   
5. An inherited HCM-causing gene variant  
(pathogenic variant) is present in the DNA in 
every cell of the body. 
   
6. There is more than one gene in humans, which if 
damaged, can cause HCM. 
   
7. If a parent has an HCM-causing gene variant 
(pathogenic variant), each child has a 50% (1 in 
2) chance of inheriting the pathogenic variant. 
   
8. An individual who has a sister or brother with an 
HCM-causing gene variant (pathogenic variant) 
has a 1 in 4 (25%) chance of also having the 
pathogenic variant. 
   
9. If a person with HCM has an indeterminate 
genetic test result (no gene variants found), this 
means HCM is not inherited in their family. 
   
10. A variant of uncertain significance (VUS) may or 
may not be the cause of HCM.  More evidence 
and information is needed to know if this is 
important. 
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PART 4 - The following questions relate to your satisfaction with the services you 
received at the HCM Clinic, RPA Hospital Medical Centre. 
 
Please circle your answers to the following questions. 
 
 Very 
dissatisfied 
Somewhat 
dissatisfied 
Somewhat 
satisfied Very satisfied 
1. Did the genetic counsellor 
explain your genetic test 
result to you clearly? 
 
1 2 3 4 
2. Did the genetic counsellor 
meet your expectations of 
him/her? 
 
1 2 3 4 
3. Did the genetic counsellor 
reassure you? 
 1 2 3 4 
4. Did the genetic counsellor 
listen to what you had to 
say? 
 
1 2 3 4 
5. Did the genetic counsellor 
show enough dedication in 
explaining your genetic test 
result? 
 
1 2 3 4 
6. Did the genetic counsellor  
understand what was really 
bothering you? 
 
1 2 3 4 
7. Can the counselling that 
you received help you cope 
better with your problem? 
 
1 2 3 4 
8. How satisfied are you with 
the information you got in 
counselling? 
 
1 2 3 4 
9. In summary, how would you 
rate your satisfaction with 
the counselling? 
 
1 2 3 4 
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PART 5 – The following questions relate to how you feel about your diagnosis	
 
Using the scale below, circle a number next to each statement to indicate how much you 
agree with the statement.  	
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 d
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e 
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e 
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ee
 
A
gr
ee
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1. I am clear in my own mind why I attended the 
HCM clinic. 1 2 3 4 5 6 7 
2. I can explain what HCM means to people in my 
family who may need to know. 1 2 3 4 5 6 7 
3. I understand the impact of the condition on my 
child(ren)/any child I may have. 1 2 3 4 5 6 7 
4. When I think about HCM in my family, I get 
upset. 1 2 3 4 5 6 7 
5. I don’t know where to go to get the medical help 
I/my family need(s). 1 2 3 4 5 6 7 
6. I can see that good things have come from 
having HCM in my family. 1 2 3 4 5 6 7 
7. I can control how HCM affects my family. 1 2 3 4 5 6 7 
8. I feel positive about the future. 1 2 3 4 5 6 7 
9. I am able to cope with having HCM in my family. 1 2 3 4 5 6 7 
10. I don’t know what could be gained from each of 
the options available to me. 1 2 3 4 5 6 7 
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11. Having HCM in my family makes me feel 
anxious. 1 2 3 4 5 6 7 
12. I don’t know if this condition could affect my 
other relatives (brothers, cousins…). 1 2 3 4 5 6 7 
13. In relation to HCM in my family, nothing I decide 
will change the future for my children/any 
children I might have. 
1 2 3 4 5 6 7 
14. I understand the reasons why my doctor referred 
me to the cardiac genetics service. 1 2 3 4 5 6 7 
15. I know how to get the non-medical help I/my 
family need(s) (e.g. educational, financial, social 
support). 
1 2 3 4 5 6 7 
16. I can explain what the condition means to people 
outside the family who may need to know (e.g. 
teachers, social workers). 
1 2 3 4 5 6 7 
17. I don’t know what I can do to change how this 
condition affects me/my children. 1 2 3 4 5 6 7 
18. I don’t know who else in my family might be at 
risk for HCM. 1 2 3 4 5 6 7 
19. I am hopeful that my children can look forward to 
a rewarding family life. 1 2 3 4 5 6 7 
20. I am able to make plans for the future. 1 2 3 4 5 6 7 
21. I feel guilty because I (might have/ or may one 
day) pass this condition onto my children. 1 2 3 4 5 6 7 
22. I am powerless to do anything about this 
condition in my family. 1 2 3 4 5 6 7 
23. I understand what concerns brought me to the 
cardiac genetics clinic. 1 2 3 4 5 6 7 
24. I can make decisions about my condition that 
may change my child(ren)’s future/the future of 
any child I might have.  
 
1 2 3 4 5 6 7 
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PART 6 – The following questions are focused on communication of the genetic 
result and diagnosis of HCM with family members.  
 
1. Have you told any of your family about your genetic test result? !  YES  !  NO 
Please tick yes if you have explained the result to at least 1 adult family member 
 
2. How many immediate adult relatives (i.e. parents, brother/sister, children) have 
you informed? (eg. 1 parent and 2 brothers) 
________________________________________________________________________
________________________________________________________________________ 
 
3. Have you told any of your family about your diagnosis of HCM? ! YES  ! NO 
Please tick yes if you have explained the result to at least 1 adult family member 
 
4. How many immediate adult relatives (i.e. parents, brother/sister, children) have 
you informed? (eg. 1 parent and 2 brothers) 
________________________________________________________________________
________________________________________________________________________ 
 
5. How many immediate adult relatives (i.e. parents, brother/sister, children) have 
you NOT informed? Would you mind explaining why? (e.g. limited contact with 
relative, no interest, unable to explain what the result means, planning to, etc.) 
________________________________________________________________________
________________________________________________________________________ 
________________________________________________________________________
________________________________________________________________________ 
________________________________________________________________________ 	
6. How would you rate your ability to communicate this information to family 
members? 
 
! No difficulties, I felt confident in explaining the information accurately to family 
! Some difficulties, it was not easy to clearly explain this 
! A lot of difficulties, it was very hard to communicate this clearly to my family 
 
Additional comments: 
________________________________________________________________________
________________________________________________________________________ 
__________________________________________________________________  
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PART 7- Adaptation to genetic information 
 
Below is a series of statements that describe how people cope with complex genetic information. 
Please circle a number (1 to 6) that describes you best.  
 
 Strongly disagree 
Moderately 
disagree 
Mildly 
disagree 
Mildly 
agree 
Moderately 
agree 
Strongly 
agree 
1. I can’t seem to stop 
myself from thinking 
about having HCM. 
1 2 3 4 5 6 
2. It’s hard for me to talk 
about having HCM with 
my relatives. 
1 2 3 4 5 6 
3. Knowing that I have 
HCM decreases my 
feelings of self-worth. 
1 2 3 4 5 6 
4. I understand how I 
came to have HCM. 1 2 3 4 5 6 
5. I understand the 
chances I have of 
passing HCM along to 
my children.  
1 2 3 4 5 6 
6. If a problem arises 
because of HCM I will 
be able to find a 
solution. 
1 2 3 4 5 6 
7. I believe that there are 
things I can do to avoid 
the problems that may 
arise from having HCM.  
1 2 3 4 5 6 
8. I would feel better about 
myself if I did not know 
that I had HCM.  
1 2 3 4 5 6 
9. I feel satisfied with my 
communication with my 
family about what 
having HCM means to 
me. 
1 2 3 4 5 6 
10. I have dreams about 
having HCM.  1 2 3 4 5 6 
11. It’s hard for me to talk 
about having HCM with 
my friends. 
1 2 3 4 5 6 
12. My friends are 
supportive when I tell 
them about having 
HCM.  
1 2 3 4 5 6 
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13. I rarely think about the 
fact that I have HCM.  1 2 3 4 5 6 
14. I am confident that I can 
deal with any effects of 
HCM.  
1 2 3 4 5 6 
15. I feel confused because 
I have been given 
different explanations of 
what having HCM 
means. 
1 2 3 4 5 6 
16. Knowing I have HCM is 
always on my mind. 1 2 3 4 5 6 
17. It makes me feel better 
to talk to my loved ones 
about having HCM.  
1 2 3 4 5 6 
18. Having HCM makes me 
feel inferior at times. 1 2 3 4 5 6 
19. I am confident that I can 
work out any problems 
having HCM might 
cause. 
1 2 3 4 5 6 
20. I feel that I can explain 
to other people what 
having HCM means. 
1 2 3 4 5 6 
21. I feel certain that I 
understand the meaning 
of having HCM.  
1 2 3 4 5 6 
22. I understand the health 
risks my relatives face 
because of HCM. 
1 2 3 4 5 6 
23. My relatives are 
supportive when I tell 
them about having 
HCM. 
1 2 3 4 5 6 
24. Knowing that I have 
HCM sometimes makes 
me feel like a failure. 
1 2 3 4 5 6 
25. Other things in my life 
always seem to make 
me think about having 
HCM.  
1 2 3 4 5 6 
26. I think about the fact 
that I have HCM when I 
don’t mean to think 
about it.  
1 2 3 4 5 6 
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Thank you very much for taking the time to complete 
this survey. 
Please ensure you have answered all questions. 
